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3. Thesis Abstract 
 
Introduction: Human Immunodeficiency Virus remains as one of the largest pandemics in the 
world, with the prevalence of more than 70% of HIV-infected individual reside in Sub-Saharan 
Africa. Moreover, other sexually transmitted viral infection such as Human Papillomavirus and 
Herpes Simplex Virus also show a high prevalence in Sub-Saharan Africa. Recent studies show 
the presence of other viral STI in the genital region may have increased HIV shedding in the 
genital region. However, it not clearly known if the presence of ART or HIV may affect the 
shedding of other viral STI in the genital region and if the combination of other viral STI 
treatment and ART is necessary to treat an individual with multiple STI infection. 
Methods: This is a secondary data analysis study, based on analysing the data collected from 
a single-site, double-blinded randomized control study (2-IUD study). The research site was 
the Gugulethu Community Health Centre, Cape Town, South Africa and samples were 
collected between 2014 and 2018. Analysis was conducted on genital tract specimens of study 
participants obtained via the Menstrual Cup (MC) and Endocervical Swabs (ECS), collected at 
baseline, 3 and 6 months’ follow up visit from randomly selected 52 ART-Naïve participants 
and 56 age-matched women from the ART-Using group of the primary study. Logistic 
regression models were constructed to measure the associations between possible risk factors 
and viral STIs. Results are presented as odds ratios (OR) with 95% confidence intervals (CI). 
Results: ART-Naïve women had higher rates of HIV shedding in the genital tract at each visit. 
However, more than half of women using ART, most of them virally suppressed, had detectable 
genital HIV at one or more visits. Most of the participants showed pre-exposure to HSV-2, but 
shedding of HSV-2 was substantially less common. HPV was detected in 72% of the 
participants, with no significant difference by ART status. Overall, 70.3% of samples had at 
least one viral pathogen detected - 60.4% among ART-Using women compared to 82.8% in 
ART-Naïve women (P<0.001). Compared to ART-Naïve women, ART-Using women were 
significantly less likely to have co-occurrence of viral shedding overall. However, ART-Using 
women with higher VL had levels of viral co-occurrence similar to those of ART-Naïve women. 
Conclusion: Our analysis demonstrated that the ART-Using women were less likely to shed 
HIV, HSV-2, HPV and viral STI co-infection in the genital tract compared to ART-Naïve 
women. This may be be driven by plasma VL levels where ART-Using women with lower VL 
are less likely to shed these viruses compared to women with elevated VL, including those not 
on ART. 
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4. List of Abbreviation 
 
2IUDnCT 2-IUD study conducted in Cape Town 
AIDS Acquired Immune Deficiency Syndrome 
aOR Adjusted Odd Ratio 
ART Antiretroviral Therapy 
ARV Antiretroviral Treatment Drugs 
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HIV Human Immunodeficiency Virus 
 (For the duration of this thesis, HIV refers to  
 Human Immunodeficiency Virus 1, group M, subtype C) 
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HREC Human Research Ethic Committee 
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L-IUD / LNG IUD Levonorgestrel Intrauterine Device 
lrHPV Low-Risk Human Papilloma Virus 
MC Menstrual Cup 
mm3 cubic millimetre 
mL Millilitre 
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NHLS National Health Laboratory Service 
OR Odd Ratio 
P-Value Probability Value 
PBS Phosphate-Buffered Saline  
% Percentage 
PCR Polymerase Chain Reaction 
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RCT Randomised Controlled Trial 
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SD Standard Deviation 
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1. Introduction 
 
1.1. Background 
The Human Immunodeficiency Virus / Acquired Immune Deficiency Syndrome (HIV / AIDS) 
pandemic has affected the globe for the past few decades, posing detrimental health risks and 
financial burden globally, particularly severe in sub-Saharan Africa (1). For decades, a massive 
amount of researches and attempted interventions took place to combat and reduce HIV 
incidence and HIV-related mortality. Over the years, despite all the efforts, HIV prevalence 
among women in sub-Saharan Africa remains persistently high, particularly among younger 
women (2). 
 
Recent findings have confirmed sexually transmitted infections (STI) are among one of the 
most well-established risk factors for HIV acquisition. A possible mechanism could be, upon 
STI infection, the protective mucosal barrier becomes more vulnerable for HIV to penetrate and 
access susceptible cells (3). This STI / HIV acquisition relationship can also be bidirectional as 
HIV infected individuals have been shown to be more susceptible to acquire other sexually 
transmitted pathogens. This is most likely due to the fact that HIV infected individuals were 
more immune-compromised which allow opportunistic STI to occur (4).    
 
Herpes Simplex Virus type 2 (HSV-2) is one of the most prevalent sexually transmitted 
pathogen worldwide (5). Symptomatic herpes infections express in the form of genital 
ulceration disease; and when being asymptomatic, the viruses stay dormant inside the host and 
cannot be cleared by the host immune system. Incidence and prevalence of HSV-2 are 
particularly high in sub-Saharan Africa, of which coincide with the high prevalence of HIV in 
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sub-Saharan Africa. Similarly, Human Papilloma Virus (HPV) is another highly prevalent 
sexually transmitted pathogen worldwide, the majority of cervical cancer can be linked to 
persistent high-risk HPV (hrHPV) infection. Cervical cancer is the most common cancer among 
young women in sub-Saharan Africa (6). Literature has shown HIV infected individual is more 
likely to acquire HSV-2 and HPV and leads to further complications such as cervical cancer (6, 
7). 
 
Following the massive rollout of Anti-Retrovirus Treatment (ART) programme, individuals 
who live with under-controlled HIV progression, increases in South Africa. Individual who are 
on ART can potentially control HIV viral load and largely increase the life expectancy of the 
HIV-infected individual.  
 
This then poses the question, individuals who were enrolled in the ART programme, shown 
viral suppression, with the semi-restored immune system, are they less susceptible to other 
sexually transmitted viral infection comparing to those that weren’t on the treatment or shown 
viral suppression. 
 
A Randomised Controlled Trial (RCT) is currently ongoing; to compare the HIV-1 viral 
shredding in the genital tract between two different intrauterine devices (IUD), hormonal and 
non-hormonal, among Cape Town HIV-positive women who are on ART programme and who 
are not yet ready for ART programme. The study was investigated by UCT, Public Health 
Department, study participants were followed for a duration of 24 months. A nested study was 
conducted within this randomized controlled trial to compare STI occurrence between 
participants who are on ART programme and who were not on ART programme at enrolment. 
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1.2. Study Aim 
The aim of this study is to compare the occurrence and co-occurrence of viral STI in HIV 
positive women who are on ART to that in HIV positive women who are ART-Naïve. 
 
1.3. Objectives 
 
1.3.1. Primary Objective  
Describe the occurrence and co-occurrence of genital HIV, HSV-2 and high-risk HPV 
in female genital tract to identify the following: 
 
1.3.2. Secondary Objectives 
a. Risk factors for detection of genital HIV, HSV-2 and hrHPV individually, focusing 
on comparing between ART-Naïve and ART-Using participants or possibly viral 
suppression status. 
 
b. Risk factors for co-occurrence of genital HIV, HSV-2, and HPV, focusing on 
comparing ART-Naïve and ART-Using participants or possibly viral suppression 
status. 
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2. Methodology 
 
2.1. Study Design 
The study design of this investigation was based on a single-site, double-blinded randomised 
controlled study (2-IUD study). The objective of the primary 2-IUD study, aims to evaluate the 
safety of hormonal levonorgestrel intrauterine device (L-IUD) and the copper T-380 
intrauterine device (C-IUD) with respect to HIV progression between HIV-positive participants 
who were on ART at enrolment and HIV-positive participants who were not eligible for ART 
at enrolment by measuring the HIV viral load in the plasma and genital tract. Upon enrolment, 
study participants were randomized to one of the IUD types and followed up for a period of 24 
months. The study took place at the Gugulethu Community Health Centre, Cape Town, South 
Africa between 2014 to 2018. 
 
For our investigation, we propose to conduct a secondary analysis of data on the specimens that 
were already-collected from the primary RCT, including from baseline prior to installation of 
IUDs, and corresponding follow-up study specimens (3, 6 months). 
 
2.2. Study Population and Sampling 
The study population of the primary 2-IUD study was HIV positive women in South Africa, 
between the age of 18 to 40 years old.  
 
The inclusion criteria for the primary study are as follow: 
- Age 18 to 40 
- Willing to provide written informed consent to be screened and participate in the 2-IUD 
study. 
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- Interested and willing to use either IUD as a family planning method. 
- Willing to participate in all aspects of the study and to comply with study procedures 
and visits, for 24 months. 
- Has documented HIV infection 
- For those fall under ART-Naïve arm: 
o Not ART eligible at the time of enrolment as per South African ART guideline. 
Referral to ART initiation will occur per local guideline. 
o No symptoms of AIDS, pregnant or newly diagnosed Tuberculosis (TB). 
o At least 6 months post-delivery and not pregnant or desiring pregnancy for the 
next 30 months. 
- For those fall under ART-Using arm: 
o Clinical records indicated ART usage. 
o Laboratory measure showed ART use and present evidence of viral suppression 
at enrolment (plasma HIV viral load < 1000 copies/mL). 
o At least 6 months post-delivery and not pregnant or desiring pregnancy for the 
next 30 months. 
 
In total, 288 women have been recruited, 154 ineligible for ART at entry and 134 using ART 
at the entry for the primary study. 
 
For our secondary data analysis, we proposed to randomly select a subset of participants from 
each arm. Investigate data collected from baseline, 3 months and 6 months follow up visits.  
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2.3. Measurement 
The outcome of interest in this study is the viral STI status in the genital region of the female 
participants. The STIs of interest are HSV-2 and HPV respectively. For detection purposes, 
menstrual cup specimens and endocervical secretion specimens were obtained from the study 
participants at each visit. Collected specimens from sites were transported to the Medical 
Microbiology Lab at the University of Cape Town for further processing and stored at -80 
degree Celsius freezer prior to the supplementary study. Collected specimens were then tested 
below: 
  
 
2.3.1. Detection of quantitative HSV-2 in the genital tract 
Menstrual cup specimens, previously collected and stored, are to be sent off to National 
Health Laboratory Service at Groote Schuur Hospital for quantitative HSV-2 detection, 
using Altona HSV 1/2 PCR kit. 
 
2.3.2. HPV status confirmation and genotyping 
Endocervical secretion specimens are to be used for HPV genotyping via Roche Linear 
Array HPV Genotyping Assay, manufactured by Roche Molecular Diagnostic. Linear 
Array Assay can detect 37 high and low-risk HPV genotype with B-globin testing as an 
internal control. The test is to be conducted via HPV accredited lab. 
 
2.4. Data Collection 
The data for this secondary analysis will be taken from the 2-IUD demographic and medical 
case report forms (appendix III), where the data were collected from face to face interview 
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during the time of visits (enrolment, 3 months and 6 months follow up visit). At each visit, after 
the interview, specimens were collected from the participants and sent off to respective 
laboratories, National Health Laboratory Service (NHLS) and Medical Microbiology Lab of 
University of Cape Town, for testing and storage. Variables of interest for this secondary 
analysis are depicted in Table A-1. 
 
3. Data Management and Analysis Plan 
 
Completed questionnaire from the parent study has already been entered into a password-
protected database. Relevant data to be used in this secondary data analysis dissertation will be 
transferred onto a password protected external hard-drive. All data relevant to the study will be 
kept at the University of Cape Town when not in use. 
 
Collected data will be analyzed using STATA software, with Linear Mix Model Algorithm and 
all statistical tests will be evaluated with statistical significance denoted by P=0.05. Data 
including HSV-2 viral load, HPV genotype and other possible variables such as HIV viral load 
will be taken into consideration to compare between ART and non-ART participants. 
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Table A-1: List of variables to be used for analysis 
 
VARIABLE NAMES TYPE OF VARIABLES CATEGORICAL 
DEMOGRAPHIC   
AGE Numerical  
WEIGHT Numerical  
EDUCATIONAL STATUS Categorical – binary < Grade 10, Grade 10 and above 
OCCUPATIONAL STATUS Categorical - binary Employed, Unemployed 
RELATIONSHIP STATUS Categorical - binary Single, in relationship 
CLINICAL 
CHARACTERISTICS 
  
NUMBER OF YEAR SINCE 
HIV DIAGNOSIS 
Numerical  
PAST TB HISTORY Categorical - binary Past TB presence, No past TB 
CD4 COUNT AT 
ENROLMENT 
Numerical  
ART STATUS Categorical - binary On ART, not on ART 
PLASMA HIV VIRAL 
LOAD 
Numerical / Categorical Suppressed, not suppressed 
GENITAL HIV VIRAL 
LOAD 
Numerical / Categorical Suppressed, not suppressed 
HIGH-RISK HPV Categorical – binary Positive, not detected 
HSV-2 VIRAL LOAD Categorical – binary Positive, not detected 
HSV-2 IGG Categorical – binary Positive, not detected 
TRICHNOMONAS Categorical – binary Positive, not detected 
GONORRHEA Categorical – binary Positive, not detected 
CHLAMYDIA Categorical – binary Positive, not detected 
BACTERIAL VAGINOSIS Categorical – binary Positive, not detected 
 
4. Ethics Approval 
 
4.1. Description of risks and benefits  
The parent study has received ethics approval from University of Cape Town since 2014 
(Appendix I). Annual renewal for the year 2018, during which this dissertation was conducted, 
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can be found in the appendices (Appendix I). This secondary analysis will go through the UCT-
HREC for ethic approval. 
 
In this dissertation, one does not directly come into contact with the study participants. All data 
received came as an encrypted data that does not include the identity of the participants and one 
will not review the actual participant folders. Hence this poses a limited risk of harming or 
losing the anonymity of the participant for the study. 
 
The secondary analysis does not have any direct benefit or harm on the study participants, as it 
does not come into contact with the participants directly. Study itself only utilizing the collected 
data from the parental study which may provide future research benefit for the better 
understanding of the HIV and STI relationship. 
 
4.2. Informed consent process 
Participants of this supplementary study were consented through the parental study (2-IUD 
study) consent process (Appendix II). The informed consent process was done with an 
interviewer in the local language (isiXhosa) with a standardized from. The standardized form 
was translated from English to isiXhosa and back to English by different ixiXhosa speaker to 
ensure fidelity. At the start of informed consent process, the study staff will describe the portion 
of the study involved in that specific consent, outlining all procedures and associated time 
commitments, duration of participation, risks and benefits of participation, and staff contact 
information. The study coordinator will be available to address any questions or concerns. The 
participation was strictly voluntary. 
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5. Potential Limitation 
 
Certain characteristics of interest, that may have affected the risk of exposure to STI requires 
self-report during the initial questionnaire interview. Characteristics such as date or partner 
association may have been incorrectly answered during the interview. Hence may have inflated 
or deflated the comparative analysis. 
 
Furthermore, analysis conducted over 6 months period (baseline, 3 months and 6 months follow 
up visits) may not completely reflect the true association of STI occurrence and co-occurrence 
due to the nature of viral shredding.  
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1. Introduction 
 
Human Immunodeficiency Virus 1 (HIV) remains one of the largest pandemics in the world. 
At World AIDS Day on 1 December 2018, the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) published that in 2017, 37 million people globally were living with HIV, of which 
only 21 million have access to HIV antiretroviral therapy. In 2017 alone, 1.8 million people 
were found to be newly infected with HIV and about 1 million people died from HIV related 
disease (1). A disturbing fact indicated that Sub-Saharan Africa only accounts for  less than 
20% of the global population, yet it contributed to more than 70% of the global HIV prevalence 
(2). In South Africa during 2017, UNAIDS reported that 7.2 million people were living with 
HIV while 270 000 people were diagnosed to be newly infected with HIV and 110 000 people 
died from HIV-related diseases. (3). Currently only 61% of HIV positive individuals who live 
in South Africa are receiving antiretroviral therapy (ART) (3).  
 
Antiretroviral treatment programme has been developed and implemented as the primary tool 
to suppress the HIV viral load in infected individuals to reduce mortality, morbidity and 
transmission. While researchers still attempt to develop a suitable vaccine for eradication of 
HIV, the focus has been on prevention of HIV-related diseases. (4-7). Similar to HIV, other 
viral sexually transmitted infections (STIs) such as Herpes Simplex Virus type 2 (HSV-2) and 
Human Papillomavirus (HPV) also have very high prevalence in Sub-Saharan Africa. HSV-2 
causes genital ulcers, whereas persistent HPV infection has been linked to cervical cancer, both 
of which appear commonly in women living with HIV. Several studies have provided the 
rationale behind the high co-prevalence of STI and HIV. HIV infection reduces the efficiency 
of the host’s immune system, and also disrupts and compromises the normal health-protective 
flora in the female genital tract. This allows HIV-infected women to become more susceptible 
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to other viral STIs which use the genital epithelial cells as an entry point (8-10). Moreover, viral 
STI co-infection particularly causes more severe damage in untreated HIV-women where a 
non-recovered and compromised immune system allows the viral STI to stay persistently in the 
genital region forming a stable viral reservoir. This then may progress to severe disease such as 
cervical cancer (11-13). Thus one of the objectives of HIV treatment is to prevent further STI 
damages. 
 
ART is highly effective in causing HIV viral suppression and preventing HIV transmission (14). 
In 2014, the World Health Organisation (WHO) and their partners launched the 90-90-90 target: 
90% of HIV-infected individuals have been tested and diagnosed; 90% of those that were tested 
have received antiretroviral therapy; and 90% of those who received treatments managed to 
achieve viral suppression (15). Increasing the coverage of antiretroviral therapy leads to a rise 
in the incidence of women with controlled HIV, a semi-restored immune system, which 
potentially reduces the danger of opportunistic infections and may boost life expectancy (14, 
16). Studies have shown initiation of antiretroviral therapy results in rapid reductions of HIV 
viral load in plasma, leading to a decline in HIV-1 shedding (expulsion of viral particle after 
successful viral replication during host-cell infection) in the genital region, which potentially 
reduces the risk of transmission (17, 18). However, some studies also show that even with 
undetectable plasma viral load, women living with HIV can still shed viral particles in the 
genital region which pose an ongoing risk of transmission. The mechanisms underlying this are 
not well understood (19). In addition, it is not well understood whether ART can also decrease 
the shedding of other opportunistic STIs in the genital tract and whether there is any 
correlation with HIV shedding in the same region. 
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A massive ART treatment programme has been rolled out in South Africa since the early 2000s 
and resultant HIV incidence and related mortality have decreased significantly (20, 21). The 
achievement of ART therapy led in an rise in the life expectancy of HIV-infected individual 
due to the lifelong infection nature of HIV (20, 22). Recent studies showed that similarly 
sexually transmitted virus such as HSV-2 and HPV also remain significantly high in South 
Africa.  
 
This then raises the question: are HIV-infected women, enrolled in the ART programme and 
possibly virally suppressed, shed less sexually transmitted viruses in the genital region and 
demonstrate more protection compared to those that not on the ART programme. 
 
2. Literature search strategy 
 
PubMed and Google Scholar were internet searches used to locate the literature for this review. 
The search was limited to English language publications with no restriction on the time period 
of publication. Search terms used in the search engines are indicated in Table B-1 below. 
 
Table B-1: Search terms used in the literature review 
Keywords Association or Keyword synonym 
HIV Plasma HIV, Genital HIV, HIV viral load 
Viral STI HSV-2, HPV, STI 
ART HIV treatment, viral suppression 
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3. Summary and interpretation from the literature 
 
3.1 HIV in the genital tract 
Plasma HIV viral load (VL) is the major determinant of disease progression as well as viral 
transmission in HIV studies (23, 24). While plasma HIV VL is the main biomarker of HIV 
infection, genital tract HIV VL, or shedding of HIV in the genital region, can affect transmission 
during heterosexual contact (25-27). There is a direct correlation with plasma HIV VL and HIV 
shedding in the genital region, as individuals with higher plasma VL tend to have detectable 
HIV VL in the genital region (19, 25, 28). 
 
The advent of ART has resulted in a huge reduction in HIV transmission and acquisition and 
ART has since been used as one of the key HIV prevention approaches (13, 14, 18, 29). Studies 
have shown that HIV-infected women receiving treatment have a considerable reduction of 
HIV viral load in their plasma and genital tract compared to untreated individuals. However, 
despite these reductions there are studies that report detectable HIV shedding in the genital tract 
despite undetectable HIV viral load in plasma (17, 19). This has implications for transmission 
of HIV to sexual partners during intercourse and in turn needs to be better understood. 
 
There are sexually transmitted infections which are associated with HIV transmission and 
acquisition (30, 31). Individuals who showed symptomatic STIs in the genital region are more 
likely to acquire HIV during sexual intercourse. Similarly, individuals with HIV are also more 
likely to acquire other STIs (31). Furthermore it has also been shown that individuals who are 
HIV-positive and infected with other viral STIs are also more likely to shed HIV particles in 
the genital region and therefore increase the rate of HIV transmission (31, 32). Localised viral 
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infection, which refers to localisation in one area of the host, can potentially recruit HIV-
infected leukocytes to the area as well as trigger a cytokine response which provides a further 
platform for HIV replication (19, 33). The combination of these effects enhances HIV 
replication and in turn increases viral shedding in the genital tract (19, 27, 32). This may be one 
of the factors that enhance HIV shedding in the genital region despite use of antiretroviral 
therapy. 
 
3.2 HPV in the genital tract 
HPV is one of the most prevalent sexually transmitted viruses among female populations 
worldwide, estimated at 11.7% worldwide (34, 35). In the recent meta-analysis shown on HPV 
information centre, sub-Saharan Africa have the highest HPV prevalence (24%) (34). South 
Africa showed high prevalence of HPV in women with healthy normal cervix, with no 
malignant lesion (17.9%) and particularly high prevalence in young adolescents (36, 37). The 
HPV infection starts soon after sexual debut, peaks in adolescence and rate decreased as age 
increased (36). Infection can later be cleared by the immune system but with the possibility of 
re-infection by the same HPV genotype. However, in some cases, persistent HPV infection can 
occur, in other words, failure by the immune system to clear infection could result in the 
development of cancer (38, 39). To date, several high-risk oncogenic HPV genotypes has 
already been identified, such as types 16, 18, 31, 33. Potential vaccines for various subtypes 
have been designed (40, 41). 
 
Invasive cervical cancer has been correlated with HPV infection in the female genital tract. 
Invasive cervical cancer is the second most common cancer in women globally, mostly 
occurring in less developed countries (42).  It is the second most common cancer in women 
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after breast cancer and is the most common cancer in women between age 15 to 44 in South 
Africa (36, 40). Cervical cancer has become one of the leading causes of death in South African 
women. 
 
In most cases, HPV infection is commensal in the epithelial layer of the skin, cervix, anus or 
mucosal layer. Once infected in the region, the infection mechanism often causes lesions in the 
localised area (41, 43). Most of these infections do not linger and the virus is usually cleared 
by the host immune response.  However, an invasive type such as type 16 and 18 together with 
other external factors, may cause persistent infection. As demonstrated in Figure B-1, HPV-
based cervical cancer generally occurs in four stages: firstly, HPV infection; next a persistent 
infection of HPV; then the progression of clones of persistently infected cells to form a pre-
cancerous lesion and finally the invasive cancer. Clinical symptoms are reversible at any time 
point in the first three stages, if HPV infection is treated and cleared. However, lack of screening 
in areas with poor infrastructure often allows detection at a very late stage of the cancer 
progression and hence treatment is difficult (41, 43).  
 
In addition to growing HPV and cervical cancer incidence, HIV/AIDS infection has caused a 
major impact on the burden of HPV-associated diseases, particularly in South Africa. As 
indicated previously individuals with HIV positive status are more prone to HPV infection with 
progression to cervical cancer as HIV positive individuals are less likely to have the strong 
immune system required to clear HPV infection (44, 45). Moreover, HIV positive individuals 
are also more likely to be infected with multiple HPV genotypes which makes treatment 
difficult.  
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Figure B-1: Schematic diagram of HPV infection and c progression (46) 
 
There is no direct evidence to show HIV accelerates the rate of cancer invasion or progression 
from pre-cancer to cancer. The effect of ART treatment on HPV remains inconclusive, although 
certain studies reported that with ART treatment, it is possible that individuals are now living 
longer with a constant higher risk of HPV acquisition and less immune defence in terms of HPV 
clearance comparing to HIV uninfected individual, thus increasing the risk of cancer 
progression (44, 47, 48).  
 
3.3 HSV-2 in the genital tract 
Herpes simplex virus type 2 (HSV-2) is one of the most prevalent sexually transmitted 
pathogens worldwide (49). Viral transmission can occur by sexual intercourse, through direct 
mucosal or skin contact (50, 51). Infection initiates from the epithelial cells under the skin layer 
and then moves to the nerve endings - sacral ganglion -where it resides, or in severe cases moves 
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to the central nervous system. Once infected, the infection is incurable and cannot be cleared 
by the immune system of the host. The infection lasts lifelong inside the host and can be 
identified with Immunoglobulin G (IgG) screening (52, 53). Disease symptoms can either be 
periodically symptomatic with the presence of a genital ulcer or mostly asymptomatic (see 
Figure B-2).  
 
 
Figure B-2: Schematic diagram of HSV-2 infection and disease progression (54) 
 
Being mostly asymptomatic, many people infected by HSV-2 are unaware of their status and 
therefore increase the risk of transmission via sexual intercourse (55). In 2012, it was estimated 
that the prevalence of HSV-2 among individuals between the ages of 15-49 is about 11% 
globally. In Africa a higher prevalence of 31.5%, coincided with a high prevalence of HIV (56). 
From a recent meta-analysis, the estimated prevalence of HSV-2 in women aged 15-24, ranges 
from 31.9% to 53.7% in the South African clinic- or community-based population. Due to the 
lifelong infection nature of HSV-2, the prevalence is a lot more higher as the age increase, 
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showing an estimated 77.8% in women aged 25-49 years old (57). This statistic matched with 
other HSV-2 prevalence studies conducted on South Africa populations (58, 59).  
 
One of the main clinical symptoms of HSV-2 infection is the periodic re-occurrence of genital 
ulcers (56). Studies have shown that HSV-2 is currently the primary contributor to genital ulcers 
globally (60-62). Soon after initial infection, clinical symptoms of genital ulcer disease appear, 
with the possibility of reoccurrence (63-65). As time progress, the rate of re-occurrence 
decreases, however, this rate is  variable due to other factors such as host immune response, 
sexual behaviour, other STDs or bacterial vaginosis (63, 65). Initially, HSV-2 viral shedding 
was thought only to occur during viral reactivation with the presence of clinical symptoms, and 
the viral particle was thought to have been shed from the genital ulcer directly. However, recent 
studies show that individuals with HSV-2 shed HSV-2 viral particles asymptomatically more 
frequently than those with clinical symptoms (51, 60, 63). In turn the true reactivation, as well 
as risk of viral transmission, are more frequent than what was originally perceived (60).  
 
One of the major public health concerns associated with the high prevalence of HSV-2 is the 
increased risk of HIV acquisition (60). Studies have shown that prevalent HSV-2 increases the 
risk of HIV acquisition by 2- to 3-fold, and possibly much higher in some other settings (53, 
60, 62). The possible mechanism could be that HSV-2 infection causes skin lesions, which 
provides an entry point for HIV (55, 60). Moreover, HSV-2 infection could also negatively 
impact the protective microflora lining the genital region, whereby a much weakened defensive 
barrier increases susceptibility to HIV acquisition (66, 67). In asymptomatic women, in the 
absence of genital ulcers, periodic HSV-2 shedding in the genital tract causes inflammation and 
recruits CD4+ T cells into the genital tract providing targets for HIV infection (66, 67). 
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Therefore, prevalent HSV-2, whether symptomatic or asymptomatic, may increases HIV 
acquisition. The relationship between HSV-2 and HIV is bidirectional as HIV-infected women 
have increased risk of HSV-2 acquisition by way of a similar bio-mechanism (55, 60). 
 
Several studies have indicated that the presence of HSV-2 in HIV-infected individuals can 
potentially increase the shedding of HIV in the genital tract (68, 69). HIV-infected women were 
reported more likely to present symptomatic genital lesions/ulcerations or have longer shedding 
episodes or shed more HSV-2 viral particles compared to HIV-uninfected women (62, 67, 70). 
Moreover HIV viral particles are more likely to be shed through HSV-2 lesions and hence 
increase detection of HIV in the genital tract, and increase the rate of HIV transmission (68, 
71). The rationale behind this could be that HSV-2 is less likely to be cleared after reactivation 
due to the host’s compromised immune system from HIV infection. This in term, allows the 
prolonged activation of HSV-2, causing clinically symptomatic ulceration in the genital tract 
(65). Formation of ulcers triggers a particular cytokine response which in turn recruits more 
immune cells to a localised area (53, 55). This then provides more target for HIV infection and 
consequently more HSV-2 and HIV shedding the genital tract (55, 60). It was thought that HIV 
infection reduces the number of CD4 cells and thus enables HSV-2 to be reactivated more 
frequently. It was therefore initially hypothesised that using HIV antiretroviral therapy, the 
semi-restored count of CD4 T cells can then decrease the rate of HSV-2 activation. Recent 
studies however showed that the impact of ART on HSV-2 shedding was inconclusive. Some 
studies have shown that initiation of ART may slightly trigger more genital lesion, while others 
have shown no true changes in the general HSV-2 shedding in the genital tract of HIV-infected 
women (55, 60, 70, 72).   
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3.4 Effect of ART on co-occurrence of viral STI 
Sexually transmitted infection (bacterial and viral) have already been established as one of the 
key risk factors associated with HIV acquisition (66, 69). Similarly, HIV-infected individuals 
are also more susceptible to other STIs as they are more immuno-compromised against 
opportunist infections. It is also not uncommon for HIV-infected individuals to acquire multiple 
different STIs at the same time point as the mode of transmissions are quite similar. Therefore 
more than one STI (bacterial and/or viral) can frequently be detected in an HIV infected 
individual (73, 74).  
 
Studies have shown that the presence of other STIs can accelerate disease progression of HIV 
by increasing the shedding of HIV in the genital region, by increasing plasma HIV viral load, 
and by decreasing host CD4 cell counts (27, 32). Moreover, this is also bidirectional, as HIV, 
weakens host immune system, causing persistent STI infection, and potentially leads to cancer 
(HPV), or severe genital ulcer (HSV-2). It can be surmised that introduction of antiretroviral 
treatment can protect the host from further damages and partially restore the immune response. 
However, several complications with regards to the impact of antiretroviral treatment on other 
STIs have been reported (70, 72). 
 
Highly active antiretroviral treatment can reduce HIV viral load at the plasma level as well as 
reduce shedding in the genital region, and thus reduce the rate of transmission. However, not 
enough evidence exists to show that ART can also reduce shedding of other STIs, and hence 
this can potentially compromise the effectiveness of ARV treatment. Although at the initial 
stage of ARV treatment HIV becomes less virulent other STIs still exist and continue to shed 
viral particles. This could result in recruitment of newly developed CD4 T cells to a localised 
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region due to immuno-inflammation. With additional CD4 T cells and immune activation and 
possible genital ulceration, this may allow HIV shedding to continue in the genital region and 
therefore increase the rate of transmission (73-75). 
 
In most cases STIs are asymptomatic and in places where STI screening is not routine many 
individuals do not know their STI status. Ignorance of STI status can then potentially reduce 
the efficacy of the antiretroviral treatment programme leading to transmission of HIV. Other 
studies also showed that the success of the ART programme has increased the incidence of 
unprotected sexual intercourse as it has given the impression that HIV viral load is under control 
and transmission will not occur (75, 76).  Therefore, the combination of not knowing STI status 
high risk, unprotected sexual behaviour resulted in increased incidence of STIs in the HIV-
positive group. High prevalence of STI/HIV, resulted in reduced efficacy of treatment program 
and hence allowing the presence of HIV shedding in the genital tract, with undetectable HIV 
viremia in the plasma level and hence allowing transmission of HIV and STI to take place. 
 
4. Conclusion 
 
HIV shedding in the female genital tract is one of the primary risk factors in HIV transmission 
during sexual intercourse. Even with the introduction of ART, HIV shedding in the female 
genital tract is still detectable despite undetectable plasma viral load. This is a major concern 
for HIV transmission. Therefore, one of the major challenges is to understand the risk factors 
that cause HIV genital shedding with undetectable plasma HIV. 
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STIs in the genital tract has long been found to be associated with HIV infection. The presence 
of STIs increase the risk of HIV acquisition and the presence of HIV increase risk of other STI. 
Therefore, it is not uncommon to find HIV and other STIs co-occurring in the genital region. 
The routes of transmission are the same, where STI may damage mucosa and cause immune 
inflammation, recruiting CD4+ T cells. Although studies have shown that HIV/STI co-
occurrence resulted in persistent infection and severe disease progression, not much of study 
has been done on the effect of HIV/STI co-occurrence on genital HIV shedding. 
 
There are limited studies indicating that in the presence of other STIs, HIV shedding may 
increase in the genital tract. This may happen when STIs cause lesions in the genital tract, then 
recruit CD4 T cells to the localised region and thus increase HIV shedding in the genital tract. 
Not much has been verified however, and not much has been done to know whether 
asymptomatic STI can also boost shedding of HIV in the genital tract. This information is 
essential as it may explain an individual’s HIV shedding phenomenon under ART with 
undetectable HIV viral load in the plasma. More and more studies have shown that more regular 
STI testing is essential in order to start early therapy, which will reduce the risk of other STI 
acquisitions. More importantly, for HIV-positive individuals, early STI therapy should be 
performed in conjunction with ART to avoid other STIs from decreasing the effectiveness of 
ART. 
 
More studies need to be conducted in order to understand the role of other STIs in the genital 
region with regards to HIV shedding. One also needs to understand if there are other risk factors 
or influences which might act as viral suppression of ART. 
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1. Introduction 
 
HIV-1 (refer to as HIV for the remainder of this manuscript) remains a major public health 
concern with more than 37 million infected individuals globally, more than 70% of whom live 
in sub-Saharan Africa (1-3). Furthermore, recent literatures show that young women between 
15 to 24 years of age are twice as likely to be living with HIV than men of the same age (1, 4). 
At the level of both populations and individuals, antiretroviral therapy (ART) has altered 
fundamentally the course of HIV (5). ART use results in reduction of plasma HIV viral load 
(VL), the key biomarker of HIV disease progression (6, 7). After initiating ART, HIV-infected 
women experience a rapid decline of plasma HIV VL as well as reductions in HIV shedding in 
the female genital tract (8, 9). Reduced genital tract HIV reduces the potential of HIV 
transmission during heterosexual intercourse (8, 9). Hence, ART has been considered and 
utilised as an approach to preventing HIV transmission (8, 10). However, some studies found 
that even with undetected plasma HIV VL women can still have detectable HIV RNA in their 
genital tract (9, 11).  
 
High rates of HIV co-infection with other sexually transmitted infections, particularly viral 
pathogens, are well documented (11-16). These infections share similar transmission routes and 
risk factors, and prevalent HIV infection can increase vulnerability to other viral pathogens 
such as Herpes Simplex Virus type 2 (HSV-2) and Human Papilloma Virus (HPV) (17, 18). 
Similarly, HSV-2 infection causes genital ulcers which provide a suitable entry point for other 
sexually transmitted infections (STIs) (19). There are limited data showing that HPV infection 
increases the risk of HIV acquisition but HIV and HPV co-infection is common and may lead 
to persistent HPV infection and, if untreated, to possible invasive cervical cancer particularly 
amongst those infected with highly invasive high risk HPV (hrHPV) (13, 20, 21).  
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HIV-infected women using ART may have suppressed HIV plasma viral load and reduced 
genital tract HIV shedding however other viral STIs may still be present in the genital tract. 
Several studies indicated that HIV-infected individuals with reasonably high CD4 counts, who 
were treated with ART demonstrated reduced incidence of hrHPV. Moreover, studies have 
indicated that hrHPV in ART-treated individuals was less persistent and less likely to develop 
invasive cervical lesions (22-24). Recent research showed that although initiation of ART may 
transiently increase HSV-2 shedding, longer periods on ART reduces the shedding of HSV-2 
in the genital tract with fewer genital ulcers observed (25, 26). However, apart from reducing 
shedding and slowing disease progression, the introduction of ART does not prevent acquisition 
or transmission of other viral STIs (25, 27). Because viral pathogens such as HSV-2 and HPV 
present mostly asymptomatically, infections may not be detected clinically. It has been reported 
that localised HSV-2 and HPV infections, even if asymptomatic, may enhance shedding of HIV 
in the genital tract (28-32). This may limit the effects of ART in reducing HIV shedding as the 
presence of other viral pathogens in the female genital tract may promote HIV RNA shedding 
(14, 33).  
 
Better understanding of the relationships between the shedding of common sexually transmitted 
viruses in the female genital tract are urgently needed. This information is crucial for HIV 
prevention as it may explain genital HIV shedding even with an undetectable HIV VL in the 
plasma. Furthermore, this may also raise awareness around the need to screen and treat other 
viral STIs in conjunction with ART use. The aims of this study are firstly to describe the 
occurrence and co-occurrence of viral STIs in women living with HIV using ART as compared 
to those who are not yet using ART, and secondly to determine factors associated with viral 
shedding in the female genital tract. 
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2. Methodology 
 
2.1. Study Design 
This is a secondary analysis of a single-site, double-blind randomised control study 
(NCT01721798). The original parent study aims to evaluate the safety of the progestin-
containing levonorgestrel intrauterine device (LNG IUD) compared to the copper T-380 
intrauterine device (C-IUD). At enrolment of the parental primary study, study participants 
were randomised to one of the IUD types and were followed up for a period of up to 24 months. 
The research site was the Gugulethu Community Health Centre, Cape Town, South Africa and 
samples were collected between 2014 and 2018.  
 
For the purpose of this secondary study, our analysis was conducted on genital tract specimens 
of study participants obtained via the Menstrual Cup (MC) and Endocervical Swabs (ECS). 
Genital tract specimens were collected from baseline (prior to IUD insertion), and then at three- 
and at six months’ follow-up visits. Of particular interest was the prevalence of risk factors for 
genital tract HIV, HSV-2 and HPV, separately and as co-infections.  
 
2.2. Study Population and Sampling 
The study population of the parent trial was HIV-infected women, between the ages of 18 and 
40 years.  Eligibility criteria included willingness to provide written informed consent, no 
planned pregnancy in the next 2 years, and willing to participate in all aspects of the study for 
24 months including compliance with study procedures and visits. We randomly selected 52 
ART-Naïve participants and 56 age-matched women from the ART-Using group. Figure C-1 
shows how the study populations were derived. 
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Figure C-1: Schematic diagram indicating the study population of the primary 2-IUD study 
and supplementary study 
 
2.3. Specimen Collection 
From the initial two type IUD (2-IUDnCT) study, three different genital tract samples 
(Menstrual Cup (MC) and Endocervical Swab (ECS)) were collected for HIV RNA detection 
at enrolment and months 3 and 6 visits. The collection procedure was described in a published 
paper (34) and is as follows:  
For the MC specimens, the study participant either self-inserted or had a clinician insert an 
individually wrapped, single use Instead Softcup™ (Evofem Inc., San Diego, California, USA) 
at enrolment, months 3, and month 6. The MC was inserted to cover the cervix and was to 
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remain in place for at least 60 minutes before removal by a clinician and transference to a sterile 
50-mL tube.  
For the ECS specimens, a clinician collected endocervical fluid with elongated tapered flocked 
swabs (Copan Diagnostics, Murrieta, California, USA) during a pelvic examination. Each swab 
was allowed to absorb fluid inside the endocervical canal for 60 seconds, without rotating the 
swab to prevent microabrasion. Collected swabs were placed into individual cryovials with 1.5 
mL phosphate-buffered saline (PBS).  
For the Plasma specimens, whole blood was collected from eligible participants. 
 
Collected specimens were sent to the Medical Microbiology Laboratory at the University of 
Cape Town for initial sample preparation and storage in a -80oC freezer before viral pathogen 
and other testing by the afore-mentioned laboratory and the National Health Laboratory Service 
at Groote Schuur Hospital, Cape Town. 
 
2.4. Specimen Processing  
Specimen processing procedures have been published (34) and are described briefly below: 
For the MC specimens, once collected from site, 50mL tubes containing MC specimens were 
weighed. The volume of secreted fluids was obtained by subtracting against the average weight 
of 50-mL tubes with an unused single-use Instead Softcup™.  The Softcup with secreted fluids 
was centrifuged at 850G for 10 minutes in order to collect secretions at the bottom of the tubes. 
The contents were then resuspended in PBS, using the determined weight of secretions and 
assuming 1 g = 1 mL genital secretion to make a 10-fold dilution. Specimens were aliquoted 
and stored at −80°C. 
For the ECS specimens, the sample (ECS with 1.5 mL PBS) was mixed and resuspended by 
using a vortex mixer for 1 minute. All fluid was removed from the swab by gently scraping the 
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swab head against the inside of the tube before discarding it. ECS samples were aliquoted and 
stored at −80°C. 
For the Plasma specimens, collected whole blood specimens were centrifuged at 1500G for 
10 minutes to separate the blood into an upper fluid layer (plasma) and lower red blood cells 
(RBC) layer. The plasma was then aliquoted and stored at -80°C.  
 
2.5. Laboratory Testing for viral STIs 
MC specimens were thawed and sent to the National Health Laboratory Service (NHLS) at 
Groote Schuur Hospital for quantitative HSV-2 detection using Altona HSV 1/2 PCR kit, and 
HIV-1 viral load detection using the Cobas Ampliprep / Cobas TaqMan system (Roche 
Diagnostics Ltd., Rotkreuz, Switzerland). Testing was conducted according to the 
manufacturer’s manual. ECS specimens were tested for HPV via Roche Linear Array HPV 
Genotyping Assay (Roche Diagnostics Ltd., Rotkreuz, Switzerland). Linear Array Assay is 
capable of detecting 37 high and low-risk HPV genotypes with B-globin testing as an internal 
control. The test was conducted in the Molecular Virology Lab at the University of Cape Town. 
 
HIV plasma VL were tested by NHLS during the parental study, using Abbott M2000SP/RT 
viral load assay (Abbott Diagnostics, Illinois, USA) with a lower limit of detection of 40 
copies/mL. Plasma specimen from baseline were thawed and sent to NHLS for serology 
detection of HSV-2 using HerpeSelect®  1 and 2 Immunoblot IgG kit (FOCUS Diagnostic, 
Cypress, California, USA). 
 
2.6. Laboratory Testing for bacterial STIs  
Participant demographic and clinical data were collected via standardised interviews at each 
visit. In addition, Neisseria gonorrhoeae and Chlamydia trachomatis were tested in real-time 
using NG/CT Xpert®  (Cepheid Diagnostics, Sunnyvale, California, USA) nucleic acid 
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amplification testing. OSOM®  BV Blue and Trichomonas (Sekisui Diagnostics, Lexington, 
Massachusetts, USA) rapid diagnostic test (RDT) were used to test for Trichomonas vaginalis 
(bacterial vaginosis). Alere®  Determine®  Syphilis (Alere Diagnostics, San Diego, California, 
USA) rapid diagnostic testing was used to test for Treponema pallidum (syphilis).  
 
2.7. Statistical Analysis 
Data were analysed using STATA software (Version 14, Stata Corporation, College Station, 
Texas, USA). Analyses used two-sided tests at alpha = 0.05. Logistic regression models 
measured the associations between possible risk factors and viral STIs. Results are presented 
as odds ratios (OR) with 95% confidence intervals (CI). Because of the close causal relationship 
between HIV plasma VL and ART use, and that the vast majority of ART-Naïve women had 
elevated VL (see Supplementary Table 1), in analysis we combined these two variables into a 
single polytomous variable categorised as ART-Naïve on ART VL<50 copies/mL; ART VL 
50-999 copies/mL; ART VL 1000-9999 copies/mL and ART VL ≥10000 copies/mL. Measures 
on each participant were repeated over time allowing for generalised estimating equations to 
account for intra-individual clustering of observations using the Huber-White (sandwich) 
estimator for standard errors (35). Adjusted models included variables either previously 
documented as confounders, or co-variates which appeared to be potential confounders in 
bivariate analysis (23, 30, 31, 36-39).  
 
3. Results 
 
Overall 108 women were included in the study: 52 ART-Naïve and 56 ART-Using participants. 
Table C-1 presents participant characteristics relevant to their ART status. The mean age in 
both groups was 31 years (similar by design), and 90% of participants had completed at least 
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Grade 10 education. At baseline, there were differences in demographic characteristics, with 
women on ART more likely to be married or cohabiting, and less likely to be employed 
compared to women not on ART.  
 
Table C-1: Demographic characteristics and health indicators of 2IUDnCT study participants 
contributing specimens for genital tract viral pathogen analysis at baseline 
 
DEMOGRAPHIC CHARACTERISTICS/ 
HEALTH INDICATORS 
 
TOTAL 
PARTICIPANTS 
(N=108) 
ART-USING 
PARTICIPANTS  
(N=56) 
ART-NAIVE 
PARTICIPANTS 
(N=52) 
P-VALUE 
AGE (MEAN, SD) 31 (4.57) 31 (4.47) 31 (4.70) P=1.000 
WEIGHT (MEAN, SD) 75 (29.64) 71 (35.94) 80 (20) P=0.114 
HIGHEST LEVEL OF EDUCATION     
BELOW GRADE 10 11 (10%) 7(12.5%) 4 (8%) P=0.409 
GRADE 10 AND ABOVE 97 (90%) 49 (87.5%) 48 (92%)  
OCCUPATION STATUS     
UNEMPLOYED 72 (67%) 42 (75%) 30 (58%) P=0.057 
EMPLOYED (FULL / PART-TIME) 36 (33%) 14 (25%) 22 (42%)  
CURRENT PARTNERSHIP     
SINGLE 20 (18%) 4 (7%) 16 (31%) P=0.002 
IN RELATIONSHIP 88 (82%) 52 (93%) 36 (69%)  
NUMBER OF YEARS SINCE HIV 
DIAGNOSIS (AT STUDY SCREENING) 
    
MEAN (STANDARD DEVIATION) 6.47 (3.94) 6.96 (3.58) 5.92 (3.94) P=0.157 
PAST TB HISTORY     
NO TB HISTORY 91 (85%) 40 (73%) 51 (98%) P<0.001 
PREVIOUSLY DIAGNOSED WITH TB 16 (15%) 15 (27%) 1 (2%)  
CD4 COUNT (count/mm3) AT 
ENROLMENT 
    
MEDIAN  
(INTER-QUARTILE REGION (IQR))  
(ONLY ART-NAÏVE PARTICIPANTS) 
638.13 
(472.5 – 738) 
 638.13 
(472.5 – 738) 
 
IUD DISTRIBUTION     
COPPER IUD 48 (44%) 24 (43%) 24 (46%) P=0.730 
LNG IUD 60 (56%) 32 (57%) 28 (54%)  
 
Table C-2 compares the plasma and genital tract viral measures between ART-Using and ART-
Naïve groups during the 6-month study period. During the follow up, 8 participants from the 
ART-Using cohort missed one or both of the 3/ 6 months’ follow-up visits (8/56, 14.3%) and 4 
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participants from the ART-Naïve cohort missed one or both of the 3/ 6 months’ follow-up visits 
(4/52, 7.7%).  
 
Table C-2: Viral pathogen markers over a six-month period among HIV-infected women who 
either use or do not use ART (N=108)  
CLINICAL AND LABORATORY STATUS TOTAL 
PARTICIPANTS 
(N=96) 
ART-USING 
PARTICIPANTS 
(N=48) 
ART-NAÏVE 
PARTICIPANTS 
(N=48) 
P-VALUE 
GENITAL HIV VIRAL LOADS     
BELOW THE LIMIT OF 
DETECTION/UNDETECTABLE 
30 (33%) 21 (45%) 9 (21%) P<0.001 
DETECTED (>40 COPIES/ML) BUT NOT 
ON ALL THREE VISITS 
43 (47%) 24 (51%) 19 (43%)  
DETECTED (>40 COPIES/ML) ON ALL 
THREE VISITS 
18 (20%) 2 (4%) 16 (36%)  
MISSING/INVALID 5 1 4  
HSV-2 IGG (PLASMA AT BASELINE, ALL 
108) 
    
UNDETECTED 6 (6%) 2 (4%) 4 (8%) P=0.316 
DETECTED 94 (94%) 49 (96%) 45 (92%)  
MISSING/INVALID 8 5 3  
GENITAL HSV-2 VIRAL LOADS (ALL)     
NOT DETECTED FROM ALL VISITS 64 (83%) 40 (85%) 24 (80%) P=0.187 
DETECTED IN ONE OF THE VISITS 11 (14%) 7 (15%) 4 (13%)  
DETECTED IN TWO OF THE VISITS 2 (3%) 0 2 (7%)  
DETECTED IN ALL THREE VISITS 0 0 0  
MISSING/INVALID 19 1 18  
MEDIAN (IQR) (LOG10 COPIES/ML) 3.35 (2.97 - 4.49) 3.24 (3.07 – 3.45) 4.38 (2.88 – 5.08) P=0.497 
TOTAL HPV     
NOT DETECTED FROM ALL VISITS 11 (28%) 8 (17%) 3 (21%) P=0.310 
DETECTED BUT NOT ALL THREE 
VISIT 
31 (35%) 15 (33%) 16 (43%)  
DETECTED IN ALL THREE VISITS 48 (37%) 23 (50%) 25 (36%)  
INVALID / MISSING SPECIMENS 6 2 4  
HR HPV     
NOT DETECTED FROM ALL VISITS 25 (28%) 16 (35%) 9 (21%) P=0.215 
DETECTED BUT NOT ALL THREE 
VISIT 
32 (35%) 13 (28%) 19 (43%)  
DETECTED IN ALL THREE VISITS 33 (37%) 17 (37%) 16 (36%)  
MISSING/INVALID 6 2 4  
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ART-Naïve women had higher rates of HIV shedding in the genital tract at each visit. However, 
more than half of women using ART had detectable genital HIV at one or more visits. The 
HSV-2 IgG results show >90% prevalence of HSV-2 infection in both ART-Using and ART-
Naïve groups however shedding of HSV-2 in the genital tract was substantially less common. 
The median log10 HSV-2 VL was 4.4 and 3.2 in ART-Naïve and ART-Using women 
respectively (p=0.50). HPV infection was detected in 72% of participants, with no significant 
difference by ART status and similar proportions of detection for HPV overall and high-risk 
subtypes. 
 
Table C-3: Prevalence of multiple viral shedding in the genital tract and endocervical region 
VIRAL STI TOTAL 
PARTICIPANTS  
ART-USING 
PARTICIPANTS 
ART-NAÏVE 
PARTICIPANTS  
P-VALUE 
AT BASELINE     
NOT DETECTED 27 (27.3%) 23 (41.1%) 4 (9.3%) P<0.001 
ONE STI DETECTED 43 (43.4%) 24 (42.9%) 19 (44.2%)  
TWO STI DETECTED 26 (26.3%) 9 (16%) 17 (39.5%)  
THREE STI DETECTED 3 (3%) 0 3 (7%)  
AT 3 MONTHS FOLLOW UP     
NOT DETECTED 26 (29.2%) 19 (38%) 7 (17.9%) P=0.010 
ONE STI DETECTED 39 (43.8%) 24 (48%) 15 (38.5%)  
TWO STI DETECTED 20 (22%) 5 (10%) 15 (38.5%)  
THREE STI DETECTED 4 (4.5%) 2 (4%) 2 (5.1%)  
AT 6 MONTHS FOLLOW UP     
NOT DETECTED 29 (33%) 19 (39.6%) 10 (25%) P=0.354 
ONE STI DETECTED 38 (43.2%) 20 (41.7) 18 (45%)  
TWO STI DETECTED 17 (19.3%) 8 (16.7%) 9 (22.5%)  
THREE STI DETECTED 4 (4.5%) 1 (2%) 3 (7.5%)  
OVERALL     
NOT DETECTED 82 (29.7%) 61 (39.6%) 21 (17.2%) P<0.001 
STI DETECTED 194 (70.3%) 93 (60.4%) 101 (82.8%)  
 
In Table C-3, we demonstrate the shedding and co-occurrence of multiple viral pathogens in 
the female genital tract. Overall, 70.3% of samples had at least one viral pathogen detected - 
60.4% among ART-Using women compared to 82.8% in ART-Naïve women (P<0.001).  
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Figure C-2 (a-c) presents Venn diagrams depicting the co-occurrence of viral pathogens at each 
visit by ART status. Most HSV-2 shedding occurred in the presence of detectable genital HIV 
and/or hrHPV at the same visit; there was also a high co-occurrence of genital HIV RNA 
shedding with hrHPV. 
 
 
Figure C-2a: Venn Diagram showing the prevalence of multiple viral STI combinations at 
baseline, comparing ART-Naïve and ART-Using women 
 
Figure C-2b: Venn Diagram showing the prevalence of multiple viral STI combinations at the 
3 Months follow-up visit, comparing ART-Naïve and ART-Using women 
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Figure C-2c: Venn Diagram showing the prevalence of multiple viral STI combinations at 6 
Months follow-up visit, comparing ART-Naïve and ART-Using women 
 
Table C-4 (a-c) shows the risk factors associated with the shedding into the genital tract of HIV, 
HSV-2 and HPV. No social or demographic factors were associated with individual pathogen 
detection. Chlamydia trachomatis (CT) increased the risk of HIV shedding (aOR=3.63, 95% 
CI: 1.07-12.31), whereas Neisseria gonorrhoeae (NG) was associated with twice the odds of 
hrHPV (aOR=1.93, 95% CI: 0.57-6.52) and Trichomonas vaginalis was associated with HSV-
2 shedding (aOR=4.16, 95% CI: 1.31-13.20).  
 
Furthermore, ART treatment was associated with reduced shedding of HIV in the genital region 
(aOR=0.37, 95% CI: 0.15-0.94). While ART-Using women with VL<1000 copies/mL were 
significantly less likely to have HIV detected in the genital tract, ART-Using women with high 
plasma VL (>1000 copies/mL) showed no difference in the detection of HIV as compared to 
ART-Naïve women (Table C-4a). HSV-2 shedding in the genital tract showed a similar pattern 
(Table C-4c). While ART use reduced the odds of HSV-2 overall (aOR=0.47, 95% CI: 0.10-
2.10), ART-Using women with a high plasma HIV VL had levels of shedding similar to ART-
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Naïve women though not all associations achieved statistical significance. High-risk HPV 
shedding followed a similar pattern also (Table C-4b). Lastly, HSV-2 detection was associated 
with concurrent HIV and HPV detection across visits (aOR=2.61, 95% CI: 0.78-8.71 and 
aOR=3.51, 95% CI: 0.91-13.54, respectively). 
 
Next, we investigated factors associated with co-occurrence of viral shedding in the female 
genital tract. Compared to ART-Naïve women, ART-Using women were significantly less 
likely to have co-occurrence of viral shedding overall (aOR=0.27, 95% CI: 0.10-0.72; Table C-
5). Mirroring the findings involving individual viruses, this was driven by ART-Using women 
with VL<1000 copies/mL, and ART-Using women with higher VL had levels of viral co-
occurrence similar to those of ART-Naïve women. In addition, both Neisseria gonorrhoeae and 
Chlamydia trachomatis increased the odds of detecting two or more viral pathogens (aOR=1.84, 
95% CI: 0.43-7.90 and aOR=2.17, 95% CI: 0.68-7.01 respectively). At baseline, married 
women or women in a relationship had reduced odds of multiple viral pathogens co-occurring 
(aOR=0.6, 95% CI: 0.214-1.826). 
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Table C-4a: Unadjusted and adjusted logistic regression models of the association between undetectable HIV shedding and detectable HIV 
shedding in the genital tract  
 UNADJUSTED MODELS* ADJUSTED MODEL A ** ADJUSTED MODEL B*** 
VARIABLES OR [95% CI] P-value aOR [95% CI] P-value aOR [95% CI] P-value 
ART STATUS (ART-NAÏVE VS ART-USING) 0.267 [0.148, 0.478] <0.001 0.372 [0.148, 0.936] 0.036   
ART AND PLASMA HIV SUPPRESSION       
ART-NAÏVE Reference    Reference  
ART PLASMA HIV VL (0-49 COPIES/ML)* 0.203 [0.110, 0.375] <0.001   0.213 [0.098, 0.463] <0.001 
ART PLASMA HIV VL (50-999 COPIES/ML) 0.390 [0.152, 1.004] 0.051   0.254 [0.086, 0.748] 0.013 
ART PLASMA HIV VL (1000-9999 COPIES/ML) 0.390 [0.067, 2.270] 0.295   0.280 [0.037, 2.093] 0.215 
ART PLASMA HIV VL (≥10000 COPIES/ML) 1.561 [0.315, 7.735] 0.586   1.543 [0.285, 8.351] 0.615 
BASELINE DEMOGRAPHIC       
AGE 0.953 [0.891, 1.020] 0.166 0.939 [0.864, 1.020] 0.136 0.934 [0.858, 1.017] 0.115 
WEIGHT 1.002 [0.992, 1.011] 0.729 0.996 [0.987, 1.006] 0.450 0.996 [0.987, 1.006] 0.440 
HIGHEST LEVEL OF EDUCATION (<GRADE 10 VS 
GRADE 10 AND ABOVE) 
1.460 [0.456, 4.678] 0.525 1.653 [0.591, 4.625] 0.339 1.796 [0.648, 4.974] 0.260 
OCCUPATION STATUS  (UNEMPLOYED VS EMPLOYED) 1.394 [0.755, 2.576] 0.288 1.070 [0.537, 2.132] 0.847 1.063 [0.528, 2.140] 0.864 
CURRENT PARTNERSHIP (SINGLE VS IN 
RELATIONSHIP 
0.532 [0.246, 1.152] 0.109 0.663 [0.260, 1.686] 0.388 0.695 [0.272, 1.774] 0.447 
NUMBER OF YEARS SINCE HIV DIAGNOSIS (AT STUDY 
SCREENING) 
1.002 [0.921, 1.090] 0.963 1.003 [0.915, 1.100] 0.953 0.993 [0.906, 1.089] 0.884 
PAST TB HISTORY (NO VS PAST TB) 0.672 [0.321, 1.407] 0.292 1.144 [0.424, 3.087] 0.790 1.176 [0.431, 3.209] 0.751 
IUD (NO IUD VS WITH IUD) 1.050 [0.693, 1.590] 0.819 0.941 [0.549, 1.616] 0.826 0.901 [0.520, 1.561] 0.709 
BACTERIAL STI       
TRICHOMONAS (NOT DETECTED VS DETECTED) 1.255 [0.594, 2.651] 0.553 1.184 [0.426, 3.291] 0.746 1.117 [0.395, 3.161] 0.835 
GONORRHEA (NOT DETECTED VS DETECTED) 2.572 [1.031, 6.421] 0.043 1.354 [0.394, 4.646] 0.630 0.933 [0.285, 3.060] 0.909 
CHLAMYDIA (NOT DETECTED VS DETECTED) 5.724 [1.687, 19.427] 0.005 2.883 [0.862, 9.646] 0.086 3.628 [1.070, 12.307] 0.039 
BACTERIAL VAGINOSIS (NOT DETECTED VS 
DETECTED) 
1.174 [0.550, 2.506] 0.678 1.001 [0.421, 2.381] 0.998 1.068 [0.444, 2.575] 0.882 
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*Unadjusted model: Logistic regression model on each variate only, clustered using participant ID, to pool all data collected from participants 
between baseline to 6 month visit. 
**Adjusted model A: Logistic regression model on outcome of HIV shedding in the genital tract (no shedding vs shedding), adjusted for all other 
co-variates (ART status, no plasma HIV VL), clustered using participant ID, to pool all data collected from participants between baseline to 6 
month visit. 
***Adjusted model B: Logistic regression model on outcome of HIV shedding in the genital tract (no shedding vs shedding), adjusted for all 
other co-variates (ART status combined with plasma HIV VL), clustered using participant ID, to pool all data collected from participant between 
baseline to 6 month visit. 
 
 
  
VIRAL STI       
HIGH RISK HPV (NOT DETECTED VS DETECTED 1.830 [1.060, 3.160] 0.030 1.309 [0.736, 2.328] 0.360 1.326 [0.739, 2.377] 0.344 
GENITAL HSV-2 (NOT DETECTED VS DETECTED) 3.438 [1.179, 10.024] 0.024 2.767 [0.876, 8.739] 0.083 2.940 [0.886, 9.757] 0.078 
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Table C-4b: Unadjusted and adjusted logistic regression models of the association between no detectable hrHPV and detectable hrHPV in the 
cervical region  
 UNADJUSTED MODELS* ADJUSTED MODEL A** ADJUSTED MODEL B*** 
VARIABLES OR [95% CI] P-value aOR [95% CI] P-value aOR [95% CI] P-value 
ART STATUS (ART-NAÏVE VS ART-USING) 0.610 [0.320, 1.164] 0.134 0.615 [0.237, 1.595] 0.318   
ART AND PLASMA HIV SUPPRESSION       
ART-NAÏVE Default Reference    Default Reference  
ART PLASMA HIV VL (0-49 COPIES/ML)* 0.583 [0.296, 1.150] 0.120   0.548 [0.230, 1.308] 0.175 
ART PLASMA HIV VL (50-999 COPIES/ML) 0.713 [0.229, 2.220] 0.559   0.557 [0.129, 2.397] 0.432 
ART PLASMA HIV VL (1000-9999 COPIES/ML) 1.267 [0.217, 7.378] 0.793   1.017 [0.103, 10.087] 0.989 
ART PLASMA HIV VL (≥10000 COPIES/ML) 0.792 [0.151, 4.140] 0.782   0.514 [0.073, 3.630] 0.505 
BASELINE DEMOGRAPHIC       
AGE 0.990 [0.927, 1.059] 0.779 1.005 [0.935, 1.081] 0.884 1.006 [0.935, 1.081] 0.879 
WEIGHT 0.997 [0.984, 1.009] 0.582 0.997 [0.984, 1.010] 0.632 0.997 [0.984, 1.010] 0.641 
HIGHEST LEVEL OF EDUCATION (<GRADE 10 VS 
GRADE 10 AND ABOVE) 
1.165 [0.360, 3.762] 0.799 1.380 [0.374, 5.085] 0.629 1.440 [0.390, 5.319] 0.585 
OCCUPATION STATUS  (UNEMPLOYED VS EMPLOYED) 1.003 [0.499, 2.013] 0.994 0.648 [0.298, 1.408] 0.273 0.646 [0.294, 1.417] 0.275 
CURRENT PARTNERSHIP (SINGLE VS IN 
RELATIONSHIP 
0.803 [0.346, 1.863] 0.610 0.846 [0.320, 2.237] 0.736 0.849 [0.325, 2.214] 0.737 
NUMBER OF YEARS SINCE HIV DIAGNOSIS (AT STUDY 
SCREENING) 
0.985 [0.903, 1.074] 0.726 0.990 [0.891, 1.099] 0.846 0.993 [0.894, 1.102] 0.892 
PAST TB HISTORY (NO VS PAST TB) 1.047 [0.399, 2.747] 0.926 1.148 [0.361, 3.646] 0.815 1.129 [0.326, 3.904] 0.848 
IUD (NO IUD VS WITH IUD) 0.813 [0.580, 1.140] 0.819 0.841 [0.579, 1.220] 0.361 0.848 [0.584, 1.230] 0.385 
BACTERIAL STI       
TRICHOMONAS (NOT DETECTED VS DETECTED) 1.998 [0.774, 5.158] 0.153 1.714 [0.596, 4.924] 0.317 1.639 [0.591, 4.547] 0.343 
GONORRHEA (NOT DETECTED VS DETECTED) 2.526 [0.807, 7.908] 0.111 1.851 [0.614, 5.584] 0.274 1.925 [0.568, 6.518] 0.293 
CHLAMYDIA (NOT DETECTED VS DETECTED) 1.146 [0.369, 3.567] 0.813 1.049 [0.281, 3.913] 0.943 1.047 [0.280, 3.909] 0.946 
BACTERIAL VAGINOSIS (NOT DETECTED VS 
DETECTED) 
1.267 [0.634, 2.531] 0.503 1.043 [0.482, 2.263] 0.913 1.008 [0.456, 2.227] 0.984 
VIRAL STI       
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GENITAL HIV (NOT DETECTED VS DETECTED 1.830 [1.060, 3.160] 0.030 1.308 [0.733, 2.336] 0.364 1.331 [0.739, 2.397] 0.341 
GENITAL HSV-2 (NOT DETECTED VS DETECTED) 4.25 [1.206, 14.973] 0.024 3.632 [0.989, 13.337] 0.052 3.650 [0.982, 13.568] 0.053 
*Unadjusted model: Logistic regression model on each variate only, clustered using participant ID, to pool all data collected from participants 
between baseline to 6 month visit. 
**Adjusted model A: Logistic regression model on outcome of hrHPV shedding in the genital tract (no shedding vs shedding), adjusted for all 
other co-variates (ART status, no plasma HIV VL), clustered using participant ID, to pool all data collected from participants between baseline to 
6 month visit. 
***Adjusted model B: Logistic regression model on outcome of hrHPV shedding in the genital tract (no shedding vs shedding), adjusted for all 
other co-variates (ART status combined with plasma HIV VL), clustered using participant ID, to pool all data collected from participants 
between baseline to 6 month visit. 
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Table C-4c: Unadjusted and adjusted logistic regression models of the association between no detectable HSV-2 shedding and presence of 
shedding in the genital tract  
 UNADJUSTED MODELS* ADJUSTED MODEL A** ADJUSTED MODEL B*** 
VARIABLES OR [95% CI] P-value aOR [95% CI] P-value aOR [95% CI] P-value 
ART STATUS (ART-NAÏVE VS ART-USING) 0.490 [0.180, 1.335] 0.163 0.465 [0.103, 2.103] 0.320   
ART AND PLASMA HIV SUPPRESSION       
ART-NAÏVE Default reference    Default reference  
ART PLASMA HIV VL (0-49 COPIES/ML)* 0.443 [0.146, 1.340] 0.149   0.501 [0.122, 2.056] 0.338 
ART PLASMA HIV VL (50-999 COPIES/ML) 1.284 [0.263, 6.266] 0.757   1.742 [0.228, 13.302] 0.593 
ART PLASMA HIV VL (1000-9999 COPIES/ML) 1 (omitted)    1 (omitted)  
ART PLASMA HIV VL (≥10000 COPIES/ML) 1 (omitted)    1 (omitted)  
BASELINE DEMOGRAPHIC       
AGE 1.011 [0.917, 1.115] 0.822 0.985 [0.881, 1.102] 0.791 0.986 [0.878, 1.107] 0.810 
WEIGHT 1.006 [0.988, 1.025] 0.524 1.003 [0.986, 1.021] 0.732 1.004 [0.986, 1.023] 0.648 
HIGHEST LEVEL OF EDUCATION (<GRADE 10 VS 
GRADE 10 AND ABOVE) 
1.636 [0.227, 11.782] 0.625 0.836 [0.140, 4.974] 0.844 0.729 [0.139, 3.827] 0.709 
OCCUPATION STATUS  (UNEMPLOYED VS EMPLOYED) 1.609 [0.577, 4.491] 0.364 1.854 [0.597, 5.752] 0.285 2.133 [0.654, 6.955] 0.209 
CURRENT PARTNERSHIP (SINGLE VS IN 
RELATIONSHIP 
0.511 [0.156, 1.671] 0.266 0.900 [0.201, 4.040] 0.891 0.909 [0.193, 4.274] 0.904 
NUMBER OF YEARS SINCE HIV DIAGNOSIS (AT STUDY 
SCREENING) 
1.104 [0.914, 1.333] 0.304 1.062 [0.887, 1.273] 0.508 1.060 [0.880, 1.277] 0.541 
PAST TB HISTORY (NO VS PAST TB) 1.095 [0.324, 3.704] 0.884 1.998 [0.429, 9.295] 0.378 1.544 [0.320, 7.444] 0.589 
IUD (NO IUD VS WITH IUD) 1.152 [0.418, 3.174] 0.785 1.512 [0.428, 5.346] 0.521 1.510 [0.428, 5.324] 0.521 
BACTERIAL STI       
TRICHOMONAS (NOT DETECTED VS DETECTED) 3.631 [1.310, 10.060] 0.013 4.628 [1.464, 14.629] 0.009 4.163 [1.312, 13.203] 0.015 
GONORRHEA (NOT DETECTED VS DETECTED) 0.901 [0.106, 7.633] 0.924 0.562 [0.035, 9.115] 0.685 0.867 [0.048, 15.786] 0.923 
CHLAMYDIA (NOT DETECTED VS DETECTED) 1.038 [0.161, 6.693] 0.969 0.321 [0.071, 1.453] 0.140 0.325 [0.071, 1.479] 0.146 
BACTERIAL VAGINOSIS (NOT DETECTED VS 
DETECTED) 
1.786 [0.565, 5.647] 0.324 1.920 [0.485, 7.599] 0.353 2.240 [0.532, 9.437] 0.272 
VIRAL STI       
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GENITAL HIV (NOT DETECTED VS DETECTED 3.438 [1.179, 10.024] 0.024 2.562 [0.777, 8.447] 0.122 2.609 [0.782, 8.710] 0.119 
HIGH RISK HPV (NOT DETECTED VS DETECTED 4.25 [1.206, 14.973] 0.024 3.540 [0.939, 13.344] 0.062 3.512 [0.911, 13.540] 0.068 
*Unadjusted model: Logistic regression model on each variate only, clustered using participant ID, to pool all data collected from participants 
between baseline to 6 month visit. 
**Adjusted model A: Logistic regression model on outcome of HSV-2 shedding in the genital tract (no shedding vs shedding), adjusted for all 
other co-variates (ART status, no plasma HIV VL), clustered using participant ID, to pool all data collected from participants between baseline to 
6 month visit. 
***Adjusted model B: Logistic regression model on outcome of HSV-2 shedding in the genital tract (no shedding vs shedding), adjusted for all 
other co-variates (ART status combined with plasma HIV VL), clustered using participant ID, to pool all data collected from participants 
between baseline to 6 month visit. 
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Table C-5: Unadjusted and adjusted logistic regression models of the association between one or less viral STI and more than one viral STI in the 
genital tract 
 UNADJUSTED MODELS* ADJUSTED MODEL A** ADJUSTED MODEL B*** 
VARIABLES OR [95% CI] P-value aOR [95% CI] P-value aOR [95% CI] P-value 
ART STATUS (ART-NAÏVE VS ART-USING) 0.289 [0.146, 0.570] <0.001 0.273 [0.104, 0.716] 0.008   
ART AND PLASMA HIV SUPPRESSION       
ART-NAÏVE Default reference    Default reference  
ART PLASMA HIV VL (0-49 COPIES/ML)* 0.257 [0.123, 0.538] <0.001   0.235 [0.097, 0.572] 0.001 
ART PLASMA HIV VL (50-999 COPIES/ML) 0.315 [0.101, 0.983] 0.047   0.250 [0.063, 0.988] 0.048 
ART PLASMA HIV VL (1000-9999 COPIES/ML) 1 (omitted)    1 (omitted)  
ART PLASMA HIV VL (≥10000 COPIES/ML) 1.176 [0.295, 4.680] 0.819   0.665 [0.117, 3.787] 0.646 
BASELINE DEMOGRAPHIC       
AGE 1.013 [0.946, 1.085] 0.701 1.008 [0.936, 1.086] 0.830 1.006 [0.933, 1.084] 0.881 
WEIGHT 1.002 [0.992, 1.012] 0.699 0.998 [0.987, 1.008] 0.634 0.997 [0.987, 1.008] 0.617 
HIGHEST LEVEL OF EDUCATION (<GRADE 10 VS 
GRADE 10 AND ABOVE) 
1.109 [0.321, 3.835] 0.871 0.963 [0.256, 3.626] 0.955 0.959 [0.253, 3.637] 0.951 
OCCUPATION STATUS  (UNEMPLOYED VS EMPLOYED) 1.343 [0.642, 2.810] 0.434 1.002 [0.450, 2.230] 0.997 1.009 [0.453, 2.248] 0.982 
CURRENT PARTNERSHIP (SINGLE VS IN 
RELATIONSHIP 
0.334 [0.134, 0.832] 0.019 0.610 [0.210, 1.773] 0.364 0.625 [0.214, 1.826] 0.390 
NUMBER OF YEARS SINCE HIV DIAGNOSIS (AT STUDY 
SCREENING) 
1.045 [0.946, 1.154] 0.388 1.053 [0.947, 1.171] 0.340 1.045 [0.936, 1.166] 0.435 
PAST TB HISTORY (NO VS PAST TB) 0.786 [0.360, 1.718] 0.546 1.392 [0.465, 4.172] 0.555 1.476 [0.462, 4.717] 0.511 
IUD (NO IUD VS WITH IUD) 0.836 [0.528, 1.322] 0.443 0.825 [0.490, 1.388] 0.468 0.798 [0.477, 1.333] 0.388 
BACTERIAL STI       
TRICHOMONAS (NOT DETECTED VS DETECTED) 1.255 [0.594, 2.651] 0.553 1.403 [0.484, 4.068] 0.533 1.491 [0.532, 4.179] 0.448 
GONORRHEA (NOT DETECTED VS DETECTED) 2.572 [1.031, 6.421] 0.043 2.216 [0.483, 10.157] 0.306 1.836 [0.427, 7.895] 0.414 
CHLAMYDIA (NOT DETECTED VS DETECTED) 5.724 [1.687, 19.427] 0.005 1.868 [0.580, 6.012] 0.295 2.174 [0.675, 7.005] 0.193 
BACTERIAL VAGINOSIS (NOT DETECTED VS 
DETECTED) 
1.174 [0.550, 2.506] 0.678 0.977 [0.401, 2.378] 0.959 1.059 [0.429, 2.614] 0.901 
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*Unadjusted model: Logistic regression model on each variate only, clustered using participant ID, to pool all data collected from participants 
between baseline to 6 month visit. 
**Adjusted model A: Logistic regression model on outcome of viral STI shedding in the genital tract (one or less vs 2 or more viral STI), 
adjusted for all other co-variates (ART status, no plasma HIV VL), clustered using participant ID, to pool all data collected from participants 
between baseline to 6 month visit. 
***Adjusted model B: Logistic regression model on outcome of viral STI shedding in the genital tract (one or less vs 2 or more viral STI), 
adjusted for all other co-variates (ART status combined with plasma HIV VL), clustered using participant ID, to pool all data collected from 
participant between baseline to 6 month visit. 
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4. Discussion 
 
In this cohort of HIV-infected women HIV, HSV-2 and HPV were prevalent in the genital tract of more 
than half of participants and were closely associated with HIV plasma VL. In the ART-Naïve group the 
shedding of HIV appeared considerably higher than in the ART-Using group suggesting that ART use may 
have an effect on HIV shedding in the genital tract. However genital shedding of HIV was still detectable 
even in women using ART- a finding with implications for ongoing HIV prevention efforts.  
 
Our analysis demonstrated that the ART-Using (virally suppressed) women were less likely to shed HIV, 
HSV-2 and HPV in the genital tract compared to ART-Naïve women. This may be driven by plasma VL 
levels where ART-Using women with lower VL are less likely to shed these viruses compared to women 
with elevated VL, including those not on ART. The bidirectional, mutualistic relationship between HIV 
and other viral STIs has been well documented (14, 29, 32) however our data are novel in showing a direct 
correlation between plasma VL and shedding of viral STIs in the female genital tract.  
 
The prevalence of low-risk and high-risk HPV types was high in this cohort where 37% of women were 
detected with HPV consistently across study visits. This high prevalence of HPV in HIV-infected women 
is well-documented in South Africa (40, 41). Past studies have shown that HPV, particularly high-risk 
HPV, tends to be more persistent in HIV-infected females and has been suggested to increase the risk of 
progressive invasive cancer (42-44). However, data on the effects of ART on HPV shedding remain 
inconclusive. Interestingly, in our cohort no significant differences in rates of detection were found 
between the ART-naïve and ART-treated group for either total or high-risk HPV detection. Similarly, in 
the regression models, no variables, including co-infections, were associated with HPV detection (for both 
low-risk and high-risk).  
 
While 94% of the cohort was IgG positive for HSV-2 reflecting previous infection, HSV-2 shedding in the 
genital tract was uncommon, involving only17% of women. This relatively low prevalence has been 
reported by other studies and is in keeping with the biology of HSV-2 where genital shedding is episodic 
(19, 45). In addition, although HSV-2 appeared to be a risk factor that increases high-risk HPV shedding, 
our analysis is inconclusive given the low prevalence of HSV-2 shedding in this cohort. HSV-2 as a risk 
factor for HPV shedding thus remains an important issue for further research. 
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We found a high prevalence of viral STI co-infection in the genital tract in this cohort, mainly involving 
HIV and HPV together, particularly in ART-Naïve women. This correlates with the past literature in regard 
to the bidirectional relationship between HIV and other viral STIs (21, 30), with ART-Using women 
appearing less likely to shed more than one viral STI in the genital tract. This is not surprising as ART 
treatment leads to a reduction in plasma HIV viral load and restores the host’s immune system, thereby 
reducing the risks of viral shedding.  
 
Apart from ART use and plasma viral load, we identified few other potential predictors of HIV, HSV-2 
and HPV in the genital tract. Data showed that the presence of Chlamydia increased the risk of HIV 
shedding. Consistent with these data, other studies indicated that both Gonorrhea and Chlamydia may 
increase HIV shedding and result in increased risk of HIV transmission (30, 46). Related to this, several 
studies have explored the connection between bacterial infections in the female genital tract and persistent 
infection of HPV (23, 47, 48). In these data, Gonorrhea appeared associated with increased hrHPV 
shedding; while this did not achieve statistical significance, the association between bacterial STI and 
hrHPV in the female genital track is an important avenue for future research. Our study showed that the 
presence of either Trichomonas or Bacterial Vaginosis lead to increased risk of shedding of HSV-2 in the 
genital tract (Table C-4c). Although the association of Bacterial Vaginosis in our cohort was not 
statistically significant, this association is in keeping with previous research that reported comparable result 
(49-51). Interestingly, Chlamydia was a strong risk factor for both the shedding of HIV and the co-
occurrence of viral STI in the genital region. However, there was no significant association between 
Chlamydia and HSV-2 and high-risk HPV. Future work needs to be carried out to understand what role 
Chlamydia plays that may result in recruiting other STIs, and particularly HIV, into the genital region as 
this potentially poses a high risk of HIV transmission despite the use of ART treatment. 
 
These data should be interpreted in light of several strengths and limitations. The low prevalence of HSV-
2 shedding in this cohort is not unusual, but limited our power to detect associations involving this virus. 
In addition, while these data are novel in their prospective examination of viral co-infections, the short 
duration of follow-up limited our ability to document true persistence or remission of HPV (52, 53). Finally, 
while the measurement of plasma HIV VL is a major strength of this work, we did not have CD4+ cell 
counts routinely available, limiting our ability to understand how overall immune deficiency may influence 
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viral shedding. Finally, the data come from a trial of IUD types, and while IUD types did not affect 
shedding of any of the three viruses, and all analyses were adjusted for trial arm, it is important to remember 
that the measures here included this contraceptive type. 
 
In conclusion, ART use is as a critical factor that reduces shedding of HIV in the genital tract of women 
living with HIV, and although not statistically significant when adjusted for other factors, the presence of 
both HSV-2 and HPV may increase the risk of HIV shedding. Taken together, these results suggest that 
ART plays a major role in reducing the co-occurrence of STIs in the female genital tract.  
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INFORMED CONSENT FOR TRIAL SCREENING
Introduction 
This consent form contains information about the screening process for the intrauterine device 
(IUD) trial. The IUD trial is a research study. In order to be sure that you are informed about the 
screening process, we are asking you to read this consent form. If you are unable to read this 
consent form, a study staff member will read and explain it to you. Someone other than the 
study staff will be present during this procedure. If you agree to take part in this screening, you 
will be asked to sign this form or make your mark in the presence of a witness. You are only 
agreeing to be screened for the ability to join, but not to enter the IUD trial, with this consent. 
Your understanding and agreement is necessary before the screening process may start. 
This consent form might contain some words that are unfamiliar to you. Please ask us to explain 
anything that you do not understand. 
General information about the research 
We are from the Desmond Tutu human immunodeficiency virus (HIV) Centre at the University of 
Cape Town. We are doing a research study to compare two IUDs (also called loops) among HIV- 
positive women. The two IUDs will be the levonorgestrel intrauterine device (LNG IUD) (called 
Mirena) and the copper IUD. HIV-positive women in Cape Town will be in the trial. We want to 
find out if the two IUDs are similar in safety and acceptability for HIV-positive women.  Both 
IUDs are equally effective at preventing pregnancy. 
An IUD is a small T-shaped flexible device about the length of an egg that is inserted into the 
womb. The IUD is very good at preventing pregnancy for 5 – 10 years. Both IUDs work mainly 
by stopping the man’s sperm from reaching the woman’s egg. The IUD can be removed at any 
time if a person decides they want to become pregnant. The IUD may change menstrual 
bleeding patterns after insertion. 
Neither IUD protects against HIV or other sexually transmitted infections. The best way to 
prevent HIV infection and other infections is through the use of a barrier method such as the 
male condom. 
This form gives information to help you decide if you want to take part in screening to find out if 
you are eligible to join the IUD research study. You can ask any questions to help you decide 
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whether to be a part of the study or not. You may ask questions about the purpose of the 
research, what will be done during study visits, the possible risks and benefits and anything else 
about the research or this form that is not clear. When all of your questions are answered, you 
can decide if you would like to take part in this screening part of the study or not. We will give 
you a copy of this form. 
Your part in the research study 
We are asking you to take part in this screening because you are a woman 18 to 40 years old, 
inclusive, with known HIV infection and willing to answer screening questions and have some 
tests. We plan to talk to about 1000 women in this screening part of the study. This part of the 
study is being done to see if you are eligible to join the longer IUD study. You may or may not 
be able to join the longer IUD study, which will last up to 24 months. The screening process will 
be only your visit today and will last for about 3 hours. 
If you decide to volunteer for this screening part of the research: 
 We will ask you questions about your medical history contraceptive use, living
situation, sexual behavior and thoughts about family planning. 
 We will review your medical chart and your other accessible medical records at this
clinic for results of confirmation of your HIV status, your last CD4 cell count or viral 
load, Pap smear, and other information. We may ask you to bring documents with 
these results from other clinics if you have received care at other sites. If you agree to 
be screened for this study, we ask that you open a folder at the Gugulethu Community 
Health Centre (GCHC). Some of your medical information collected through this study 
will be recorded in this folder; however, you will not be identified as a study 
participant in your GCHC folder. 
 If we cannot document your HIV status with your medical records, we will ask you to
have HIV counseling and a test at the study clinic today. 
 You will give urine for a pregnancy test. If you are pregnant, you cannot participate in
the study and will be referred for care. Also, if you plan to become pregnant in the 
next two years, you cannot participate in the study. 
 We will contact you by telephone if it is necessary to return to the clinic for test
results and referrals for appropriate care. 
 You will have your blood collected and it will be tested for syphilis and, if you are not
taking antiretroviral therapy (ART), a CD4 count. 
 You will have an individual risk-reduction counseling session. 
 If you are currently menstruating, you will be asked to come again for the remainder
of the screening. You will be provided with another appointment for 2 days after 
bleeding has stopped. 
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 You will have a physical exam including a pelvic exam. A pelvic exam looks at the part 
of your womb that the doctor can see when looking into the vagina. We will take 
samples to test for infections passed through sex. We will give you free treatment for 
yourself and your partner(s) for any of the curable infections passed through sex that 
we find during your exam. 
 You will be asked questions about your understanding of the screening. 
 You will provide your contact information. 
 If you are eligible, an enrollment visit will be scheduled for you. It is important to 
know that all women who take part in the screening process may not be able to enroll 
in the IUD study. If you are scheduled for an enrollment visit and do not attend, we 
may call, text message (SMS), or visit you at your home to schedule follow-up and see 
if you would still like to participate in the study. 
 If you are not eligible or decide to withdraw from the study after screening begins, we 
would like to ask you a few brief questions about your age and family planning 
method choice before you leave. 
 You will sign this consent form or make your mark in front of a witness, if you decide 
to take part in this screening. 
If you do not want to do any of these procedures or tests, you do not have to take part in this 
screening. Your participation in this screening is voluntary. If you do not take part in the 
screening, you cannot take part in the longer IUD study. 
Whether or not you decide to participate in this screening will not affect your treatment and 
care at this clinic or other clinics. 
Possible risks 
Your participation in this part of the study will involve some risks. Some of the questions we ask 
will be of a personal nature, which may make you uncomfortable. 
With the blood draw, there may be slight pain when a needle is inserted into your arm to get 
the blood sample. There may be minor bruising or pain that may last for up to 2-3 days at the 
site of the blood draw. Although rare, you may become lightheaded (feel dizzy) or faint when 
you have blood drawn, and there is a very small risk of infection at the site from where we take 
your blood. 
We will minimize the risks of bruising or infection by cleaning your skin before using a needle to 
draw blood. We will use a new needle for each person. We will also apply pressure and a 
bandage to the site after we are done. These discomforts are usually small. If you get an 
infection because of the blood draw, we will treat you here. 
The visit will involve collecting cells inside the vagina with a swab and may feel uncomfortable 
and you may experience a bit of spotting afterward. 
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Possible benefits 
You will receive free condoms. We will demonstrate how to use them. 
You will receive individual risk-reduction counseling. 
You will be screened and we will give you and your partner free treatment for any of the curable 
infections passed through sex that we find during your exam for free. 
There are no other direct benefits to participating, but if you need referral for additional 
services, we will assist with this. The information you give may help us to understand ways to 
improve IUD use for women living with HIV in the Cape Town area. 
Choosing to be in this study 
You do not have to join this research study if you do not want to. If you join, you can leave at 
any time. You also have the right to refuse to answer any specific questions, or to end the 
interview at any time without penalty. 
If you choose not to take part in the screening, the staff will ask you to participate in a portion of 
the study for women not interested in participating in the IUD trial. If you do not want to sign 
the consent form today, you are welcome to return at a later date if you decide you want to be 
screened. Once we start the screening process, if you decide to stop, you cannot take part in 
the screening process again. 
If you are eligible but are not able to come for enrollment within 28 days of your screening visit, 
you will need repeat the enrollment process, including consent, before you can enroll in the IUD 
study. 
Confidentiality 
Any information collected during this study that can identify you by name will be kept 
confidential. This includes all medical record reports we review to determine whether you can 
join the IUD trial. These record documents will be kept in a chart that is kept in a locked office; 
only study staff will be able to see this chart. We will do everything we can to keep your data 
secure, but complete confidentiality cannot be promised. Your name will not appear in any 
study reports or on any blood samples. Despite all of our efforts, unanticipated problems such 
as a stolen computer could occur, although it is highly unlikely. Your specimens and 
questionnaire answers will be assigned a code number, and separated from your name or any 
other information that could identify you. 
The following individuals and/or agencies will be able to look at and copy your research records 
(such as this consent form, completed questionnaires, lab results, etc.): 
 The investigator, study staff and other medical professionals who may be evaluating the 
study; 
Authorities from the University of Cape Town, including the Institutional Review Board 
(IRB); 
Authorities from FHI 360, including the Protection of Human Subjects Committee 
(PHSC); 


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 The United States Food and Drug Administration ('FDA') and/or the Office of Human 
Research Protections ('OHRP'); 
The sponsors of this study, NIH, USAID, including persons or organizations working with 
or owned by the sponsor; 
Other South African government regulatory agencies. 


Compensation 
You will receive compensation valued at 150 Rand at this screening visit. This is for your time 
and travel costs. 
If there is anything that is unclear or if you need further information, please ask us and we will 
provide it. Do you have any questions? 
Contacts for more information 
If you have any questions or are hurt while taking part in this research study, you should 
contact: 
Dr. B. Landon Myer 
School of Public Health and Family Medicine 
Faculty of Health Sciences, University of Cape Town (UCT) 
Tel: +27 21 406 6661 or the study clinic at 074-931-6740 
Email: Landon.Myer@uct.ac.za 
If you are sick or have a health problem due to taking part in the screening process, you will not 
have to pay to see study staff. If you need more help, we will refer you to other clinics, where 
you may have to pay. 
Your Rights as a Participant 
Before a research study can be carried out, it must be approved by an ethics committee. An 
ethics committee is a group of people who review details of a proposed research study and 
determine whether the research may be conducted. Their main goal is to help protect 
participants. 
This protocol has been approved by the ethics committees of: 


The University of Cape Town and 
FHI 360 (Protection of Human Subjects Committee). 
If you have any questions about how you are being treated by the study your rights as a 
research participant, you may contact: 
UCT Ethics Committee 
Prof. Marc Blockman 
 
Chair, Human Research Ethics Committee 
Faculty of Health Sciences, UCT 
Tel: +27 21 406 6338 
You may also contact: 
FHI 360 Protection of Human Subject Committee 
P. O. Box 21059 
Durham, NC 27703, USA 
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Tel: +1 919 405 1445 
Email: phsc@fhi360.org 
If you have questions about this trial you should first discuss them with your doctor or the ethics 
committee (contact details as provided on this form). After you have consulted your doctor or 
the ethics committee and if they have not provided you with answers to your satisfaction, you 
should write to the South African Medicines Control Council (MCC) at: 
The Registrar of Medicines 
Medicines Control Council 
Department of Health 
Private Bag X828 
PRETORIA 
0001 
Fax: (012) 395 9201 
e-mail: mogobm@health.gov.za 
VOLUNTEER AGREEMENT 
I understand that the purpose of this part of the study is to find participants for a research study 
titled “Comparison of Two IUDs among Cape Town HIV-positive Women.” The study will 
compare two IUDs among HIV-positive women. 
I have read the information in the informed consent form, or it has been read to me. I have had 
the opportunity to ask questions about it, and the questions that I have asked have been 
answered to my satisfaction. I consent voluntarily to be screened for possible participation in 
the IUD study. I understand that this session is screening for possible entry into the IUD study 
and I am only consenting to screening at this time. I understand that I have the right to 
withdraw from this screening session at any time without affecting the care that I can get at this 
clinic or other clinics. 
Printed Name of Volunteer Date 
Signature (or mark) of Volunteer Date 
If a volunteer cannot read the form for herself, a witness must sign here: 
I was present while all information in this consent form, including the benefits, risks and 
procedures were read to the volunteer. All questions were answered and the volunteer has 
agreed to take part in the research. 
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Printed Name of Witness Date 
Signature of Witness Date 
I certify that all information in this consent form, including the nature and purpose, the 
potential benefits, and possible risks associated with participating in this study have been 
explained to the volunteer. 
Printed Name of Person Who Obtained Consent Date 
Signature of Person Who Obtained Consent Date 
A signed copy of this consent form was offered to the participant. 
Initials of Person Who Obtained Consent Date 
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VERBAL INFORMED CONSENT FOR DECLINERS/INELIGIBLE 
We are from the Desmond Tutu HIV Centre at the University of Cape Town. We are collecting 
information from women who declined entry or are ineligible for entry into the Intrauterine 
Device (IUD) trial during the screening process. We want to find out their thoughts about IUDs 
and other birth control methods. 
Your participation in this part of the study is voluntary. Whether or not you decide to 
participate in this study will not affect your treatment and care at this clinic or other clinics. 
If you decide to participate: 
 You will meet with a study staff for about 10 minutes to complete a brief anonymous 
questionnaire. 
 We will ask about your thoughts of IUDs and other birth control methods. 
 We will ask about your past and current contraceptive use and other basic information 
such as your age and education. 
 Your name will not be collected or recorded; the information will be completely 
anonymous. 
 You do not have to join this study if you do not want to. If you do join, you can refuse to 
answer any questions, or to end the interview at any time without penalty. 
 The information you provide may help us to find ways to improve IUD use. The 
information may improve family planning use for women living with HIV in Cape Town. 
Possible risks 
Your participation in this part of the study may involve risks. Some of the questions we ask will 
be of a personal nature, which may make you uncomfortable. 
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Possible benefits 
There are no direct benefits to participating. If you need referral for additional services, we will 
assist with this. 
Data Confidentiality 
No information will be collected during this study that can identify you by name. We will do 
everything we can to keep your data secure, however, complete confidentiality cannot be 
promised. Despite all of our efforts, unanticipated problems, such as a stolen computer may 
occur, although it is highly unlikely. Your responses will be assigned a code number separate 
from the screening process, and your name will not be collected. 
The following individuals and/or agencies will be able to look at and copy your research records: 
 The investigator, study staff and other medical professionals who may be evaluating the 
study; 
 Authorities from the University of Cape Town, including the Institutional Review Board 
(IRB); 
 Authorities from FHI 360, including the Protection of Human Subjects Committee (PHSC); 
 The United States Food and Drug Administration ('FDA') and/or the Office of Human 
Research Protections ('OHRP'); 
 The sponsors of this study, NIH, USAID, including persons or organizations working with or 
owned by the sponsor; 
 Other South African government regulatory agencies. 
Compensation 
You will not receive compensation for participating in this portion of the study. 
If there is anything that is unclear or if you need further information, please ask us and we will 
provide it. Do you have any questions? 
Contacts for more information 
If you have any questions or are hurt while taking part in this research study, you should 
contact: 
Dr. B. Landon Myer 
School of Public Health and Family Medicine 
Faculty of Health Sciences, University of Cape Town (UCT) 
Tel: +27 21 406 6661 or the study clinic at 074-931-6740 
Email: Landon.Myer@uct.ac.za 
Your Rights as a Participant 
Before a research study can be carried out, it must be approved by an ethics committee. An 
ethics committee is a group of people who review details of a proposed research study and 
determine whether the research may be conducted. Their main goal is to help protect 
participants. 
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This protocol has been approved by the ethics committees of: 


The University of Cape Town and 
FHI 360 (Protection of Human Subjects Committee). 
If you have any questions about how you are being treated by the study your rights as a 
research participant, you may contact: 
UCT Human Research Ethics Committee 
Prof. Marc Blockman 
Chair, Human Research Ethics Committee 
Faculty of Health Sciences, UCT 
Tel: +27 21 406 6338 
You may also contact: 
FHI 360 Protection of Human Subject Committee 
P. O. Box 21059 
Durham, NC 27703, USA 
Tel: +1 919 405 1445 
Email: phsc@fhi360.org 
If you have questions about this trial you should first discuss them with your doctor or the ethics 
committee (contact details as provided on this form). After you have consulted your doctor or 
the ethics committee and if they have not provided you with answers to your satisfaction, you 
should write to the South African Medicines Control Council (MCC) at: 
The Registrar of Medicines 
Medicines Control Council 
Department of Health 
Private Bag X828 
PRETORIA 
0001 
Fax: (012) 395 9201 
e-mail: mogobm@health.gov.za 
VERIFICATION OF VOLUNTEER AGREEMENT 
I was present while all information in this informed consent, including the benefits, risks and 
procedures, were read to the volunteer. All questions were answered and the volunteer has 
verbally agreed to take part in this research. 
Printed Name of Witness Date 
Signature of Witness 
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I certify that all information in this consent form, including the nature and purpose, the 
potential benefits, and possible risks associated with participating in this study have been 
explained to the volunteer. 
Printed Name of Person Who Obtained Consent Date 
Signature of Person Who Obtained Consent Date 
A signed copy of this consent form was offered to the participant. 
Initials of Person Who Obtained Consent Date 
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INFORMED CONSENT FOR TRIAL ENTRY 
Introduction 
This consent form contains information about the intrauterine device (IUD) trial. The IUD trial is 
a research study. In order to be sure that you are informed about the research study, we are 
asking you to read this consent form. If you are unable to read this consent form, a study staff 
member will read and explain it to you. Someone other than the study staff will be present 
during this procedure. If you agree to take part in this study, you will be asked to sign this form 
or make your mark in the presence of a witness. 
This consent form might contain some words that are unfamiliar to you. Please ask us to explain 
anything that you do not understand. 
General information about the research 
We are from the Desmond Tutu HIV Centre at the University of Cape Town. We are doing a 
research study to compare two IUDs (“loops”) among HIV-positive women. The two IUDs will be 
the levonorgestrel IUD (LNG IUD) (called Mirena) and the copper IUD. HIV-positive women in 
Cape Town will be in the trial. We want to find out if the two IUDs are similar in safety and 
acceptability for HIV-positive women. The IUDs are equally effective at preventing pregnancy. 
An IUD (also called a loop) is a small T-shaped flexible device about the length of an egg that is 
inserted into the womb. The IUD is very good at preventing pregnancy for 5 – 10 years. Both 
IUDs work mainly by stopping the man’s sperm from reaching the woman’s egg. The IUD can be 
removed at any time if a person decides they want to become pregnant. The IUD may change 
menstrual bleeding patterns after insertion, including causing menstrual bleeding to stop. This 
is not harmful to you and does not change likelihood of future fertility. 
Neither IUD protects against human immunodeficiency virus (HIV) or other sexually transmitted 
infections. The best way to prevent HIV and other infections is through the use of a barrier 
method such as the male condom. 
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You have completed the screening visit for this study and are eligible at this point to take part in 
the study. This form gives information to help you decide if you want to take part in a research 
study. The purpose of today’s enrollment visit is to explain all the details of the trial to you, 
review all your test results to confirm that you can take part in the study, obtain your consent to 
take part, and enroll you. 
You can ask any questions to help you decide whether to be a part of the study or not. You may 
ask questions about the purpose of the research, what will be done during study visits, the 
possible risks and benefits and anything else about the research or this form that is not clear. 
When all of your questions are answered, you can decide if you would like to take part in this 
study or not. 
Your part in the research study 
288 women will take part in this study. You have successfully completed the medical screening 
part of this study and are being asked to join the study. Women in the study are 18 to 40 years 
old with known HIV infection and either a CD4 count greater than the level for antiretroviral 
therapy (ART) eligibility by Western Cape Province guidelines with no acquired immune 
deficiency syndrome (AIDS)-defining conditions or taking ART with no HIV virus in blood at the 
last test. It is important for you to know that you must have a negative pregnancy test before 
joining this trial and have no plans to get pregnant in the next 2.5 years. 
Women in the study will be put into different groups. Each woman will receive one of the IUDs 
to use for 2 years. The IUD that you get will be chosen by a computer, and half of the women 
will get an LNG IUD and half of the women will get a copper IUD. Participants will have a 50/50 
chance (like tossing a coin) of being placed in one of two groups. But you will not know which 
kind of IUD you get. This does not mean that one IUD is less effective than the other as both are 
equally effective at preventing pregnancy. We do not know if there is a difference in safety 
between the two IUDs, which is why we are doing this study. Which IUD you get will be told to 
you at the end of the study or sooner if there is a scientific reason to do so. 
Taking part in this study will last up to 24 months and will include 5 visits after today. Each visit 
will last about 2 to 3 hours on 6 separate days, including today. 
If you decide to volunteer for this study, the schedule of study visits and the procedures that will 
be done at each visit are as follows: 
Enrollment/ Insertion visit 
 At today’s visit you should ask any questions about the study and anything you may not 
understand. Before you sign this consent form, please be sure that you understand 
what this study is about and what you will be asked to do. You will be asked questions 
about your understanding of the study. You will sign this consent form or make your 
mark in front of a witness, if you decide to take part in this study. You will be given a 
copy of the informed consent form. 
You will give a urine sample for a pregnancy test. If you are pregnant, you cannot take 
part in the study and will be referred for care. 
You will be randomly assigned by the computer to use one of the IUDs. 
We will ask you to insert a menstrual cup into the vagina to collect cells. The cup will be 
removed later by the nurse-practitioner during your examination. 



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 We will ask you personal questions about various areas, including your medical history, 
your current living and economic situation, your sexual relationships, and your attitudes 
about birth control and childbearing, within a baseline questionnaire. 
You will have your blood collected to check blood count to check for anemia and HIV 
viral load. 
You will have an individual risk-reduction counseling session. 
You will have a pelvic exam. A pelvic exam looks at the part of your womb that the 
doctor can see when looking into the vagina. We will remove the menstrual cup and 
take several sample of cells from your cervix and vagina, using swabs and a small 
amount of liquid. We will insert the IUD. 
You will receive counseling on symptoms and warning signs of IUD expulsion and pelvic 
inflammatory disease. 




Follow-up visits 
You will return to the clinic for a follow-up visit at 3, 6, 12, 18 and 24 months. You will be called 
a few days before your appointment as a reminder and, if you are bleeding, you will be asked to 
delay your visit until bleeding has stopped for at least 2 days. You will be asked to not insert 
anything in the vagina or have sexual intercourse for three days before each visit. We may call, 
text message (SMS), or visit you at home if you do not come for an appointment or to remind 
you of an upcoming appointment. 
At each visit: 
 You will be asked questions about your health, sexual behavior, and thoughts about 
using the IUD. 
You will give urine for a pregnancy test. 
You will have your blood collected to test for syphilis and check viral load. 
You will have a pelvic exam to check IUD position and collect cervical and vaginal cells 
with swabs to test for infections passed through sex. We will give you free treatment 
for any of the curable infections passed through sex that we find during your exam. We 
may not be able to do the testing for all infections immediately following your visit and 
will freeze those samples for possible testing at a later date. 
We will provide you with a disposable menstrual cup and ask you to place it in your 
vagina at the beginning of your visit. The cup will be removed at the time of 
examination and the nurse practitioner will take several samples of cells with swabs. 
You will have an individual risk-reduction counseling session. 
You will update your contact information if it changes. 






In addition at follow-up visits at 6, 12, 18, and 24 months: 
 You will have your blood collected to check blood count, viral load, and, if not on ART, 
CD4 count. You should always follow up at your home clinic for updated viral load 
testing. 
We will periodically review your medical chart and your other accessible medical records for any 
new laboratory results, including plasma viral loads if you are using ART, and other information 
that applies to your safety in this study. We may ask you to bring documents from other clinics 
if you have received care at other sites. 
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If you do not want to do any of these procedures or tests, you do not have to take part in this 
study. Your participation in this study is voluntary. If you choose to take part in this study, you 
cannot take part in another study that involves a biomedical intervention, like new types of ART 
medicine. Please discuss your participation in another study with study staff to determine 
eligibility. 
It is very important that you come to each scheduled visit. If you think you cannot keep your 
scheduled clinic visits over the next two years, please consider not taking part in this study. 
If you are not taking ART, if your CD4 count drops below the eligibility level for ART based on 
local guidelines or you develop AIDS-defining conditions during the study, you will be referred to 
a clinic for free HIV care and treatment services.  If this happens, you will be given a choice 
about whether you would like to keep your IUD or have it removed. You may remain in this 
study. If you are taking ART and are found to have increasing HIV levels in your blood based on 
plasma viral load results, you will be referred to your clinic for medication counseling and 
possible change. If this happens, you will be given a choice about whether you would like to 
keep your IUD or have it removed. You may remain in this study. 
You can come at any time for an unscheduled visit for IUD removal or for any other medical 
problem. If you decide to have the IUD removed, you may remain in the study with the same 
follow-up schedule and may change to a different method of birth control. We may interview 
you with questions about the IUD and why you chose to have it removed. If you become 
pregnant after IUD removal, we will refer you for appropriate care in the public sector health 
system. Obstetric care is not provided through the study. 
The 24 hour telephone number with which you can reach the study doctor or another 
authorized person will be provided to you before you complete the first visit. If you have any 
problems, please call the 24 hour telephone number and study staff can assist you in making an 
appointment. If you decide to leave the study before it is completed, you may keep the IUD. 
At the end of the study, you will be given the choice to keep your IUD in or have it removed. If 
you choose to keep it, we will tell you what type of IUD you have and how long it will remain 
effective for preventing pregnancy. You will need to visit your regular clinic and obtain a new 
IUD or other form of birth control when the period of effectiveness for your IUD is finished. We 
may call you after the end of the study visits to follow up on any medical conditions you 
experience during the study. You may come for care related to these issues at the study clinic 
after you complete all study visits. 
Future use of specimens 
We are specifically looking at the IUD in this study. However, the information (data) and 
samples being collected from all participants may also help answer other questions about HIV, 
other infections, or safety of other family planning methods. We may want to use your 
questionnaire information, blood and/or genital tract sample(s) so that other research studies 
can be done during or after this research study for up to 3 years.  
 
 
 
 
 
 
 
 
 
 
The researchers do not plan to contact you or your regular doctor with any results from tests 
done on your stored samples.  Should a rare situation come up where the researchers decide 
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that a specific test result could help your health, the researchers will try to notify your study 
doctor. Your study doctor will try to contact you. 
Your samples may be shipped to another country for storage and/or testing, because some of 
the tests may not be available in South Africa. Only approved researchers will have access to 
the samples and they will not have any information that identifies you. 
You can be in the IUD study and not agree to have these samples stored. You can withdraw 
your consent for the storage of your samples at any time. 
There are no additional risks involved in the long-term storage of samples compared to those in 
IUD study. 
Your participation in this research may benefit other women in the future by answering 
important research questions about HIV infection. 
There are no costs to you for agreeing to have your samples stored. 
You will not receive any additional compensation if you agree to have your samples stored long- 
term. Some research using blood or other samples allows the researchers to make medical tests 
or treatments that may have commercial value. If this happens, there are no plans to pay you 
for any products or treatments that are made, or for using your samples. 
Permission for use of coded specimens: 
Please initial below to indicate whether or not you give permission for your data and specimens 
to be used for research in addition to the core study. 
  (initial) I agree to have my specimens and data stored for future research by the 
investigators who are conducting this study or other research collaborators in related areas. 
  (initial) I do not consent to the use of my blood/genital tract sample for any reason 
outside of this specific study. 
Possible risks 
Your participation in this part of the study will involve some risks, which include: 
 Possible changes in the chance of HIV transmission to your male sexual partner. We do 
not know how use of the study IUDs affects the chance of infecting a sex partner with 
HIV. You should always use condoms during sex, and condoms will be offered to you at 
each study visit. 
Excessive bleeding with the copper IUD is a risk. 
Possible changes in your HIV disease with the LNG IUD. We know that the copper IUD 
does not affect HIV disease, but we do not know whether the LNG IUD does affect HIV 
disease. 


Other risks include problems that can happen with IUD insertion, like creating a hole in the 
uterus, having the IUD ejected from the uterus, pregnancy, and pelvic inflammatory disease. 
The IUD may also increase or decrease your menstrual bleeding. Heavy bleeding is possible and 
is a risk of the copper IUD and study staff should be notified with any bleeding similar to the 
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heaviest day of a normal period for 7 or more days. The risk of these events or conditions is 
quite low. 
Pregnancy with the IUD in place is very rare. If you get pregnant with the IUD in place, an 
ultrasound will be performed right away to find the location of the IUD and of the pregnancy. 
Depending on the location of the pregnancy and whether the IUD is still in the uterus, you will 
be counseled on your options. 
With the blood draw, there may be slight pain when a needle is inserted into your arm to get 
the blood sample. There may be minor bruising or pain that may last for up to 2-3 days at the 
site of the blood draw. Although rare, you may become lightheaded (feel dizzy) or faint when 
you have blood drawn, and there is a very small risk of infection at the site from where we take 
your blood. 
We will minimize the risks of bruising or infection by cleaning your skin before using a needle to 
draw blood. We will use a new needle for each person. We will also apply pressure and a 
bandage to the site after we are done. These discomforts are usually small. If you get an 
infection because of the blood draw, we will treat you here. 
The visit will involve collecting cells inside the vagina with a swab and possibly with a liquid. This 
process may feel uncomfortable and you may experience a bit of spotting afterward. 
There is no known risk associated with menstrual cups. There may be slight discomfort if the 
cup is not inserted correctly. You will be provided with clear instructions on how to insert the 
cup. 
Some of the questions we ask will be of a personal nature, which may make you uncomfortable. 
There may be other risks of taking part in this research study that we don't know about. If we 
learn about other risks, we will let you know what they are so that you can decide whether or 
not you want to continue to be in the study. If there are any future findings regarding the safety 
or acceptability of the IUDs we are investigating for HIV-positive women, we will also notify you. 
Possible benefits 
You will not have to pay for the LNG IUD, if you receive this IUD by chance, in this study, or for 
any tests that we do. 
You will receive free condoms. We will demonstrate how to use them. 
You will receive individual risk-reduction counseling with trained staff about the need for 
condom use for sexually transmitted infection and HIV transmission prevention, tips for 
negotiating condom use, and we will give you male and/or female condoms, if you wish. 
We will give you free treatment for any of the curable infections passed through sex that we 
find by nurse diagnosis or, where possible, infection tests, during your exams. 
There are no other direct benefits to being in the study. If you need referral for more care 
somewhere else, we will assist with this, but you may have to pay for care at other clinics. We 
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will not provide payment for injuries or complications resulting from being in the study but will 
provide or refer for appropriate care. Your participation in this research may benefit other 
women in the future by helping us understand IUD safety and acceptability in HIV positive 
women. 
Choosing to be in this study 
You do not have to take part in this study to get treatment for your condition. You may 
continue with routine HIV care and receive family planning methods at the Desmond Tutu HIV 
Center and/or Gugulethu Community Health Centre with no penalty. Whether or not you 
decide to join this study will not affect your treatment and care at this clinic or any other clinic. 
Confidentiality 
Any information collected during this study that can identify you by name will be kept 
confidential. We will do everything we can to keep your data secure, but complete 
confidentiality cannot be promised. Your name will not appear in any study reports or on any 
blood samples. Despite all of our efforts, unanticipated problems such as a stolen computer 
may occur, although it is highly unlikely. Your specimens and questionnaires will be assigned a 
code number, and separated from your name or any other information that could identify you. 
The following individuals and/or agencies will be able to look at and copy your research records 
(such as this consent form, completed questionnaires, lab results, etc.): 
 The investigator, study staff and other medical professionals who may be evaluating the 
study; 
Authorities from the University of Cape Town, including the Institutional Review Board 
(IRB); 
Authorities from FHI 360, including the Protection of Human Subjects Committee 
(PHSC); 
The United States Food and Drug Administration ('FDA') and/or the Office of Human 
Research Protections ('OHRP'); 
The sponsors of this study, NIH, USAID, including persons or organizations working with 
or owned by the sponsor; 
Other South African government regulatory agencies. 





Study staff may request copies of your medical records if you receive any treatment at any other 
facility. We will request your permission to look at these records. 
Compensation 
You will receive compensation valued at 150 Rand at this visit. You will receive compensation 
valued at 150 Rand at each study visit. This is for your time and travel costs. There is no 
compensation for missed visits. 
WHAT ABOUT INSURANCE? 
There are no experimental medicines being used in this study. Therefore no insurance has been 
obtained. However you will be protected in terms of the study staffs’ personal malpractice 
insurance or that of the university’s insurance cover in the event of injury or illness that is 
caused by you taking part in this study (details of this insurance cover are attached in appendix 
at the end of this document). 
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Leaving the Research 
You may leave this research study at any time. If you decide to stop taking part, please tell the 
study staff why you wish to leave. 
Also, you may be asked to leave the research if: 



The research doctor or study staff feel it is best for you, or 
You are not able to follow the study procedures, or 
The research is stopped. If the research is stopped, you may be asked additional 
questions about your participation in the study. You may choose not to answer these 
questions if you wish. 
We will tell you if we learn something new about the IUD that could affect your choice to stay in 
the study. When you are no longer in the research, you will still be able to receive care at this 
clinic. 
If there is anything that is unclear or if you need further information, please ask us and we will 
provide it. Do you have any questions? 
Contacts for more information 
If you have any questions after you leave the clinic, or if you are hurt while taking part in this 
research study, you should contact: 
Dr. B. Landon Myer 
School of Public Health and Family Medicine, 
Faculty of Health Sciences, University of Cape Town (UCT) 
Tel: +27 21 406 6661 or the study clinic at 074-931-6740 
Email: Landon.Myer@uct.ac.za 
If you are sick or have a health problem due to taking part in the study, you will not have to pay 
to see study staff. If you need more help, we will refer you to other clinics, where you may have 
to pay. 
Your Rights as a Participant 
Before a research study can be carried out, it must be approved by an ethics committee. An 
ethics committee is a group of people who review details of a proposed research study and 
determine whether the research may be conducted. Their main goal is to help protect 
participants. 
This protocol has been approved by the ethics committees of: 


The University of Cape Town and 
FHI 360 (Protection of Human Subjects Committee). 
If you have any questions about how you are being treated by the study your rights as a 
research participant, you may contact: 
UCT Ethics Committee 
Prof Marc Blockman 
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Chair, Human Research Ethics Committee 
Faculty of Health Sciences, University of Cape Town 
Tel: +27 21 406 6338 
You may also contact: 
FHI 360 Protection of Human Subject Committee 
P. O. Box 21059 
Durham, NC 27703, USA 
Tel: +1 919 405 1445 
Email: phsc@fhi360.org 
If you have questions about this trial you should first discuss them with your doctor or the ethics 
committee (contact details as provided on this form). After you have consulted your doctor or 
the ethics committee and if they have not provided you with answers to your satisfaction, you 
should write to the South African Medicines Control Council (MCC) at: 
The Registrar of Medicines 
Medicines Control Council 
Department of Health 
Private Bag X828 
PRETORIA 
0001 
Fax: (012) 395 9201 
e-mail: mogobm@health.gov.za 
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VOLUNTEER AGREEMENT 
I understand that the purpose of the research study titled “Comparison of Two IUDs among 
Cape Town HIV-positive Women,” is to compare the safety of two IUDs among HIV-positive 
women. 
I have read the information in the informed consent form, or it has been read to me. I have had 
the opportunity to ask questions about it, and the questions that I have asked have been 
answered to my satisfaction. I consent voluntarily to participate in this study.  I understand that 
I have the right to withdraw from the study at any time without affecting the care that I can get 
at this clinic or other clinics. 
Printed Name of Volunteer Date 
Signature (or mark) of Volunteer Date 
If a volunteer cannot read the form for herself, a witness must sign here: 
I was present while all information in this consent form, including the benefits, risks and 
procedures were read to the volunteer. 
agreed to take part in the research. 
All questions were answered and the volunteer has 
Printed Name of Witness Date 
Signature of Witness Date 
I certify that all information in this consent form, including the nature and purpose, the 
potential benefits, and possible risks associated with participating in this study have been 
explained to the volunteer. 
Printed Name of Person Who Obtained Consent Date 
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Signature of Person Who Obtained Consent Date 
A signed copy of this consent form was offered to the participant. 
Initials of Person Who Obtained Consent Date 
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Details of UCT’s no-fault insurance 
What if Something Goes Wrong? 
The University of Cape Town (UCT) has insurance cover for the event that research- 
related injury or harm results from your participation in the study. The insurer will pay all 
reasonable medical expenses in accordance with the South African Good Clinical 
Practice Guidelines (DoH 2006), based on the Association of the British Pharmaceutical 
Industry Guidelines (ABPI) in the event of an injury or side effect resulting directly from 
your participation in the study. You will not be required to prove fault on the part of the 
University. 
The University will not be liable for any loss, injuries and/or harm that you may sustain 
where the loss is caused by 
• The use of unauthorised medicine or substances during the study 
• Any injury that results from you not following the protocol requirements or the 
instructions that the study doctor may give you 
• Any injury that arises from inadequate action or lack of action to deal adequately 
with a side effect or reaction to the study medication 
• An injury that results from negligence on your part 
By agreeing to participate in this study, you do not give up your right to claim 
compensation for injury where you can prove negligence, in separate litigation. In 
particular, your right to pursue such a claim in a South African court in terms of South 
African law must be ensured. Note, however, that you will usually be requested to accept 
that payment made by the University under the SA GCP guideline 4.11 is in full 
settlement of the claim relating to the medical expenses. 
An injury is considered trial-related if, and to the extent that, it is caused by study 
activities. You must notify the study doctor immediately of any side effects and/or 
injuries during the trial, whether they are research-related or other related complications. 
UCT reserves the right not to provide compensation if, and to the extent that, your injury 
came about because you chose not to follow the instructions that you were given while 
you were taking part in the study. Your right in law to claim compensation for injury 
where you prove negligence is not affected. Copies of these guidelines are available on 
request. 
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INFORMED CONSENT FOR FINAL STUDY VISIT & IUD CONTINUATION TELEPHONE FOLLOW- 
UP 
Introduction 
This consent form contains information about the final study visit for women not in the 24- 
month visit window at the last day of scheduled follow-up due to study closure or did not 
complete their 24 month visit by the last day for scheduled study visits of June 8, 2018. This 
consent also contains information about follow-up calling for women already participating in the 
intrauterine device (IUD) trial. The purpose of today’s visit is to explain changes in the study if 
you were not yet eligible or did not complete your 24-month visit. The study is closing and you 
will not be able to complete the 24-month visit. Today, we will tell you which IUD you received 
and ask you if you wish to continue using the IUD. If you decide to continue your IUD, we 
request your consent to call you when you are eligible for the 24-month visit to ask if you are 
still using your IUD. The IUD continuation call is part of the current research study.  In order to 
be sure that you are informed about the changes to the final study visit and the additional 
follow-up calling as part of the research study, we are asking you to read this consent form. If 
you are unable to read this consent form, a study staff member will read and explain it to you. 
Someone other than the study staff will be present during this procedure. If you agree to take 
part in this study, you will be asked to sign this form or make your mark in the presence of a 
witness. 
General information about the research 
We are from the Desmond Tutu HIV Centre at the University of Cape Town. We are doing a 
research study to compare two IUDs (“loops”) among HIV-positive women and you are currently 
participating in that study. 
The study is now ending and this has happened before some participants were able to come for 
their 24-month visit or before they were eligible for their 24-month visit. This change has 
happened for budget reasons and we have no reason to believe there are any safety concerns 
with the IUD you are using. 
Submitted to IRBs 19JUN2018 
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This form gives information to help you decide if you want to take part in the final study visit 
and added telephone call follow-up. We are asking you, as someone who is not yet eligible for or 
did not complete the 24-month visit, if you would be willing to complete the final study visit. If 
so and you want to continue the IUD, we are also asking you if you would be willing to receive a 
telephone call at the 24-months visit date to ask about your IUD use. 
You can ask any questions to help you decide whether to continue with this part of the study or 
not. You may ask questions about the purpose of the research, what will be done during the 
call, the possible risks and benefits and anything else about the research or this form that is not 
clear. When all of your questions are answered, you can decide if you would like to take part in 
this study or not. You will sign this consent form or make your mark in front of a witness, if you 
decide to take part in this study. You will be given a copy of the informed consent form. 
Your part in the research study 
Today’s visit will last for about 30-60 minutes. Around 20 women will be involved in this part of 
the study. If you decide to volunteer for the final study visit, the visit details are as follows: 
 You will be asked questions about your health, sexual behavior, and thoughts about 
using the IUD. 
We will follow-up on any outstanding medical issues and provide a referral for any 
issues that have not yet resolved. 
We will tell you which IUD you received and you will be given the choice to keep your 
IUD in or have it removed. 
o If you choose to keep it, we will tell you how long it will remain effective for 
preventing pregnancy and test you for pregnancy if you wish. 
o If you chose to remove the IUD, we will remove it during this visit and perform a 
pregnancy test. We will also counsel with available methods and provide you 
with your selected method or a referral as applicable. 
We will test you for any reproductive infections if you wish. 
If you decide to continue your IUD, we request your consent to call you when you are 
eligible for the 24-month visit to ask if you are still using your IUD. 




If you do not want to do any of these procedures or tests, you do not have to take part in this 
study. Your participation in this study is voluntary. 
If you have decided to keep your IUD and are not yet eligible for your 24-month visit, with your 
consent you may receive 1-2 follow-up telephone calls in a few months that will last about 20 
minutes. Around 20 women will be involved in this part of the study. If you decide to volunteer 
for this part of the study, the call details are as follows: 
Follow-up Call: 
 You will be asked to provide best telephone numbers and times at which to reach you in 
a few months when you are eligible for the 24-month visit. 
At around 24 months after you received the IUD, the study manager or a female study 
representative will call you. They will identify themselves as being from UCT and then 
ask if it is you. 

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 You will be asked some basic questions, like your birthdate, to confirm it is really you 
with whom they are speaking. 
The person calling will then ask you a series of questions about whether you are using 
the IUD and if you are satisfied with it. If you have had the IUD removed between 
today’s visit and the call, they will ask when and why it was removed and what you are 
now using for family planning. 
You may request an additional call if you are unable to complete the questionnaire at 
the time of the first call. 
If you are having any problems, you may discuss them with the study member who calls 
you and they can suggest follow-up at your home clinic to address the problem. 



Permission to be called at 24-month post study insertion: 
Please initial below to indicate whether or not you give permission for the additional follow-up 
calls. 
  (initial) I agree to have the follow-up calls as described above. 
  (initial) I do not consent to the follow-up calls as described above. 
Possible risks 
Your participation in this part of the study will involve some risks, which include: 
 Possible disclosure of your participation in the study to others answering your 
telephone. We will make every effort to confirm your identity with full name and birth 
date before we start the questionnaire. 
Some of the questions we ask will be of a personal nature, which may make you uncomfortable. 
Possible benefits 
If you opt to have testing for reproductive infections, we will give you free treatment for any of 
the curable infections passed through sex that we find by nurse diagnosis or, where possible, 
infection tests. 
You will receive free condoms. We will demonstrate how to use them. 
There are no other direct benefits to being in this part of the study. If you need referral for care, 
we will assist with this, but you may have to pay for care at other clinics. Your participation in 
this research may benefit other women in the future by helping us understand IUD acceptability 
in HIV positive women. 
Choosing to be in this study 
You do not have to take part in this study to get treatment for your condition.  You may 
continue with routine HIV care and receive family planning at the Desmond Tutu HIV Center 
and/or Gugulethu Community Health Centre with no penalty. Whether or not you decide to join 
this part of the study will not affect your treatment and care at this or any other clinic. 
Confidentiality 
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Any information collected during this part of the study that can identify you by name will be 
kept confidential. We will do everything we can to keep your data secure, but complete 
confidentiality cannot be promised. Your name will not appear in any study reports or on any 
blood samples. Despite all of our efforts, unanticipated problems such as another person 
answering your phone or a stolen computer may occur, although it is highly unlikely. Your 
questionnaires will be assigned a code number, and separated from your name or any other 
information that could identify you. 
The following individuals and/or agencies will be able to look at and copy your research records 
(such as this consent form, completed questionnaires, etc.): 
 The investigator, study staff and other medical professionals who may be evaluating the 
study; 
Authorities from the University of Cape Town, including the Institutional Review Board 
(IRB); 
Authorities from FHI 360, including the Protection of Human Subjects Committee 
(PHSC); 
The United States Food and Drug Administration ('FDA') and/or the Office of Human 
Research Protections ('OHRP'); 
The sponsors of this study, NIH, USAID, including persons or organizations working with 
or owned by the sponsor; 
Other South African government regulatory agencies. 





Study staff may request copies of your medical records if you receive any treatment at any other 
facility. We will request your permission to look at these records. 
Compensation 
You will receive compensation valued at 150 Rand at this visit. This is for your time and travel 
costs. 
You will not receive compensation for the follow-up phone calls. 
Leaving the Research 
You may leave this research study at any time. If you decide to stop taking part, please tell the 
study staff why you wish to leave. 
Also, you may be asked to leave the research if: 



The research doctor or study staff feel it is best for you, or 
You are not able to follow the study procedures, or 
The research is stopped. If the research is stopped, you may be asked additional 
questions about your participation in the study. You may choose not to answer these 
questions if you wish. 
We will tell you if we learn something new about the IUD that could affect your choice to stay in 
the study. 
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If there is anything that is unclear or if you need further information, please ask us and we will 
provide it. Do you have any questions? 
Contacts for more information 
If you have any questions after you leave the clinic, or if you are hurt while taking part in this 
research study, you should contact: 
Dr. B. Landon Myer 
School of Public Health and Family Medicine, 
Faculty of Health Sciences, University of Cape Town (UCT) 
Tel: +27 21 406 6661 or the study clinic at +27 21 633 9735 
Email: Landon.Myer@uct.ac.za 
Your Rights as a Participant 
Before a research study can be carried out, it must be approved by an ethics committee. An 
ethics committee is a group of people who review details of a proposed research study and 
determine whether the research may be conducted. Their main goal is to help protect 
participants. 
This protocol has been approved by the ethics committees of: 


The University of Cape Town and 
FHI 360 (Protection of Human Subjects Committee). 
If you have any questions about how you are being treated by the study your rights as a 
research participant, you may contact: 
UCT Ethics Committee 
Prof Marc Blockman 
Chair, Human Research Ethics Committee 
Faculty of Health Sciences, University of Cape Town 
Tel: +27 21 406 6338 
You may also contact: 
FHI 360 Protection of Human Subject Committee 
359 Blackwell Street, Suite 200 
Durham, NC 27701 USA 
Tel: +1 919 405 1445 
Email: phsc@fhi360.org 
If you have question about this part of the study you should first discuss them with your doctor 
or the ethics committee (contact details as provided on this form). After you have consulted 
your doctor or the ethics committee and if they have not provided you with answers to your 
satisfaction, you should write to the South African Medicines Control Council (MCC) at: 
The Registrar of Medicines 
Medicines Control Council 
Department of Health 
Private Bag X828 
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PRETORIA 
0001 
Fax: (012) 395 9201 
e-mail: mogobm@health.gov.za 
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VOLUNTEER AGREEMENT 
I understand that the purpose of the research study titled “Comparison of Two IUDs among 
Cape Town HIV-positive Women,” is to compare the safety of two IUDs among HIV-positive 
women. I further understand that I, as an already-consented study participant, am being asked 
to participate in the final study visit and to participate in additional phone calls to discuss IUD 
use. 
I have read the information in the informed consent form, or it has been read to me. I have had 
the opportunity to ask questions about it, and the questions that I have asked have been 
answered to my satisfaction. I consent voluntarily to participate in this part of the study. I 
understand that I have the right to withdraw from the study at any time without affecting the 
care that I can get at this clinic or other clinics. 
Printed Name of Volunteer Date 
Signature (or mark) of Volunteer Date 
If a volunteer cannot read the form for herself, a witness must sign here: 
I was present while all information in this consent form, including the benefits, risks and 
procedures were read to the volunteer. All questions were answered and the volunteer has 
agreed to take part in the research. 
Printed Name of Witness Date 
Signature of Witness Date 
I certify that all information in this consent form, including the nature and purpose, the 
potential benefits, and possible risks associated with participating in this study have been 
explained to the volunteer. 
Printed Name of Person Who Obtained Consent Date 
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Signature of Person Who Obtained Consent Date 
A signed copy of this consent form was offered to the participant. 
Initials of Person Who Obtained Consent Date 
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Pre-ART Baseline Questionnaire: 2IUDnCT 
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# 
 
Umbuzo /Question 
[To be read verbatim] 
 
Impendulo / Answer 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / Write in 
unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempend
u lo Code 
  
Siyabulela ngokuthatha inxaxheba nokugqiba inkqubo yohluzo. Namhlanje ndiza kubuza 
imibuzo ngembali yempilo, indlela ophila ngayo, kunye neembono zakho ngocwangciso ntsapho. 
Siza kuthetha sobabini mhlawumbi ixesha elingaphezulwana kwemizuzu engama 60. Ukuba 
akuwuqondi umbuzo ndicela undazise, sikwazi ukuxoxa ngawo. 
Thank you for participating and completing the screening process. Today, I am going to ask you some questions about your health 
history, current living situation, and ideas about family planning. We will probably talk together for a little over an hour. If you don’t 
understand a question, please let me know and we can discuss it. 
Demographic Information (200s) 
201 
 
Umhla wakho wokuzalwa? 
What is your date of birth? 
 
 
Mingaphi iminyaka yakho? 
What is your age? 
 
 
DOB: 
| | | / | | | | / | | | | | 
(dd/mmm/yyyy) 
 
|  |  | iminyaka / years 
 
  
202 
 
Loluphi ulwimi olu 
phambili olisebenzisayo 
ekhaya? 
What is the primary language you 
use at home? 
 
1…..IsiXhosa / Xhosa 
2…..IsiZulu / Zulu 
3…..IsiBhulu / 
Afrikaans 4…..Isingesi 
/ English 
5…..Olunye (chaza) / Other   
  
203 
 
Sithini isimo sakho 
sobudlelwane 
neqabane? 
What is your current partnership 
status? 
 
1….Andinamntu Single/ no steady 
partner/boyfriend 2….Sitshatile sihlala 
kunye/Married and live together 
3….Sitshatile asihlali kunye 
Married, live apart 
4….Sihlala kunye asitshatamga 
Live together, not married 
6 …Ndineqabane lwisisigxina, 
asihlali kunye/ Steady 
partner/boyfriend, not living together 
5 ... Okunye (chaza) Other (describe): 
 
  
204 
 
Uya sebenza ngoku? 
Are you currently employed? 
 
0…. Hayi / No 
1… Ewe, manq phanqapha / Y s, part-time 
2…. Ewe, isigxina / Yes, full time 
 
  
205 
 
Hlobo luni lwendlu ohlala 
kuyo? What type of house do you 
live in? 
 
1…..Imbacu / ityotyombe 
Informal dwelling / 
hokkie 
2…. ndihlala endlini/ Live in a home 
3….Ifleti / indlu kamasipala 
Flat / municipal housing 
4.… Enye (chaza) / Other (specify): 
 
  
Place Enrolment PTID 
label here 
e.g. PTID: 7  -    
 
  
   
   
 
 
 
 
 
 
 
 
 
 
Page 108 of 219 
 
 
Date:  /  __/ __    
2IUDnCT: Baseline Questionnaire Pre-ART (Combined), Version 6.0 
FHI 360 Study #10369, IRB Net# 398733 
Last revised on 08 Sept 2015 
Translation verified 28 Sept 2015 Interviewer Initials:     Page 2 of 27 
# 
 
Umbuzo /Question 
[To be read verbatim] 
 
Impendulo / Answer 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / Write in 
unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempend
u lo Code 
 206 
 
Bangaphi abatwana 
nabantu abadla abahlala 
endlini yakho? 
How many adults and children 
live in your house? 
 
 
| | | abadala (kuquka nawe) 
adults (including yourself)) 
 
| | | abantwana / children 
 
  
   
 
207 
 
Liliphi elona banga 
eliphezulu 
oligqibileyo 
eskolweni? 
What is the highest level of school 
you have completed? 
 
Grade (1-12): 
|  | 
 
  
or Standard (1-10): 
|  | 
 
  
or Imfundo ephakamileyo (cacisa) 
Post secondary (explain) 
 
  
208 
 
Ingaba ungumfundi ngoku? 
Are you currently a student? 
 
0…. Hayi / No 
1…. Ewe, manqaphanqapha / Yes, part-time 
2…. Ewe, isigxina / Yes, full time 
  
209 
 
Unawo amanzi 
ahamba ngopipe 
endlini yakho? 
Do you have piped water in 
your house? 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
210 
 
Unayo indlu 
yangasese 
egungxulwayo? 
Do you have a flushing toilet in 
your house? 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
211 
 
Unawo na umbane 
endlini yakho? 
Do you have electricity in your 
house? 
 
0…. Hayi / No 
1…. Ewe, owam okanye igenerator / 
Yes, my own or a generator 
2…. Ewe owam osuka kummelwane / 
Yes, from my neighbor 
 
  
212 
 
Unaye umabona-kude 
osebenzayo endlini 
yakho? 
Is there a functioning television in 
your house? 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
213 
 
Unayo ifowuni 
ohamba uyiphethe 
esebenzayo? 
Do you have a functioning 
mobile phone? 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
Menstrual, pregnancy and fertility history (300s) 
Uqhuba kakuhle.Siza kubuza ngoku ngamava akho ngokuya exesheni. 
You are doing very well. I am now going to ask you some questions about your experiences with menses. 301 
 
Wawuneminyaka 
emingaphi ukuqala 
kwakho ukuya exesheni? 
How old were you when you 
started your menses? 
 
 
| | | iminyaka /years 
 
  
   
 
Place Enrolment PTID 
label here 
e.g. PTID: 7  -    
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# 
 
Umbuzo /Question 
[To be read verbatim] 
 
Impendulo / Answer 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / Write in 
unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempend
u lo Code 
 302 
 
Kwinyanga ezintathu 
ezidlulileyo, zingaphi 
intsuku phakathi kosuku 
lokuqala lokuya exesheni 
nosuku lokuqala phambi 
kokuya exesheni 
kwinyanga elandeleyo? 
 
In the last three months, about how 
many days were there between the 
first day of your menstrual cycle 
and the first day of your next 
menstrual cycle? 
 
 
| | | | iintsuku /days 
 
999….andiyi exesheni /ukuya exesheni 
manqaphanqapha kuhlobo 
locwangciso ntsapho 
endilidebenzisayo (BCM) Amenorrheic 
/ not menstruating / 
irregular menses on current BCM 
 
[Show participant calendar to 
determine interval between bleeding 
episodes] 
 
 
 
999306 
 
303 
 
Kwezinyanga zi-3 
zidlulileyo uqhele 
ukopha intsuku 
ezingaphi xa usiya 
exesheni? 
In the last 3 months, for how many 
days did you usually bleed during 
your menses? 
 
| | | iintsuku /days 
 
  
304 
 
Ungayichaza njani imini 
owopha kakhulu ngayo 
(khetha eyona 
mpendulo)? 
How would you describe a 
“heavy bleeding” day? 
 
[Do not read 
responses, circle those 
that are mentioned by 
the respondent] 
 
1… Ngamaxa enditshintsha ngawo 
iiphedi 
By the number of times I change my 
menstrual product 
  
2….Xa ndibona amahlwili 
By whether I see blood clots 
  
3….Xa ndinentlungu okanye 
ezinye ingqaqambo 
By whether I have cramping or other pain 
  
4….Xa ndiphumela kwiphedi 
nokuba ndiyitshintshe 
amaxa amaninzi 
By whether I bleed through the product I am 
using even after changing frequently 
  
5… Ezinye cacisa / Other (specify): 
 
  
305 
 
Ngosuku owophe ngalo, 
uyitshintsha kangaphi 
ipadi? 
On one of these heavy days, about 
how many times did you have to 
change your menstrual product? 
 
| | | inani lamaxesha / times 
 
  
   
 
Place Enrolment PTID 
label here 
e.g. PTID: 7  -    
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Umbuzo /Question 
[To be read verbatim] 
 
Impendulo / Answer 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / Write in 
unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempend
u lo Code 
 306 
 
Ungakuchaza njani ukuya 
kwakho  exesheni 
kwezinyanga zi-3 
zidlulileyo? In the last 3 months, 
how would you describe your bleeding 
pattern overall? 
 
[Read each of these 
options and have them 
select one best answer] 
 
1…. Ukuya exesheni 
ngokwesiqhelo iintsuku ezi 3 
ukuya kwezi 7 kungekho 
kopha phakathi 
kwalamaxesha 
Regular menstruation of 3-7 days with no 
bleeding in between these times 
2…. Manqapha nqapha (nganeno 
kwamatyeli amabini kweli 
xesha)Infrequent (less than 2 bleeding 
events in this time) 
3…. Ukopha qho, amatyeli 
angaphezulu kwesiqhelo okuya 
exesheni(ngaphezu kwamatyeli 
amane >=ngaphezu kwentsuku 
ezimbini kwinyanga ezintathu 
ezidlulileyo) / Frequent bleeding events 
that are more frequent than menstruation 
(more than 4 events (>=2 days) in last 3 
months) 
4…. Ukopha ngokutsalileyo 
(mhlawumbi ityeli elinye litsale 
iintsuku ezilishumi 
nangaphezulu); kungenzeka 
ngokongezelelekileyo kunokuya 
exesheni ngokwesiqhelo / 
Prolonged bleeding (at least one event 
lasting >=10 days); may occur in addition to 
regular menstruation 
5….Ukopha manqaphanqapha 
okanye amachaphaza egazi 
kukho isiqabu phakathi 
kweziqendu ezide kune ntsuku 
ezili17/ Irregular bleeding/spotting with 
interval between episodes longer than 17 
days 
6….Khange ndophe kwezinyanga 
zintathu zidlulileyo. / No bleeding 
episodes in last 3 months 
7….Ezinye (chaza)/ Other (specify 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6308 
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307 
 
Kwinyanga ezintathu ezidlulileyo, ingaba oku kulandelayo kuye kwenzeka na 
kuwe? 
(funda nganye) 
In the last 3 months, did you experience any of the following? [READ EACH ONE] 
 
A1 
 
Amantsi esisu 
anxulumene nokutya, 
ukuchama 
nokuyangasese. 
Lower abdominal pain related to 
eating/urination/having bowel 
movements; not pelvic pain. 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
B 
 
Ukopha kakhulu / amahlwili 
xa usexesheni 
Heavy bleeding or clots during menses 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
C 
 
Ukopha 
manqaphanqapha 
(ukungayi exesheni 
nyanga zonke 
Irregular bleeding (not having 
menses every month; menses less 
than 1/month) 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
C1 
 
Ukopha 
okungaqhelekanga 
(ukuya exesheni kanye 
nangaphezulu 
enyangeni enye) 
Irregular bleeding (having menses 
more than once in a month.) 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
D 
 
Ukopha phakathi 
kwentsuku zakho zokuya 
exesheni okanye 
amachaphaza egazi 
(ukopha kwenzeke 
ngaphezu kwentshuku 
ezimbini phambi kokuya 
exesheni nasemva kokuya 
exesheni kwaye 
kungeyonxalenye yokuya 
kwakho exesheni. 
Bleeding in between your menstrual 
cycle or spotting,(bleeding occurred 
more than two days before or after 
you had your cycle and was not part 
of cycle bleeding) 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
E 
 
Ezinye chaza 
Other, explain 
 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
308 
 
Uyathanda ukuya exesheni? 
Do you like having periods? 
 
0…. Hayi / No 
1…. Ewe / Yes 
99…. Andazi / Don’t know 
  
309 
 
Ukuba ungakhetha, 
ungathanda ukuya 
kangaphi exesheni? 
If you could choose, how often would 
you like to have a period? 
 
0…Andifuni / Never 
1….Ngenyanga/ Monthly 
2… Emva kwenyanga ezintatu 
At least every 3 months 
3….Ezinye chaza / Other (specify): 
 
  
310 
 
Wawukhe wasebenzisa 
ucwangciso ntsapho 
olwamisa ukuya kwakho 
exesheni? 
Have you ever used a 
contraceptive method which 
stopped your periods? 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
Place Enrolment PTID 
label here 
e.g. PTID: 7  -    
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Ngoku ndizakubuza imibuzo malunga nolwazi lwakho ngokhulelo? Now I am going to ask you some questions about your experiences with pregnancies. 
311 
 
Wakhe wakhululelwa? Have you ever been pregnant? 
 
0…. Hayi / No 
1…. Ewe /Yes 
0 skip to 316 
 
 
Previous Pregnancy History 
312 (Ukuba Ewe)Kumitho ngalunye uqale ngolokugqibela, nceda cacisa oku kulandelayo: [If Yes] for each pregnancy starting with the most recent please specify the following: 
 A. Unyaka 
[isiphumo
] 
Year 
[of outcome] 
 
B. Isiphumo? Outcome? 
 
1= Ukuzala usana oluphilayo 
/live birth 
2= Ukukhutswa kwesisu 
ngenjongo /induced 
abortion 
3= Ukuphuma 
kwesisu/ozelwe engaphili 
/miscarriage- still birth 
 
Ukuba 2 okanye 3, gqithela 
kumitho olulandelayo. 
Ukuba alukho olunye, yiya 
ku 313 
[If 2 or 3, go to next pregnancy. If 
no other pregnancy go to 313] 
C. Isini? Sex? 
 
1 = inkwenkwe 
male 
2= Intombi 
femal
e 
 
D. Isimo 
sentsholongwane sosana 
ngexesha ezalwa? HIV 
status of child at birth? 
 
0 = alikho ichaphaza 
/negative 1 = likhona 
ichaphaza / positive 
99 = Andazi, 
aluka vavanywa 
usana 
unknown: child untested 
 
E. Luyaphila ngoku? 
Currently alive? 
 
0= Hayi /no 
1= Ewe /yes 
 
Ukuba 1, gqithela 
kumitho 
olulandelayo. Ukuba 
alukho olunye, yiya 
ku 313 
[If 1, go to next pregnancy. If 
no other pregnancy go to 
313] 
 
F. Ubudala ngelixa esweleka? 
Age at death? 
 
Cacisa iinyanga okanye iminyaka 
[indicate in months or years] 
 
 
Gqithela kumitho olulandelayo. 
Ukuba alukho lolunye, yiya ku 313 
[Go to next pregnancy. If no other pregnancy go 
to 313] 
 
1 
 
      
2 
 
      
3 
 
      
4 
 
      
5 
 
      
6 
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uyalelwe ngolunye uhlobo / 
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Ikhowudi 
Yempendul
o 
Code 
 
313 
 
Kukhulelo lwakho lwangaphambili, wawukhe wadiban  nezinye zezingxaki zilandelayo? [Funda 
ngezantsi uphedulo] 
During your previous pregnancy or pregnancies did you ever experience any of the following? [Read list to participant] 
A 
 
Ukopha kakhulu de uthiwe 
igazi 
Excessive bleeding/needed transfusion 
0…. Hayi / No 
1…. Ewe / Yes 
  
B 
 
Uqhaqho lokubeleka 
Need for Cesarean section 
0…. Hayi / No 
1…. Ewe / Yes 
  
C 
 
Ukunyukelwa yi 
Highblood/ elumithweni 
/ High blood pressure/ pre-
eclampsia 
0…. Hayi / No 
1…. Ewe / Yes 
  
D 
 
Ukuxhuzula kwilixa 
lokusondela ukubeleka / 
Seizures around time of birth/ 
eclampsia 
0…. Hayi / No 
1…. Ewe / Yes 
  
E 
 
Ulwasuleleko 
ngelixesha ubelekayo 
okanye emva 
kokubeleka / Infection at 
time of delivery or immediately 
after 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
F 
 
Ukrazuko ebufazini 
okwenze 
ukuchama,ukuzithuma,oka
nye ukwabelana ngesondo 
kubenzima / Large tear or 
incision in vaginal area 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
314 
 
Ukuya kwakho exesheni 
kuye kwatshintsha enyakeni 
emva nje kokukhulelwa? Did 
your menses change within the year 
after your most recent pregnancy? 
0…. Hayi / No 
1…. Ewe / Yes 
99… Andazi / I don’t know 
 
0 316 
99 316 
 
 
315 
 
Ukuba ngu Ewe, njani? 
If yes, in what way? 
 
1….Ukuya exesheni kunqabile 
Menses became less regular 
2….Ukuya exesheni kubenje 
ngesiqhelo / Menses became 
more regular 
3….Ukuya exesheni akujiyanga / 
akuthathanga xesha elide / 
Menses became lighter or didn’t last as 
long 
4….Ukuya exesheni kakhulu / 
kwathatha ixesha elide / 
Menses became heavier/ lasted 
longer 
5….Andikaqalisi ukususela oko 
bendi khulelwe / Have not 
resumed menses following last 
pregnancy 
  
316 
 
Wakhe wacetyiswa ukuba 
ungabinabantwana ngenxa 
yezizathu zempilo yakho? 
Have you ever been advised for 
medical reasons not to get pregnant 
(again)? 
0…. Hayi / No 
1…. Ewe / Yes 
99… Andazi / I don’t know 
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# 
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ebhalwe ngalo /To be read 
verbatim] 
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(Bhala ngaphandle kokuba 
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Skip 
 
Ikhowudi 
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o 
Code 
 
Olu luhlu lulandelayo lwemibuzo lungeengcinga zak o ngoku nokuba uziva njani ngokuba 
nabantwana kwixesha elizayo. Ukuba umbuzo ukwenza ungakhululeki, nceda ndixelele sixoxe 
ngawo. Unako ukusala ukuphendula loo mbuzo. The next set of questions is about your CURRENT thoughts and feelings 
about having children in the future. If any question makes you uncomfortable, let me know so we may discuss it. You can also decline to 
answer that question 317 
 
Ungathanda ukuba 
nomntwana/abantwana, 
okanye ukheta ukungabi 
nabantwana konke konke? 
Would you like to have (a/another) 
child, or would you prefer not to have 
any (more) children? 
0….Andifuni konke konke 
No more / none 
1….Ndiyamfuna omnye umntwana 
Have a/nother child 
99…Andazi / andiqinisekanga 
Undecided/don’t know 
 
0 320 
 
99 320 
 
 
318 
 
Ungathanda ukulinda 
ixesha elingakanani 
ukususela ngoku phambi 
kokuba ubenomnye 
umntwana/ubenabanye 
abantwana? 
How long would you like to wait 
from now before the birth of 
a/nother child? 
 
 
 
|  |  | iminyaka / years 
or 
|  |  | iinyanga/ months 
 
Ukuba 
ngaphants
i 
kweminya
k a emi 2, 
yazisa 
umphathi 
wovavany
o 
[If less than 2 
years, alert 
the study 
coordinator] 
 
 
Yrs:    
 
 
Mos:    
 
319 
 
Bangaphi abantwana 
(abongezelelekileyo) 
onqwenela ukuba 
nabo kwixesha 
elizayo? 
How many (new) children do you 
wish to have in the future? 
 
|  |  | Bantwana / children 
 
  
320 
 
Likhe waxoxa ngomnqweno 
wakho wokufuna ukuba 
nabanye abantwana okanye 
umnqweno wakho 
wokungafuni ukuba 
nabantwana neqabane 
lakho lokugqibela 
obunalo/onalo? 
Have you discussed your desire to 
have more children or to not have 
more children with your most recent 
sexual partner? 
0…. Hayi / No 
1…. Ewe /Yes 
 
  
321 
 
Ingaba ukuba nesif  seHIV 
sakutshintsla kwizigqibo 
zakho zokuba 
nomntwana/okanye 
ukungabi namntwana? Did 
HIV diagnosis change your decision 
about WHETHER to have (a)nother 
child? 
0…. Hayi / No 
1…. Ewe /Yes 
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# 
 
Umbuzo / Question 
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ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
322 
 
Ing ba IHIV ithe yabangela 
ukuba utshintshe izigqibo 
zokuba uzakumfumana nini 
na umntwana/omnye 
umntwana? 
Did HIV diagnosis change your 
decision about WHEN to have 
(a)nother child? 
 
0…. Hayi / No 
1…. Ewe indenze ndafuna ukuba 
naye ngokukhawuleza. /Yes, 
made me want to have one sooner 
2…. Ewe indenze ndafuna 
ukulinda ixesha elide Yes, made 
me want to wait longer 
-8….Andifuni abanye abantwana 
Do not want a(nother) 
child 
 
  
Sexual Health and HIV (400s) 
Olu luhlu lulandelayo lwemibuzo luzakubuza ngempilo yakho yesondo namava esondo, ngamava 
akho ngezesondo kwanesimo sakho seHIV. Ukuba ufuna ixesha elongezelelweyo ukuphendula 
lemibuzo okanye uziva ungakhulelekanga, nceda undixelele. The next section of questions will ask about your sexual 
health and experiences as well as the HIV diagnosis. If you would like some extra time to answer these questions or are uncomfortable, 
please let me know. 
401 
 
Wawuneminyaka 
emingaphi ukuqala kwakho 
ukwabelana ngesondo? How 
old were you the first time you had 
sexual (vaginal) intercourse? 
 
|  |  | iminyaka / years 
 
  
402 
 
Mangaphi amaqabane 
akho esondo owakhe 
wanawo ebomini? How 
many sexual partners have you had 
in your lifetime? 
 
 
|  |  | inani labantu 
persons 
 
[If they cannot give an exact 
number, ask them to estimate] 
 
  
403 
 
Mangaphi amaqabane akho 
esondo okhe wanawo kulo 
nyaka uphelileyo? How many 
sexual partners have you had in the 
last year? 
 
 
|  |  | inani labantu 
Persons 
[If none enter 00] 
 
 
00 412 
 
 
404 
 
Unalo iqabane 
elisisigxina 
lokwabelana 
ngesondo? 
Do you currently have a steady 
sex partner? 
0…. Hayi / No 
1…. Ewe / Yes 
 
0 406 
 
 
405 
 
Kukangaphi wena 
neqabane lakho 
elisisigxina nisebenzisa 
ikhondom kwezi nyanga zi 
3 zigqithileyo? How often did 
you use condoms with your steady 
partner in the last 3 months? 
 
1….Rhoqo / always 
2….Phantse onke amaxesha 
(>75%) almost all the time (>75%) 
3….Maxesha onke (50% - 75%) 
most of the time (50% - 75%) 
4….Ngamanye amaxesha 
(25% - 50%) 
some of the time (25% - 50%) 
5….Andifane ndiyisebenzisa 
(<25%) 
rarely (<25%) 
6…Zange / never 
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# 
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ebhalwe ngalo /To be read 
verbatim] 
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(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
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Ikhowudi 
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o 
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406 
 
Ing ba unawo amanye 
amaqabane obelana 
ngawo ngesondo? 
Do you currently have any (other) 
sexual partners? 
0…. Hayi / N  
1…. Ewe /Yes 
 
0 408 
 
 
407 
 
Ukuba ewe, 
kukangaphi 
usebenzisa ikhondom 
neliqabane 
kwezinyanga zintathu 
zidlulileyo? 
If yes, how often did you use condoms 
with this partner/these partners in the 
last 3 months? 
 
1….Rhoqo / always 
2….Phantse onke amaxesha 
almost all the time (>75%) 
3….Maxesha onke 
most of the time (50% - 75%) 
4….Ngamanye amaxesha 
some of the time (25% - 50%) 
5….Andifane ndiyisebenzisa 
rarely (<25%) 
6…Zange / never 
  
408 
 
Xa usebenzisa 
iikhondom, zeziphi 
ezona zizathu 
zibalulekileyo zokuba 
usebenzise ikhondom? 
When you use condoms, what are the 
most important reasons you use 
condoms? 
 
 
Sukufunda 
okubhaliweyo, 
qwalasela okuphuma 
kumthathi nxaxeba 
[Do not read responses, note all 
the responses that are stated by 
the participants] 
 
0…Andisebenzisi ikhondom/ I 
don’t use condoms 
  
1 …Ukuthintela 
ukumitha/andifuni 
mntwana 
Protection against pregnancy/ doesn’t 
want child 
  
2….Isimo sentsholongwane 
seqabane asaziwa / Partner’s 
HIV status unknown 
  
3….Iqabane alinachaphaza 
lentsholongwane / Partner 
HIV negative 
  
4….Iqabane liphila 
nentsholongwane; 
ukukhusela ulwasuleleko 
oliphindeneyo / Partner HIV 
positive; prevent re-infection 
  
5….Ukhuselo kwizifo 
ezifumaneka 
ngokwabelana 
ngesondo/intsholongwane 
STI/HIV protection 
  
6….Iqabane liyagxininisa 
ukusebenzisa ikhondom / 
Partner insists to use them 
  
7….Ixhala lokuba 
ucwangcisontsapho 
aluthembekanga 
ngokupheleleyo/alusebenzi 
ngokupheleleyo / Concerned 
birth control method is unreliable/ not 
completely effective 
  
8….Andifuni iqabane lazi 
ukuba ndisebenzisa 
olunye uhlobo 
locwangcisontsapho / Don’t 
want partner to know I am using 
another birth control method 
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Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
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  9….Ok ye(bhala) / Other (write in): 
 
  
409 
 
Xa uqikelela 
wabelana kangaphi 
ngesondo 
kwezinyanga 
zintathu zidlulileyo? 
In the last 3 months, about how 
often did you have sexual 
intercourse? 
 
0….Khange, ndabelane 
ngesondo kwezi nyanga zi 
3 zigqithileyo 
Not sexually active in the last 3 months 
1….Ngaphantsi kwenyanga 
<1 per month 
2….Kanye – kathathu ngenyanga 
1-3 times per month 
3….Kanye ngeveki / 1 per week 
4….Kabini ukuya kathathu evekini 
2-3 per week 
5….Kane ukuya kathandathu 
evekini 
4-6 per week 
6….Yonke imihla okanye kaninzi 
Daily or more frequently 
  
 
409a 
 
Zingaphi iintsuku ogqibele 
ngazo ukwabelana 
ngesondo? 
How many days ago did you last 
have sexual intercourse? 
 
 
  days 
(Enter 99 if participant does 
not remember) 
 
  
 
409b 
 
Ingaba iqabane lakho 
lisebenzise ikhondom 
yotata okanye wena 
usebenzise eyotata 
okugqibela kwakho 
ukwabelana ngesondo? 
Did your partner use a male condom or 
did you use a female condom the last 
time you had sex? 
0….H i / No 
1….Ewe /Yes 
99…Andikhumbuli/andazi .I don’t 
know/ recall 
 
  
  
Ngoku, ndingakubuza imibuzo malunga netsholongwane kagawulayo nokhathalelo. Now I would like 
to ask you some questions about your HIV diagnosis and care 
412 
 
Uzaze nini ukuba 
uphila neHIV? 
When were you diagnosed with HIV? 
 
 
|  |  |  |month 
 
|  |  |  |  | year 
 
[If participant unsure, please 
show them calendar and ask 
them to estimate. If they really 
do not know the month, enter 
999] 
 
  
Mo  
Yr     
 
413 
 
Uqale ukuzazi ukuba 
uneHIV ngexesha 
ubukhulelwe? 
Were you first diagnosed with HIV 
during a pregnancy? 
0….Hayi / No 
1….Ewe /Yes 
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[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
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Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
414 
 
Uye watshintsha indlela 
yocwangisontsapho 
ngenxa yokuphila 
nentsholongwane? 
Did you change your birth control 
method due to your HIV diagnosis? 
 
0….Hayi / No 
1….Ewe /Yes 
 
0 416 
 
 
415 
 
Ukuba Ewe, ngoba? If yes, why? 
 
   
416 
 
Ukuya kwakho exesheni 
kuye kwatshintsha 
wakuzazi ukuba uphila 
neHIV? 
Did your menses change after you 
were diagnosed with HIV? 
0…. Hayi / No 
1…. Ewe / Yes 
 
0 418 
 
 
417 
 
Ukuba ngu ewe, njani? 
[If yes], how? 
 
1….Ukuya exesheni kunqabile 
Menses became less regular 
2….Ukuya exesheni kubenje 
ngesiqhelo / Menses became 
more regular 
3….Ukuya exesheni akujiyanga/ 
akuthathanga xesha elide / 
Menses became lighter or didn’t last as 
long 
4….Ukuya exesheni kakhulu / 
kwathatha ixesha elide / 
Menses became heavier/ lasted 
longer 
5…. Okunye(bhala) / Other (write in): 
 
  
418 
 
Kwinyanga ezi 6 ezidlulileyo, 
kukangaphi ubonana 
nomnikezi wezempilo kule 
kliniki ngokhathalelo lwakho 
lweHIV? 
In the last 6 months, how many 
times did you see a provider at clinic 
for your HIV care? 
 
|  |  | kangaphi/times 
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419 Usichazile isimo sakho sentsholongwane kwaba...? 
Have you disclosed your HIV status to…? 
  
A 
 
Abantwana / your children 
 
0…. Hayi / No 
1…. Ewe /Yes 
-8…Not applicable 
  
B 
 
Mama / mother 
 
0…. Hayi / No 
1…. Ewe /Yes 
-8…Not applicable 
  
C 
 
Tata / father 
 
0…. Hayi / No 
1…. Ewe /Yes 
-8…Not applicable 
  
D 
 
Utatomkhulu/makhulu 
/grandparents 
 
0…. Hayi / No 
1…. Ewe /Yes 
-8…Not applicable 
  
E 
 
Umnakwenu/dadewenu / 
Brothers or sisters 
 
0…. Hayi / No 
1…. Ewe / Yes 
-8…Not applicable 
  
F 
 
Iqabane lokugqibela 
okanye 
langokulokwabelana 
ngesondo 
Current/most recent sexual partner 
 
0…. Hayi / No 
1…. Ewe / Yes 
-8….Not applicable 
 
  
420 
 
Uyasazi i imo 
sentsholongwane 
kagawulayo seqabane 
lakho langoku okanye 
lokugqibela ubunalo? 
Do you know your current/most 
recent partner’s HIV status? 
0…. Hayi / No 
1…. Ewe /Yes 
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Contraceptive History (500s) 
Ngoku ndizakubuza imibuzo eyongeziweyo malunga namava akho ngocwanciso-ntsapho. 
Now I am going to ask you some additional questions about your experiences with birth control or family planning 
501 
 
Ngaphambi kokungenela 
oluphando, wakhe weva 
nge IUD okanye iloop? 
Prior to joining this study, had you 
ever heard of the IUD or loop? 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
502 
 
Wakhe weva ngolunye 
uhlobo locwangciso-
ntsapho olufakelwayo 
olubizwa ngokuba yi-
implant? 
Have you ever heard of the 
contraceptive method known as the 
implant? 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
503 
 
Wena okanye iqabane lakho nakhe nazisebenzisa na i…. Have you or your partner ever used….. . 
[funda into nganye] A 
 
Ipilisi / eziselwayo 
Pill or Oral Contraceptive 
 
0….Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
B 
 
Net-en / naliti (istofu 
senyanga ezi 2) 
Net-en/2 monthly injectable 
0… Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
C 
 
Idepo naliti (istofu senyanga 
ezi 3) 
DepoProvera/3 monthly Injectable 
0… Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
D 
 
Isivalo-mlomo sesibeleko 
(loop) 
IUD (Loop) 
 
0… Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
E 
 
Ikhondom yamadoda 
Male condom 
 
0… Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
F 
 
Ikhondom yabafazi 
Female condom 
 
0….Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
G 
 
Isivalo nzala samadoda 
Male sterilization 
 
0… Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
H 
 
Ukurhoxisa ubudoda 
phambi kokuchama 
imbewu yobudoda 
Withdrawal (removal of penis 
before ejaculation) 
0… Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
I 
 
Okunye (chaza) / other 
method (explain) 
   
 
0….Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
 
  
504 
 
Uye watshintsha uhlobo 
locwangciso ntsapho 
kwezi nyanga zi 12 
zidlulileyo? 
Did you change your method of 
contraception in the past 12 
months? 
0…. Hayi / No 
1…. Ewe / Yes 
 
0 506 
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verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
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Skip 
 
Ikhowudi 
Yempendul
o 
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505 
 
Ukuba ewe, kutheni / If Yes, 
why? 
 
[Ungazifundeli ngaphandle 
iiopshini Rhangqa konke 
umthathi nxaxheba 
akuxelela kona] 
[DO NOT READ OPTIONS. CIRCLE ALL 
THAT THE PARTICIPANT IS TELLING 
YOU HERSELF] 
 
1….Ndifuna 
ukukhulelwa 
Wanted to fall pregnant 
  
2….Andabelani ngesondo 
Not sexually active 
  
3….Ndohlukene neqabane 
Broke up with partner 
  
4….Ukopha 
kakhulu/ 
manqaphanqap
ha 
Heavy/irregular bleeding 
  
5….Ndandingayi exesheni 
rhoqo 
Did not have regular menstruation 
  
6….Ukuba nentlungu 
nengqaqambo xa 
ndisexesheni/ Too much 
pain/cramping with periods 
  
7….Luyandityebisa / Gained weight 
 
  
8….Luyandibhityisa / Lost weight 
 
  
9….Iqabane alifuni sisebenzise 
ucwangciso ntsapho 
lwangaphambili / Partner did not 
want us to use the prior method of 
contraception 
  
10...Andazi ukuba uhlobo 
locwangciso ntsapho luza 
kusichaphazela njani isifo 
sam seHIV / Did not know how the 
method will affect my HIV illness 
  
11… Ndixhalabile lulosuleleko / 
Worried abour risk of infections 
  
12….Ezinye, cacisa / Other, specify: 
 
  
506 
 
Ugqibele nini 
ukusebenzisa 
ucwangciso ntsapho 
ngaphambi 
kwanamhlanje? 
When was the last time you 
used a contraceptive method 
before today? 
 
UMYALEZO KUMSEBENZI: ikhondom 
lolunye uhlobo locwangciso ntsapho. 
Ukuba ibisisitofu (DMPA okanye NET-
EN, yongeza inani eliqikelelweyo 
lwenyanga ukususela kwisitofu 
sokugqibela) 
 
STAFF NOTE: Condom use is also a 
contraceptive method. If it was an 
injectable (DMPA or Net-En, add 
approximate number of months 
since last injection] 
 
|  |  | iinyanga /months ago 
 
00 = Ukuba ngeneno 
kwenyanga enye ukuza 
kuthi ga namhlanje, xa 
ubuza kubuyela istofu 
esilandelayo 
00 = if less than 1 month ago 
 
Bhala “24” iinyanga ukuba 
kungaphezu kweminyaka 
emi 2 / Enter ‘24” if 2 or more years 
ago 
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# 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
507 
 
Loluphi uhlobo 
locwangciso- ntsapho 
obulusebenzisa 
ngaphambi 
kwanamhlanje? 
What is the last contraceptive 
method you used before today? 
 
Khetha ibenye. Ukuba 
usebenzise ikhondom 
nolunye uhlobo 
locwangciso, khetha olunye 
uhlobo] 
 
[STAFF NOTE: Select only one. If they 
used a condom plus another method, 
choose the non-condom method] 
 
1….Ipilisi / eziselwayo / Pill or 
Oral Contraceptive 
2….Net-en inaliti yenyanga 
ezimbini 
Net-en 2 monthly injectable 
3….Idepo inaliti yenyanga 
ezintathu 
DepoProvera 3 monthly Injectable 
4….Isivalo-mlomo sesibeleko (loop) 
IUD (Loop) 
5….Isiciko somlomo wesibeleko 
Diaphragm 
6….Ikhondom yamadoda / Male 
condom 7….Ikhondom yabafazi / 
Female condom 8….Isivalo nzala 
samadoda 
Male sterilization 
9.... Ukurhoxisa ubudoda phambi 
kokuchama imbewu yobudoda 
Withdrawal (removal of penis 
before ejaculation) 
10..Ukungabelani ngesondo 
Abstinence (not having sexual intercourse) 
11..Okunye (chaza) /other (explain) 
 
  
508 
 
Ngeloxesha, iqabane lakho 
belisazi ukuba usebenzisa 
olu hlobo? At that time, did your 
sexual partner know you were using 
this method? 
0…..Hayi / No 
1…..Ewe / Yes 
99…Andazi / I don’t 
know 
  
509 
 
Ungaluncoma uhlobo 
lwakho lokugqibela 
locwangciso- ntsapho 
kwisihlobo okanye 
kwilungu losapho lwakho? 
Would you recommend your last 
method of birth control to a friend or 
family member? 
 
1….Ewe, gokuqin sekileyo 
Yes, I would definitely recommend it 
2….Ewe, ndingazama 
Yes, I would probably 
recommend it 
3….Andiqinisekanga / I am 
unsure 4….Hayi, andinako 
No, I would probably not recommend it 
5….Hayi ngokuqinisekiley 
No, I would definitely not recommend it 
  
510 
 
Ukuba olu 
phandobelungaqhu beki 
ubuzakuba nomdla 
kangakanani 
wokuqhubekeka 
usebenzisa uhlobo lwakho 
lokugqibela lo wangciso- 
ntsapho? If this study were not 
occurring, how willing are you to 
continue using your last birth control 
method? 
1….Ukuba nomdla kakhulu 
kakhulu ndingaqhubeka / 
Extremely willing 
2…Ukubanomdla kakhulu / Very 
willing 3….Ukubanomdla nje / 
Somewhat willing 
4….Ukungabinamdla tu / Not at all 
willing 
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# 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / Write in 
unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
511 
 
Lilonke, ubuwoneliseke 
kangakanani luhlobo 
lwakho lokugqibela 
logcwanciso- ntsapho. ? 
Overall, how satisfied were you with 
your last birth control method? 
 
1….Ndoneliseke ngokugqithileyo/ 
Extremely satisfied 
2. …Ndoneliseke kakhulu 
Very satisfied 
3. …Ndoneliseke nje 
Somewhat 
satisfied 
4….Ndonelisekile 
andonelisekanga / Neither 
satisfied nor dissatisfied 
5….Andonelisekanga nje / 
Somewhat dissatisfied 
6….Andonelisekanga kakhulu / 
Very dissatisfied 
7….Andonelisekanga 
ngokugqithileyo// 
Extremely dissatisfied 
  
Kolu luhlu lulandelayo lwemibuzo, ndizakubuza izimvo zakho ngokunxulumene noluhlobo lokugqibela 
locwagciso- ntsapho ubulisebenzisa phambi kwanamhlanje. For the next series of questions, I will ask about your opinions 
regarding this last method of birth control you used before today 
512 
 
Uthintelo nzala luyalelwe 
ukusetyenziswa ngama-
xesha athile 
acwangcisiweyo. 
Kukulungele kangakanani 
okanye akukulungelanga 
kangakanani ukusebenzisa 
uthintelo nzala ngendlela 
oyalelwe ngayo ngqo (umz: 
yonke imihla, ngeveki, 
ngenyanqa, qho kwinyanga 
ezintathu)? Birth control is 
prescribed to be used on a specific 
schedule. How convenient or 
inconvenient was it for you to use or 
take your birth control exactly as 
directed (e.g., daily, weekly, monthly, 
every 3 monhts)? 
1….Kuluge ngokugqithileyo 
Extremely convenient 
2….Kulunge kakhulu / Very convenient 
3….Kungan ilung la /Somewhat 
convenient 4….Kulungile 
kungalunganga / Neither 
convenient or inconvenient 
5….Kungangandilungeli 
Somewhat inconvenient 
6….Kungangandilungeli kakhulu Very 
inconvenient 
7….Kungandandilung
eli 
ngokugqithileyo 
Extremely inconvenient 
-8…. Ayichaphazeli / Not applicable 
 
  
513 
 
Kukangaphi ulibala 
u uthatha okany  u e 
ucwangcisontsapho lwakho 
ngendlela oyalelwe ngayo 
ngqo? 
How often did you forget to use or take 
your birth control exactly as directed? 
 
1….Andikhe ndiluphose 
(ndilusebenzisa ngendlela 
ngalo lonke xesha) / None of the 
time (use perfectly all the time) 
2….Ixeshana nje /A little of the time 
3. …Ngamanye amaxesha/ Some of 
the time 
4. …Ixesha elininzi / Much of the time 
5. … Ngamaxesha amaninzi/ Most 
of the time 
6….Ngawo onke amaxesha 
All of the time 
-8…Ayichaphazeli / Not applicable 
  
514 
 
Ikuxhalabisa kangakanani 
into yokumitha nangona 
usebenzisa ucwagciso 
ntsapho? How much did you worry 
about getting pregnant even though you 
were using or taking birth control? 
1….Hayi konk  konke/ Not at 
all 2….Kancinci/ A little bit 
3….Kancinci nje /Somewhat 
4…Ngaphezulwana nje /Quite 
a bit 5…Kakhulu /A great deal 
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# 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / Write in 
unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
515 
 
Ubunexhala kangakanani 
lokuba ungakhulelwa 
kwixesha elizayo emva 
kokuyeka uthintelo nzala 
lwakho? How worried were you that 
you would not be able to get pregnant 
in the future after you stopped your 
birth control? 
1….Hayi konke konke/ Not at all worried 
2….Ndixhalabile kancinci 
/Somewhat worried 
3.…Ndixhalabe kakhulu /Very worried 
4….Ndixhalabe ngokugqithileyo 
Extremely worried 
  
Abafazi abaninzi a asebenzisa ucwangciso ntsapho banamava ngeempawu . Kule mibuzo ilandelayo, 
nceda usazise ukuba uphawu ngalunye lukukhathaze kangakanani na kwinyanga edlulileyo. Ukuba 
awukhange ufumane mava ngempawu, nceda uthi “kange ndibe nalo” 
Many women who use birth control experience symptoms. For these next questions, please let us know how much each of these symptoms have 
bothered you during the past month. If you did not experience a symptom, please say “did not have”. 
516 
 
Zikhu khathaze njani naziphina kwezimpawu kwinyanga ephelileyo. How bothered were you by any 
of the following symptoms in the last month: [FUNDA NGANYE NGANYE] [READ EACH ONE AND CIRCLE THEIR 
RESPONSE]   
Khangendi
- benayo 
Did not 
have 
 
Khange 
indikhathazeke 
konke konke 
Not at all 
bothered 
Indikhathaze 
kancinci 
A little 
bothered 
 
Ndikhathazeke 
nje 
Somewhat 
bothered 
Indikhathaze 
kakhulu 
Very bothered 
 
Indikhathaze 
ngokugqithil
e yo 
Extremely 
bothered 
 
Code 
 
A 
 
Ukukrala 
kwamabele 
Breast tenderness 
0 1 2 3 4 5 
 
B 
 
Ukuziva 
ungatyhilekangaFe
elin 
g moody 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
C 
 
Ukucaphuka 
Feeling irritated 0 1 2 3 4 5 
 
D 
 
Amaqhakuva/ 
amabala / Acne / 
spots 
0 1 2 3 4 5 
 
E 
 
Isiluma/amazantsi 
esisu/Cramping/ pelvic 
pain 
0 1 2 3 4 5 
 
F 
 
Amachaphaza/ 
ukopha phakathi 
kwamathuba 
okuba sexesheni 
/ Spotting/ bleeding 
between periods 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
G 
 
Intl ko e uhlungu 
H adaches 0 1 2 3 4 5 
 
H 
 
Umoya esuswini 
Bloating 0 1 2 3 4 5 
 
I 
 
Isicaphu-caphu 
Nausea 0 1 2 3 4 5 
 
J 
 
Ukutyeba / 
Weight gain 0 1 2 3 4 5 
 
K 
 
Ukuwelwa 
zinwele/ inwele 
eziyephuyephu 
Hair loss/ thinning 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
L 
 
Ezinye iimpawu 
(cacisa) Other 
symptoms 
(specify):   
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
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# 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / Write in 
unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
517 
 
Abanye abafazi baya 
exesheni nyanga zonke, 
ngelixesha abanye bengayi 
roqo ngenxa yocwangciso 
ntsapho abalusebenzisayo. 
Woneliseke kangakanani 
okanye awonelisekanga 
kangakanani 
bubungakanani bokuya 
kwakho exesheni? 
Some women experience a period every 
month, while others experience it less 
frequently due to their method of birth 
control. How pleased or displeased are 
you with the frequency with which you 
have a menstrual period? 
1….Ndoneliseke ngokugqitheleyo 
Extremely pleased 
2….Ndoneliseke kakhulu 
Very pleased 
3….Ndingoneliseka / Somewhat pleased 
4….Ndonelisekile ndingoneliseki 
Neither pleased nor displeased 
5….Ndinokungoneliseki nje 
Somewhat displeased 
6….Andonelisekanga kakhulu 
Very displeased 
7….Andonelisekan
ga 
ngokugqhithile
yo 
Extremely displeased 
 
  
518 
 
Ungawalinganisela kangakanani amandla ocwangciso-ntsapho 
lwakho lokugqibela ekwenzeni oku kulandelayo. [FUNDA NGANYE 
NGANYE] 
How would you rate the ability of your last birth control method to do the following: [READ 
EACH ONE] 
  
A 
 
Icutha isiluma 
Reduce menstrual pain 
 
1…Ngokugqithisil yo / 
Excellent 2…Kakuhle kakhulu 
/ Very good 3…Kakuhle / Good 
4…Phakathi / Fair 
5…Kakubi / Poor 
-8…Ayichaphazeli /Not applicable 
  
B 
 
Icwengisa igazi xa 
ndisexesheniLighten the flow of 
your menstrual period 
 
1…Ngokugqithisileyo / 
Excellent 2…Kakuhle kakhulu 
/ Very good 3…Kakuhle / Good 
4…Phakathi / Fair 
5…Kakubi / Poor 
-8…Ayichaphazeli /Not applicable 
  
C 
 
Icutha inani leentsuku 
endiya ngazo exesheni 
Reduce the number of days of your period 
 
1…Ngokugqithisileyo / 
Excellent 2…Kakuhle kakhulu 
/ Very good 3…Kakuhle / Good 
4…Phakathi / Fair 
5…Kakubi / Poor 
-8…Ayichaphazeli / Not applicable 
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523 Bonisa izinga lokuvumelana nezintetha 
zilandelayo ngokurhangqa impendulo 
Indicate level of agreement with the following statements by 
circling their response. 
Ndivuma 
ngamandl
a 
Strongly agree 
 
Ndiyavum
a nje 
Somewhat Agree 
 
Ndivuma 
ndingavu
mi 
Neither agree 
or disagree 
Andivu
mi nje 
Somewha
t 
Disagree 
Andivumi 
ngamandl
a 
Strongly 
Disagre
e 
Ayihapha
z eliNot 
Applicable 
 
Ikhowudi 
Yempendul
o 
Code 
 
A 
 
Ndiziva njengesiqhelo nangona 
ndisebenzisa ucwangciso ntsapho 
I feel like my usual self even though I am using birth control 
1 
 
2 
 
3 
 
4 
 
5 
 
-8 
 
 
B 
 
Akukho miphumela (umz: ukopha 
kancinci, isacaphu-caphu, 
ukungatyhileki,) ezayanyaniswa 
nocwangciso ntsapho 
There are no side effects (for example spotting. 
nausea, moodiness) associated with my birth 
control. 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
C 
 
Imiphumela yocwangciso ntsapho 
iphazamisa ubom bam bemihla ngemihla 
The side effects of my birth control interfere with my 
everyday life 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
D 
 
Imiphumela yocwangciso ntsapho 
iphazamisa ubom bam bokwabelana 
ngesondo. 
The side effects of my birth control interfere with my sex 
life 
1 
 
2 
 
3 
 
4 
 
5 
 
-8 
 
 
E 
 
Ubomi bami bokwabelena ngesondo 
buyazenzekela koluhlobo locwangciso 
ntsapho ndilusebenzisayo / My sex life has 
become more spontaneous with my current birth 
control 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
F 
 
Ucwangciso ntsapho buphazamisa 
imisebenzi yam yemhla ngemihla. 
My birth control interferes with my daily activities 
1 
 
2 
 
3 
 
4 
 
5 
 
-8 
 
 
G Ndonwabile nocwangciso ntsapho lwam. 
I am happy with my birth control 
1 2 3 4 5 -8 
 
H 
 
Inzuzo yocwangciso ntsapho lwam 
zidlula izinto ezingeyiyo inzuzo 
kucwangciso. 
The advantages of my birth control outweigh 
any of its disadvantages 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
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523 Bonisa izinga lokuvumelana nezintetha 
zilandelayo ngokurhangqa impendulo 
Indicate level of agreement with the following statements by 
circling their response. 
Ndivuma 
ngamandl
a 
Strongly agree 
 
Ndiyavum
a nje 
Somewhat Agree 
 
Ndivuma 
ndingavu
mi 
Neither agree 
or disagree 
Andivu
mi nje 
Somewha
t 
Disagree 
Andivumi 
ngamandl
a 
Strongly 
Disagre
e 
Ayihapha
z eliNot 
Applicable 
 
Ikhowudi 
Yempendul
o 
Code 
 
I 
 
Kube lula ukufakelela olucwangciso 
ntsapho kubom bam bemihla ngemihla / I 
have easily incorporated my birth control into my usual 
way of life or routine. 
1 
 
2 
 
3 
 
4 
 
5 
 
-8 
 
 
J 
 
Ucwangcis  ntsapho luphazamisa 
amandla endlela endisebenza ngayo 
okanye endizonwabisa ngayo. / My birth 
control interferes with my ability to work or engage in 
recreational activities 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
K 
 
Ucwangciso ntsapho lwam lwaziwa 
kuphela ngabo ndakhetha ukubaxelela 
okanye ukubabonisa (ndiyakwazi 
ukuligcina luyimfihlo ucwangcisontsapho 
lwam) 
My birth control is only known to those I chose to tell or 
show (I am able to keep my birth control private) 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
L 
 
Ndiziva ndizithembile ukuba 
ndisebenzisa ucwangciso ntsapho 
olundilungeleyo. 
I feel confident that I am using birth control that is right for 
me 
1 
 
2 
 
3 
 
4 
 
5 
 
-8 
 
 
M 
 
Ndiyakholwa ukuba ucwangiso-ntsapho 
lwam luhlobo olululungeleyo 
iqabane/amaqabane am kanye nam. / I 
believe that my birth control is the right method for my 
partner(s) and me 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
N 
 
Ndonelisekile kukuba kufuneka 
ndiluthathe roqo kangakanani 
ucwangciso ntsapho lwam. 
I am pleased with how often I need to use or take 
my birth control 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
O 
 
Ndiziva ndikhuselekile kukwazi 
ukuba ucwangciso ntsapho lwam 
luyasebenza. 
I feel secure knowing that my birth control works 
1 
 
2 
 
3 
 
4 
 
5 
 
-8 
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523 Bonisa izinga lokuvumelana nezintetha 
zilandelayo ngokurhangqa impendulo 
Indicate level of agreement with the following statements by 
circling their response. 
Ndivuma 
ngamandl
a 
Strongly agree 
 
Ndiyavum
a nje 
Somewhat Agree 
 
Ndivuma 
ndingavu
mi 
Neither agree 
or disagree 
Andivu
mi nje 
Somewha
t 
Disagree 
Andivumi 
ngamandl
a 
Strongly 
Disagre
e 
Ayihapha
z eliNot 
Applicable 
 
Ikhowudi 
Yempendul
o 
Code 
 
P 
 
Ndiqinisekile uku ucwangciso-ntsapho 
endilustebenzisayo alubeki 
emngciphekweni isifo sam seHIV./ I am 
confident that the method I am using poses no risk 
with my HIV disease 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
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ALCOHOL AND CIGARETTE USE (AUDIT SCALE – 600s) 
 
 
Ngoku sizakubuza imibuzo ngokusebenzisa kwakho utywala. Nceda urhangqe impenduloeyiyo ngombuzo ngamnye kule 
ingezantsi: 
We are now going to ask you some questions about your use of alcohol. Please circle the relevant answer for each question bellow: 
 
 
Score 0 1 2 3 4 Code 
 
 
 
601 
 
 
Ubusela kangakanani utywala? 
How often do you have a drink containing alcohol? 
 
 
Zange 
never 
 
Kanye 
ngenyanga 
okanye 
nangaphantsi 
Once per month 
or less 
Kabini 
ukuya 
kwisine 
enyangeni 
2-4 times a 
month 
Kabini 
ukuya 
kwisithathu 
evekini 
2-3 times per 
week 
Kane 
nangaphezulu 
evekini 
4 times or more 
per week 
 
 
If 0 604 
 
 
602 
 
Zingaphi iglasi zesiselo esinxilisayo 
oziselayo ngemini? 
How many standard drinks containing alcohol do you 
have on a typical day when drinking? 
1 okanye 
2 
1 or 2 
 
3 okanye 4 
3 or 4 
 
5 okanye 6 
5 or 6 
 
 
7 ukuya 9 
7 to 9 
 
10 okanye 
ngaphezulu 
10 or more 
 
 
 
603 
 
 
Kukangaphi usela iglasi ezintandathu 
nangaphezulu ngexesha? 
How many times do you have six standard drinks or more 
at time? 
 
 
Zange 
Never 
 
 
Ngaphantsi 
kwenyanya 
Less than monthly 
 
 
Ngenyanga 
Monthly 
 
 
Ngeveki 
Weekly 
 
Ngosuku 
okanye 
malunga 
nosuku 
Daily or almost 
daily 
 
 Umbuzo /Question 
 
Impendulo / Answer 
 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
604 
 
Ukhe watshaya isigareti kwezinyanga zilishumi elinambini zidlulileyo? 
Have you smoked cigarettes in the previous 12 months? 
 
0…. Hayi / No 
1…. Ewe / Yes 
 
0701 
 
 
605 
 
Utshaya izigareti ezingaphi ngosuku okanye ngeveki? 
On average, how many cigarettes do you smoke each day or week? 
 
  cigarettes per 
day or 
  cigarettes per week 
 
 Day:  
Wk:    
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 MENTAL HEALTH (KESSLER-10, 700s) 
Le mibuzo ilandelayo ikubuza ukuba ubuziva njani kule nyanga idlulileyo. Ngombuzo ngamnye yakha isangqa phants 
kwempendulo echaza ngokupheleleyo ubungakanani bexesha uvakalelwa njalo 
The following questions ask about how you have been feeling in the past 30 days. For each question, circle the option that best describes the amount of time that you feel that way. 
 
  Akukhange 
kubekhi 
xesha 
None of the 
time 
Kubekhona 
ixeshana 
A little of the 
time 
Abekhona 
amanye 
amaxesha 
Some of the 
time 
Kubekho 
amaxesha 
amaninzi 
Most of the 
time 
 
Ibilixesha 
lonke 
All of the time 
 
 
Code 
 
701 
 
Kule nyanga iphelileyo, kukangaphi uziva udiniwe 
ngaphandle kwesizathu? / During the last 30 days, about how often 
did you feel tired out for no good reason? 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
702 
 
Kule nyanga iphelileyo, kukangaphi uziva uphakuphaku? 
During the last 30 days, about how often did you feel nervous? 
0 
 
1 
 
2 
 
3 
 
4 
 
 
703 
 
Uphakuphaku kangangokuba kungekho nto 
inokukuthomalalisa? / During the last 30 days, about how often did 
you feel so nervous that nothing could calm you down? 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
704 
 
Kule nyanga iphelileyo, kukangaphi uziva uphelelwa 
ngamathemba? / During the last 30 days, about how often did you feel 
hopeless? 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
705 
 
Ungazinzanga okanye ugungqa? 
During the last 30 days, about how often did you feel restless or fidgety? 
0 
 
1 
 
2 
 
3 
 
4 
 
 
706 
 
Ungazinzanga de ugugqagungqe xa uhleli? / During the last 30 
days, about how often did you feel so restless you could not sit still? 
0 
 
1 
 
2 
 
3 
 
4 
 
 
707 
 
Kule nyanga iphelileyo, kukangaphi uziva ulusizana 
udakumbile? 
During the last 30 days, about how often did you feel depressed? 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
708 
 
Kule nyanga iphelileyo, kukangaphi uva yonke into 
ibiyimigudu? / During the last 30 days, about how often did you feel that 
everything was an effort? 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
Place Enrolment PTID 
label here 
e.g. PTID: 7  -    
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Date:  /  __/ __    
Score:  (to be calculated by study nurse or study coordinator) 
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 MENTAL HEALTH (KESSLER-10, 700s) 
Le mibuzo ilandelayo ikubuza ukuba ubuziva njani kule nyanga idlulileyo. Ngombuzo ngamnye yakha isangqa phants 
kwempendulo echaza ngokupheleleyo ubungakanani bexesha uvakalelwa njalo 
The following questions ask about how you have been feeling in the past 30 days. For each question, circle the option that best describes the amount of time that you feel that way. 
 
  Akukhange 
kubekhi 
xesha 
None of the 
time 
Kubekhona 
ixeshana 
A little of the 
time 
Abekhona 
amanye 
amaxesha 
Some of the 
time 
Kubekho 
amaxesha 
amaninzi 
Most of the 
time 
 
Ibilixesha 
lonke 
All of the time 
 
 
Code 
 
709 
 
Udakumbile kangangokuba kungekho nanye into 
engakonwabisayo? /During the last 30 days, about how often did you 
feel so sad that nothing could cheer you up? 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
710 
 
Kule nyanga iphelileyo, kukangaphi uziva ungena 
xabiso? /During the last 30 days, about how often did you feel worthless? 0  
1 
 
2 
 
3 
 
4 
 
 
Place Enrolment PTID 
label here 
e.g. PTID: 7  -    
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Violence Against Women (WHO, 800s) 
Sikwisigaba sokugqibela Siza kubuza imibizo yokugqibela embalwa ngokunxulumene nobundlobongela 
beqabane. 
We are at the last section of the survey. We are going to ask you a few last questions relating to partner violence. 
Kwinyanga ezi 12 ezidlulileyo ubukhe wehlelwa koku kulandelayo? 
Did you experience any of the following in the last 12 months? 
# 
 
Umbuzo / Question 
[Funda: To be read verbatim] 
Impendulo 
/Answer 
 
Ikhowudi 
Yempendul
o 
Code 
Uhlukumezo lwengqon 
Psychological Violence 801 
 
Iqabane lakho likhe lakuthuka okanye lakwenza awaziva 
kamnandi? 
Has your partner insulted you or made you feel bad about yourself? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
802 
 
Likhe lakwenze wazina umncinci phambi kwabanye abantu 
okanye lakwenza intlekisa phambi kwabanye abantu?? 
Has he belittled or humiliated you in front of other people? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
803 
 
Likhe lenza izinto likoyikisa okanye lakungcungcuthekisa 
ngabom? / Has he done things to scare or intimidate you on purpose? 
 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
804 
 
Like lakugrogrisa ngokonzakalisa okanye umntu 
okhathalayo ngaye? 
Has he threatened to hurt you or someone you care about? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
Uhlukumezo lomzimba 
Physical Violence 805 
 
Likhe lakuqhwaba ngempama okanye lakugibisela ngento 
enokukwenzakalisa? 
Has he slapped you or thrown something at you that could hurt you? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
806 
 
Likhe lakutyhala okanye lakunyola? 
Has he pushed or shoved you? 
 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
807 
 
Likhe lakubetha ngenqindi okanye ngento 
enokukonzakalisa? 
Has he hit you with a fist or with something else that could hurt you? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
808 
 
Likhe likukhabe, likurhuqe okanye likubethe? 
Has he kicked you, dragged you or beaten you up? 
 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
809 
 
Likhe likukrwitshe okanye likutshise ngabom? 
Has he choked or burnt you on purpose? 
 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
810 
 
Likhe likugrogrise ngokusebenzisa okanye lisevenzise 
umpu, imesi okanye nasiphina isixhobo kuwe? Has he 
threatened to use or actually used a gun, knife or other weapon against you? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
Sexual Violence 
811 
 
Likhe likunyanzele lise ngokwebalana ngesondo wena 
ungafuni? 
Has he physically forced you to have sexual intercourse when you didn’t want to? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
812 
 
Wakhe wabelane naye ngesondo ungafuni kuba usoyika 
into anokuyenza? 
Did you ever have sexual intercourse when you didn’t want because you were 
afraid of what he might do? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
Place Enrolment PTID 
label here 
e.g. PTID: 7  -    
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Date:  /  __/ __    
Enkosi ngexesha lakho ekuphenduleni le mibuzo. Inxaxheba yakho ibalulekile kuthi. 
Thank you for taking the time to answer these questions! Your responses are very important to us. 
To be completed by study nurse or study coordinator: 
Tick all to show completed. 
 ALCOHOL USE: Check questions 602 and 603, if question 602 has been coded 
as 2, 3 or 4, or 603 has been coded as 3 or 4, refer for alcohol counselling. 
 MENTAL HEALTH: Tally the score for 701-710 and record below. Refer for 
counselling if score is greater than or equal to 25 
Mental Health Score:    
 VIOLENCE: Check questions 803-813. If participant answered YES to ANY 
question, provide referral for partner violence services. 
Signature of study nurse or study coordinator:    
Signature date:    
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Violence Against Women (WHO, 800s) 
Sikwisigaba sokugqibela 813 
 
Likhe likunyanzelise ngokwabelana ngesondo ngendlela 
oyifumanisa ithoba isidima (eyeanyelisayo) okanye 
ekwenza intlekisa? 
Has he forced you to do something sexual that you found degrading or 
humiliating? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
 
Place Enrolment PTID 
label here 
e.g. PTID: 7  -    
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ART User Baseline Questionnaire: 2IUDnCT 
ART-User (Combined), Version 3.0 
on 28 Sept 2015 Page 1 9
# 
 
Umbuzo /Question 
[To be read verbatim] 
 
Impendulo / Answer 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / Write in 
unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempend
u lo Code 
  
Siyabulela ngokuthatha inxaxheba nokugqiba inkqubo yohluzo. Namhlanje ndiza kubuza 
imibuzo ngembali yempilo, indlela ophila ngayo, kunye neembono zakho ngocwangciso ntsapho. 
Siza kuthetha sobabini mhlawumbi ixesha elingaphezulwana kwemizuzu engama 60. Ukuba 
akuwuqondi umbuzo ndicela undazise, sikwazi ukuxoxa ngawo. 
Thank you for participating and completing the screening process. Today, I am going to ask you some questions about your health 
history, current living situation, and ideas about family planning. We will probably talk together for a little over an hour. If you don’t 
understand a question, please let me know and we can discuss it. 
Demographic Information (200s) 
201 
 
Umhla wakho wokuzalwa? 
What is your date of birth? 
 
 
Mingaphi iminyaka yakho? 
What is your age? 
 
 
DOB: 
| | | / | | | | / | | | | | 
(dd/mmm/yyyy) 
 
|  |  | iminyaka / years 
 
  
202 
 
Loluphi ulwimi olu 
phambili olisebenzisayo 
ekhaya? 
What is the primary language you 
use at home? 
 
1…..IsiXhos  / Xhosa 
2…..IsiZulu / Zulu 
3…..IsiBhulu / 
Afrikaans 4…..Isingesi 
/ English 
5…..Olunye (chaza) / Other   
  
203 
 
Sithini isimo sakho 
sobudlelwane 
neqabane? 
What is your current partnership 
status? 
 
1….Andinamntu / Single/ no steady 
partner/boyfriend 2….Sitshatile sihlala 
kunye /Married and live together 
3….Sitshatile asihlali kunye 
Married, live apart 
4….Sihlala kunye asitshatamga 
Live together, not married 
6 …Ndineqabane lwisisigxina, 
asihlali kunye/ Steady 
partner/boyfriend, not living together 
5 ... Okunye (chaza) Other (describe): 
 
  
204 
 
Uya sebenza ngoku? 
Are you currently employed? 
 
0…. Hayi / No 
1…. Ewe, manqaphanqapha / Yes, part-time 
2…. Ewe, isigxina / Yes, full time 
 
  
205 
 
Hlobo luni lwendlu ohlala 
kuyo? What type of house do you 
live in? 
 
1…..Imbacu / ityotyombe 
Informal dwelling / 
hokkie 
2…. ndihlala endlini / Live in a home 
3….Ifleti / indlu kamasipala 
Flat / municipal housing 
4.… Enye (chaza) / Other (specify): 
 
  
Place Enrol ent PTID 
label here 
e.g. PTID: 8  -    
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo /Question 
[To be read verbatim] 
 
Impendulo / Answer 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / Write in 
unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempend
u lo Code 
 
 
206 
 
Bangaphi abatwana 
nabantu abadla abahlala 
endlini yakho? 
How many adults and children 
live in your house? 
 
 
| | | abadala (kuquka nawe) 
adults (including yourself)) 
 
| | | abantwana / children 
 
  
   
 
207 
 
Liliphi elona banga 
eliphezulu 
oligqibileyo 
eskolweni? 
What is the highest level of school 
you have completed? 
 
Grade (1-12): 
|  | 
 
  
or Standard (1-10): 
|  | 
 
  
or Imfundo ephakamileyo (cacisa) 
Post secondary (explain) 
 
  
208 
 
Ingaba ungumfundi ngoku? 
Are you currently a student? 
 
0…. Hayi / No 
1…. Ewe, manqaphanqapha / Yes, part-time 
2…. Ewe, isigxina / Yes, full time 
  
209 
 
Unawo amanzi 
ahamba ngopipe 
endlini yakho? 
Do you have piped water in 
your house? 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
210 
 
Unayo indlu 
yangasese 
egungxulwayo? 
Do you have a flushing toilet in 
your house? 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
211 
 
Unawo na umbane 
endlini yakho? 
Do you have electricity in your 
house? 
 
0…. Hayi / No 
1…. Ewe, owam okanye igenerator / 
Yes, my own or a generator 
2…. Ewe owam osuka kummelwane / 
Yes, from my neighbor 
 
  
212 
 
Unaye umabona-kude 
osebenzayo endlini 
yakho? 
Is there a functioning television in 
your house? 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
213 
 
Unayo ifowuni 
ohamba uyiphethe 
esebenzayo? 
Do you have a functioning 
mobile phone? 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
Menstrual, pregnancy and fertility history (300s) 
Uqhuba kakuhle.Siza kubuza ngoku ngamava akho ngokuya exesheni. 
You are doing very well. I am now going to ask you some questions about your experiences with menses. 301 
 
Wawuneminyaka 
emingaphi ukuqala 
kwakho ukuya exesheni? 
How old were you when you 
started your menses? 
 
 
| | | iminyaka /years 
 
  
   
 
302 Kwinyanga ezintathu    
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo /Question 
[To be read verbatim] 
 
Impendulo / Answer 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / Write in 
unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempend
u lo Code 
 
 
 ezidlulileyo, zingaphi 
intsuku phakathi kosuku 
lokuqala lokuya exesheni 
nosuku lokuqala phambi 
kokuya exesheni 
kwinyanga elandeleyo? 
 
In the last three months, about how 
many days were there between the 
first day of your menstrual cycle 
and the first day of your next 
menstrual cycle? 
 
| | | iintsuku / ays 
 
999…. Andiyi exesheni /ukuya 
exesheni manqaphanqapha 
kuhlobo locwangciso ntsapho 
endilidebenzisayo (BCM) / 
Amenorrheic / not menstruating / 
irregular menses on current BCM 
 
[Show participant calendar to 
determine interval between bleeding 
episodes] 
 
 
999306 
 
303 
 
Kwezinyanga zi-3 
zidlulileyo uqhele 
ukopha intsuku 
ezingaphi xa usiya 
exesheni? 
In the last 3 months, for how many 
days did you usually bleed during 
your menses? 
 
| | | iintsuku /days 
 
  
304 
 
Ungayichaza njani imini 
owopha kakhulu ngayo 
(khetha eyona 
mpendulo)? 
How would you describe a 
“heavy bleeding” day? 
 
[Do not read 
responses, circle those 
that are mentioned by 
the respondent] 
 
1… Ngamaxa enditshintsha ngawo 
iiphedi 
By the number of times I change my 
menstrual product 
  
2….Xa ndibona amahlwili 
By whether I see blood clots 
  
3….Xa ndinentlungu okanye 
ezinye ingqaqambo 
By whether I have cramping or other pain 
  
4….Xa ndiphumela kwiphedi 
nokuba ndiyitshintshe 
amaxa amaninzi 
By whether I bleed through the product I am 
using even after changing frequently 
  
5… Ezinye cacisa / Other (specify): 
 
  
305 
 
Ngosuku owophe ngalo, 
uyitshintsha kangaphi 
ipadi? 
On one of these heavy days, about 
how many times did you have to 
change your menstrual product? 
 
| | | inani lamaxesha / times 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo /Question 
[To be read verbatim] 
 
Impendulo / Answer 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / Write in 
unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempend
u lo Code 
 
 
306 
 
Ungakuchaza njani ukuya 
kwakho  exesheni 
kwezinyanga zi-3 
zidlulileyo? In the last 3 months, 
how would you describe your bleeding 
pattern overall? 
 
[Read each of these 
options and have them 
select one best answer] 
 
1…. Ukuya exesheni 
ngokwesiqhelo iintsuku ezi 3 
ukuya kwezi 7 kungekho 
kopha phakathi 
kwalamaxesha 
Regular menstruation of 3-7 days with no 
bleeding in between these times 
2…. Manqapha nqapha (nganeno 
kwamatyeli amabini kweli 
xesha)Infrequent (less than 2 bleeding 
events in this time) 
3…. Ukopha qho, amatyeli 
angaphezulu kwesiqhelo okuya 
exesheni (ngaphezu kwamatyeli 
amane 
>=ngaphezu kwentsuku 
ezimbini kwinyanga ezintathu 
ezidlulileyo) / 
Frequent bleeding events tha are more 
frequent than menstruation (more than 4 
events (>=2 days) in last 3 months) 
4…. Ukopha ngokutsalileyo 
(mhlawumbi ityeli elinye litsale 
iintsuku ezilishumi 
nangaphezulu); kungenzeka 
ngokongezelelekileyo kunokuya 
exesheni ngokwesiqhelo / 
Prolonged bleeding (at least one event 
lasting >=10 days); may occur in addition to 
regular menstruation 
5….Ukopha manqaphanqapha 
okanye amachaphaza egazi 
kukho isiqabu phakathi 
kweziqendu ezide kune ntsuku 
ezili17 / Irregular bleeding/spotting with 
interval between episodes longer than 17 
days 
6….Khange ndophe kwezinyanga 
zintathu zidlulileyo. / No bleeding 
episodes in last 3 months 
7….Ezinye (chaza)/ Other (specify 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6308 
 
307 
 
Kwinyanga ezintathu ezidlulileyo, ingaba oku kulandelayo kuye kwenzeka na 
kuwe? 
(funda nganye) 
In the last 3 months, did you experience any of the following? [READ EACH ONE] 
 
A1 
 
Amantsi esisu 
anxulumene nokutya, 
ukuchama 
nokuyangasese. 
Lower abdominal pain 
related to 
eating/urination/having 
bowel movements; not 
pelvic pain. 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
B 
 
Ukopha kakhulu / amahlwili 
xa usexesheni 
Heavy bleeding or clots during menses 
0…. Hayi / No 
1…. Ewe / Yes 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo /Question 
[To be read verbatim] 
 
Impendulo / Answer 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / Write in 
unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempend
u lo Code 
 
 
C 
 
Ukopha 
manqaphanqapha 
(ukungayi exesheni 
nyanga zonke) 
Irregular bleeding (not having 
menses every month; menses less 
than 1/month)) 
 
0…. Hayi / No
1…. Ewe / Yes 
 
 
C1 
 
Ukopha 
okungaqhelekanga 
(ukuya exesheni 
nangaphezulu 
enyangeni enye) 
Irregular bleeding (having menses 
more than once in a month.) 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
D 
 
Ukopha phakathi 
kwentsuku zakho zokuya 
exesheni okanye 
amachaphaza egazi 
(ukopha kwenzeke 
ngaphezu kwentshuku 
ezimbini phambi kokuya 
exesheni nasemva kokuya 
exesheni kwaye 
kungeyonxalenye yokuya 
kwakho exesheni. 
Bleeding in between your menstrual 
cycle or spotting,(bleeding occurred 
more than two days before or after 
you had your cycle and was not part 
of cycle bleeding) 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
E 
 
Ezinye chaza 
Other, explain 
 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
308 
 
Uyathanda ukuya exesheni? 
Do you like having periods? 
 
0…. Hayi / No 
1…. Ewe / Yes 
99…. Andazi / Don’t know 
  
309 
 
Ukuba ungakhetha, 
ungathanda ukuya 
kangaphi exesheni? 
If you could choose, how often would 
you like to have a period? 
 
0…Andifuni / Never 
1….Ngenyanga/ Monthly 
2… Emva kwenyanga ezintatu 
At least every 3 months 
3….Ezinye chaza / Other (specify): 
 
  
310 
 
Wawukhe wasebenzisa 
ucwangciso ntsapho 
olwamisa ukuya kwakho 
exesheni? 
Have you ever used a 
contraceptive method which 
stopped your periods? 
0…. Hayi / No 
1…. Ewe / Yes 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 
 
Ngoku ndizakubuza imibuzo malunga nolwazi lwakho ngokhulelo? Now I am going to ask you some questions about your experiences with pregnancies. 
311 
 
Wakhe wakhululelwa? Have you ever been pregnant? 
 
0…. Hayi / No 
1…. Ewe /Yes 
0 skip to 316 
 
 
Previous Pregnancy History 
312 (Ukuba Ewe)Kumitho ngalunye uqale ngolokugqibela, nceda cacisa oku kulandelayo: [If Yes] for each pregnancy starting with the most recent please specify the following: 
 A. Unyaka 
[isiphumo
] 
Year 
[of outcome] 
 
B. Isiphumo? Outcome? 
 
1= Ukuzala usana oluphilayo 
/live birth 
2= Ukukhutswa kwesisu 
ngenjongo /induced 
abortion 
3= Ukuphuma 
kwesisu/ozelwe engaphili 
/miscarriage- still birth 
 
Ukuba 2 okanye 3, gqithela 
kumitho olulandelayo. 
Ukuba alukho olunye, yiya 
ku 313 
[If 2 or 3, go to next pregnancy. If 
no other pregnancy go to 313] 
C. Isini? Sex? 
 
1 = inkwenkwe 
male 
2= Intombi 
femal
e 
 
D. Isimo 
sentsholongwane sosana 
ngexesha ezalwa? HIV 
status of child at birth? 
 
0 = alikho ichaphaza 
/negative 1 = likhona 
ichaphaza / positive 
99 = Andazi, 
aluka vavanywa 
usana 
unknown: child untested 
 
E. Luyaphila ngoku? 
Currently alive? 
 
0= Hayi /no 
1= Ewe /yes 
 
Ukuba 1, gqithela 
kumitho 
olulandelayo. Ukuba 
alukho olunye, yiya 
ku 313 
[If 1, go to next pregnancy. If 
no other pregnancy go to 
313] 
 
F. Ubudala ngelixa esweleka? 
Age at death? 
 
Cacisa iinyanga okanye iminyaka 
[indicate in months or years] 
 
 
Gqithela kumitho olulandelayo. 
Ukuba alukho lolunye, yiya ku 313 
[Go to next pregnancy. If no other pregnancy go 
to 313] 
 
1 
 
      
2 
 
      
3 
 
      
4 
 
      
5 
 
      
6 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
313 
 
Kukhulelo lwakho lwangaphambil , wawukhe wadiban  nezinye zezingxaki zilandelayo? [Funda 
ngezantsi uphedulo] 
During your previous pregnancy or pregnancies did you ever experience any of the following? [Read list to participant] 
A 
 
Ukopha kakhulu de uthiwe 
igazi 
Excessive bleeding/needed transfusion 
0…. Hayi / No 
1…. Ewe / Yes 
  
B 
 
Uqhaqho lokubel ka 
Need for Cesarean section 
0…. Hayi / No 
1…. Ewe / Yes 
  
C 
 
Ukunyukelwa yi 
Highblood/ elumithweni 
/ High blood pressure/ pre-
eclampsia 
0…. Hayi / No 
1…. Ewe / Yes 
  
D 
 
Ukuxhuzula kwilixa 
lokusondela ukubeleka / 
Seizures around time of birth/ 
eclampsia 
0…. Hayi / No 
1…. Ewe / Yes 
  
E 
 
Ulwasuleleko 
ngelixesha ubelekayo 
okanye emva 
kokubeleka / Infection at 
time of delivery or immediately 
after 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
F 
 
Ukrazuko ebufazini 
okwenze 
ukuchama,ukuzithuma,oka
nye ukwabelana ngesondo 
kubenzima / Large tear or 
incision in vaginal area 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
314 
 
Ukuya kwakho exesheni 
kuye kwatshintsha enyakeni 
emva nje kokukhulelwa? Did 
your menses change within the year 
after your most recent pregnancy? 
0…. Hayi / No 
1…. Ewe / Yes 
99… Andazi / I don’t know 
 
0 316 
99 316 
 
 
315 
 
Ukuba ngu Ewe, njani? 
If yes, in what way? 
 
1….Ukuya exesheni kunqabile 
Menses became less regular 
2….Ukuya exesheni kubenje 
ngesiqhelo / Menses became 
more regular 
3….Ukuya exesheni akujiyanga / 
akuthathanga xesha elide / 
Menses became lighter or didn’t last as 
long 
4….Ukuya exesheni kakhulu / 
kwathatha ixesha elide / 
Menses became heavier/ lasted 
longer 
5….Andikaqalisi ukususela oko 
bendi khulelwe / Have not 
resumed menses following last 
pregnancy 
  
316 
 
Wakhe wacetyiswa ukuba 
ungabinabantwana ngenxa 
yezizathu zempilo yakho? 
Have you ever been advised for 
medical reasons not to get pregnant 
(again)? 
0…. Hayi / No 
1…. Ewe / Yes 
99… Andazi / I don’t know 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
Olu luhlu lulandelayo lwemibuzo lungeengcinga zak o ngoku nokuba uziva njani ngokuba 
nabantwana kwixesha elizayo. Ukuba umbuzo ukwenza ungakhululeki, nceda ndixelele sixoxe 
ngawo. Unako ukusala ukuphendula loo mbuzo. The next set of questions is about your CURRENT thoughts and feelings 
about having children in the future. If any question makes you uncomfortable, let me know so we may discuss it. You can also decline to 
answer that question 317 
 
Ungathanda ukuba 
nomntwana/abantwana, 
okanye ukheta ukungabi 
nabantwana konke konke? 
Would you like to have (a/another) 
child, or would you prefer not to have 
any (more) children? 
0….Andifuni konke konke 
No more / none 
1….Ndiyamfuna omnye umntwana 
Have a/nother child 
99…Andazi / andiqinisekanga 
Undecided/don’t know 
 
0 320 
 
99 320 
 
 
318 
 
Ungathanda ukulinda 
ixesha elingakanani 
ukususela ngoku phambi 
kokuba ubenomnye 
umntwana/ubenabanye 
abantwana? 
How long would you like to wait 
from now before the birth of 
a/nother child? 
 
 
 
|  |  | iminyaka / years 
or 
|  |  | iinyanga/ months 
 
Ukuba 
ngaphants
i 
kweminya
k a emi 2, 
yazisa 
umphathi 
wovavany
o 
[If less than 2 
years, alert 
the study 
coordinator] 
 
 
Yrs:    
 
 
Mos:    
 
319 
 
Bangaphi abantwana 
(abongezelelekileyo) 
onqwenela ukuba 
nabo kwixesha 
elizayo? 
How many (new) children do you 
wish to have in the future? 
 
|  |  | Bantwana / children 
 
  
320 
 
Likhe waxoxa ngomnqweno 
wakho wokufuna ukuba 
nabanye abantwana okanye 
umnqweno wakho 
wokungafuni ukuba 
nabantwana neqabane 
lakho lokugqibela 
obunalo/onalo? 
Have you discussed your desire to 
have more children or to not have 
more children with your most recent 
sexual partner? 
0…. Hayi / No 
1…. Ewe /Yes 
 
  
321 
 
Ingaba ukuba nesif  seHIV 
sakutshintsla kwizigqibo 
zakho zokuba 
nomntwana/okanye 
ukungabi namntwana? Did 
HIV diagnosis change your decision 
about WHETHER to have (a)nother 
child? 
0…. Hayi / No 
1…. Ewe /Yes 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
322 
 
Ing ba IHIV ithe yabangela 
ukuba utshintshe izigqibo 
zokuba uzakumfumana nini 
na umntwana/omnye 
umntwana? 
Did HIV diagnosis change your 
decision about WHEN to have 
(a)nother child? 
 
0…. Hayi / No 
1…. Ewe indenze ndafuna ukuba 
naye ngokukhawuleza. /Yes, 
made me want to have one sooner 
2…. Ewe indenze ndafuna 
ukulinda ixesha elide Yes, made 
me want to wait longer 
-8….Andifuni abanye abantwana 
Do not want a(nother) 
child 
 
  
323 
 
Ingaba ukuqala amachiza 
okuthomalalisa iHIV 
kusitshintshile na 
isigqibo sakho ngokuba 
nomntana okanye 
omnye umntwana ? 
Did starting ART change your decision 
about WHETHER to have (a)nother 
child? 
0…. Hayi / No 
1…. Ewe /Yes 
 
  
324 
 
Ingaba ukuqalisa 
amachiza okuthomalalisa 
iHIV kusitshintshile 
isigqibo sakho sokuba 
umfuna nini na 
umntwana okanye omnye 
umntwana. 
Did starting ART change your 
decision about WHEN to have 
(a)nother child? 
 
0…. Hayi / No 
1…. Ewe indenze ndafuna ukuba 
naye ngokukhawuleza. /Yes, 
made me want to have one sooner 
2…. Ewe indenze ndafuna 
ukulinda ixesha elide Yes, made 
me want to wait longer 
-8….Andifuni abanye abantwana 
Do not want a(nother) 
child 
 
  
Sexual Health and HIV (400s) 
Olu luhlu lulandelayo lwemibuzo luzakubuza ngempilo yakho yesondo namava esondo, ngamava 
akho ngezesondo kwanesimo sakho seHIV. Ukuba ufuna ixesha elongezelelweyo ukuphendula 
lemibuzo okanye uziva ungakhulelekanga, nceda undixelele. The next section of questions will ask about your sexual 
health and experiences as well as the HIV diagnosis. If you would like some extra time to answer these questions or are uncomfortable, 
please let me know. 
401 
 
Wawuneminyaka 
emingaphi ukuqala kwakho 
ukwabelana ngesondo? How 
old were you the first time you had 
sexual (vaginal) intercourse? 
 
|  |  | iminyaka / years 
 
  
402 
 
Mangaphi amaqabane 
akho esondo owakhe 
wanawo ebomini? How 
many sexual partners have you had 
in your lifetime? 
 
 
|  |  | inani labantu 
persons 
 
[If they cannot give an exact number, 
ask them to estimate] 
 
  
403 
 
Mangaphi amaqabane akho 
esondo okhe wanawo kulo 
nyaka uphelileyo? How many 
sexual partners have you had in the 
last year? 
 
 
|  |  | inani labantu 
Persons 
[If none enter 00] 
 
 
00 410 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
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 # 
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[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
404 
 
Un lo iqabane 
elisisigxina 
lokwabelana 
ngesondo? 
Do you currently have a steady 
sex partner? 
0…. Hayi / No 
1…. Ewe / Yes 
 
0 406 
 
 
405 
 
Kukangaphi wena 
neqabane lakho 
elisisigxina nisebenzisa 
ikhondom kwezi nyanga zi 
3 zigqithileyo? How often did 
you use condoms with your steady 
partner in the last 3 months? 
 
1….Rhoqo / always 
2….Phantse onke 
amaxesha(>75%) 
almost all the time (>75%) 
3….Maxesha onke (50% - 75%) 
most of the time (50% - 75%) 
4….Ngamanye amaxesha (25% 
- 50%) 
some of the time (25% - 50%) 
5….Andifane ndiyisebenzisa 
(<25%) 
rarely (<25%) 
6…Zange / never 
  
406 
 
Ingaba unawo amanye 
amaqabane obelana 
ngawo ngesondo? 
Do you currently have any (other) 
sexual partners? 
0…. Hayi / No 
1…. Ewe /Yes 
 
0 408 
 
 
407 
 
Ukuba ewe, 
kukangaphi 
usebenzisa ikhondom 
neliqabane 
kwezinyanga zintathu 
zidlulileyo? 
If yes, how often did you use condoms 
with this partner/these partners in the 
last 3 months? 
 
1….Rhoqo / always 
2….Phantse onke 
amaxesha(>75%) 
almost all the time (>75%) 
3….Maxesha onke(50% - 75%) 
most of the time (50% - 75%) 
4….Ngamanye amaxesha(25% - 
50%) 
some of the time (25% - 50%) 
5….Andifane 
ndiyisebenzisa(<25%) 
rarely (<25%) 
6…Zange / never 
  
408 
 
Xa usebenzisa 
iikhondom, zeziphi 
ezona zizathu 
zibalulekileyo zokuba 
usebenzise ikhondom? 
When you use condoms, what are the 
most important reasons you use 
condoms? 
 
 
Sukufunda 
okubhaliweyo, 
qwalasela okuphuma 
kumthathi nxaxeba 
[Do not read responses, note all 
the responses that are stated by 
the participants] 
 
0…Andisebenzisi ikhondom/ I 
don’t use condoms 
 
  
1 …Ukuthintela 
ukumitha/andifuni 
mntwana 
Protection against pregnancy/ doesn’t 
want child 
  
2….Isimo sentsholongwane 
seqaban  asaziwa / Partner’s 
HIV status unknown 
  
3….Iqabane alinachaphaza 
lentsholongwane / Partner 
HIV negative 
  
4….Iqabane liphila 
nentsholongwane; 
ukukhusela ulwasuleleko 
oliphindeneyo / 
Partner HIV positive; prevent re-infection 
  
5….Ukhuselo kwizifo 
ezifumaneka 
ngokwabelana 
ngesondo/intsholongwane 
STI/HIV protection 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
  6….Iqabane liyagxinin sa 
ukusebenzisa ikhondom / 
Partner insists to use them 
  
7….Ixhala lokuba 
ucwangcisontsapho 
aluthembekanga 
ngokupheleleyo/alusebenzi 
ngokupheleleyo / Concerned 
birth control method is unreliable/ not 
completely effective 
  
8….Andifuni iqabane lazi 
ukuba ndisebenzisa 
olunye uhlobo 
locwangcisontsapho / Don’t 
want partner to know I am using 
another birth control method 
  
9….Okunye(bhala) / Other (write in): 
 
  
409 
 
Xa uqikelela 
wabelana kangaphi 
ngesondo 
kwezinyanga 
zintathu zidlulileyo? 
In the last 3 months, about how 
often did you have sexual 
intercourse? 
 
0….Khange, ndabelane 
ngesondo kwezi nyanga zi 
3 zigqithileyo 
Not sexually active in the last 3 months 
1….Ngaphantsi kwenyanga 
<1 per month 
2….Kanye – kathathu ngenyanga 
1-3 times per month 
3….Kanye ngeveki / 1 per week 
4….Kabini ukuya kathathu evekini 
2-3 per week 
5….Kane ukuya kathandathu 
evekini 
4-6 per week 
6….Yonke imihla okanye kaninzi 
Daily or more frequently 
  
 
409a 
 
Zingaphi iintsuku ogqibele 
ngazo ukwabelana 
ngesondo? 
How many days ago did you last 
have sexual intercourse? 
 
 
  days 
(Enter 99 if participant does 
not remember) 
 
  
 
409b 
 
Ingaba iqabane lakho 
lisebenzise ikhondom 
yotata okanye wena 
usebenzise eyotata 
okugqibela kwakho 
ukwabelana ngesondo? 
Did your partner use a male condom or 
did you use a female condom the last 
time you had sex? 
0….H i / No 
1….Ewe /Yes 
99…Andikhumbuli/andazi .I don’t 
know/ recall 
 
  
  
Ngoku, ndingakubuza imibuzo malunga netsholongwane kagawulayo nokhathalelo. Now I would like 
to ask you some questions about your HIV diagnosis and care 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
412 
 
Uzaze nini ukuba 
uphila neHIV? 
When were you diagnosed with HIV? 
 
 
|  |  |  |month 
 
|  |  |  |  year 
 
[If participant unsure, please 
show them calendar and ask 
them to estimate. If they really 
do not know the month, enter 
999] 
 
  
Mo  
Yr     
 
413 
 
Uqale ukuzazi ukuba 
uneHIV ngexesha 
ubukhulelwe? 
Were you first diagnosed with HIV 
during a pregnancy? 
0….Hayi / No 
1….Ewe /Yes 
 
  
414 
 
Uye watshintsha indlela 
yocwangisontsapho 
ngenxa yokuphila 
nentsholongwane? 
Did you change your birth control 
method due to your HIV diagnosis? 
 
0….Hayi / No 
1….Ewe /Yes 
 
0 416 
 
 
415 
 
Ukuba Ewe, ngoba? If yes, why? 
 
   
416 
 
Ukuya kwakho exesheni 
kuye kwatshintsha 
wakuzazi ukuba uphila 
neHIV? 
Did your menses change after you 
were diagnosed with HIV? 
0…. Hayi / No 
1…. Ewe / Yes 
 
0 418 
 
 
417 
 
Ukuba ngu ewe, njani? 
[If yes], how? 
 
1….Ukuya exesheni kunqabile 
Menses became less regular 
2….Ukuya exesheni kubenje 
ngesiqhelo / Menses became 
more regular 
3….Ukuya exesheni akujiyanga/ 
akuthathanga xesha elide / 
Menses became lighter or didn’t last as 
long 
4….Ukuya exesheni kakhulu / 
kwathatha ixesha elide / 
Menses became heavier/ lasted 
longer 
5…. Okunye(bhala) / Other (write in): 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
418 
 
Kwinyanga ezi 6 ezidlulileyo, 
kukangaphi ubonana 
nomnikezi wezempilo kule 
kliniki ngokhathalelo lwakho 
lweHIV? 
In the last 6 months, how many 
times did you see a provider at clinic 
for your HIV care? 
 
|  |  | kangaphi/times 
 
  
419 Usichazile isimo sakho sentsholongwane kwaba...? 
Have you disclosed your HIV status to…? 
A 
 
Abantwana / your children 
 
0…. Hayi / No 
1…. Ewe /Yes 
-8…Not applicable 
  
B 
 
Mama / mother 
 
0…. Hayi / No 
1…. Ewe /Yes 
-8…Not applicable 
  
C 
 
Tata / father 
 
0…. Hayi / No 
1…. Ewe /Yes 
-8…Not applicable 
  
D 
 
Utatomkhulu/makhulu 
/grandparents 
 
0…. Hayi / No 
1…. Ewe /Yes 
-8…Not applicable 
  
E 
 
Umnakwenu/dadewenu / 
Brothers or sisters 
 
0…. Hayi / No 
1…. Ewe / Yes 
-8…Not applicable 
  
F 
 
Iqabane llokugqibela 
okanye langokul 
lokwabelana ngesondo 
Current/most recent sexual partner 
0…. Hayi / No 
1…. Ewe / Yes 
-8….Not applicable 
  
420 
 
Uyasazi isimo 
sentsholongwane 
kagawulayo seqabane 
lakho langoku okanye 
lokugqibela ubunalo? 
Do you know your current/most 
recent partner’s HIV status? 
0…. Hayi / No 
1…. Ewe /Yes 
 
  
421 
 
Ingaba iqabana lakho 
langoku liyazi ukuba 
uthatha amachiza 
okuthomalalisa iHIV? 
Does your current/most recent 
sexual partner know you are 
taking ART? 
 
0…. Hayi / No 
1…. Ewe /Yes 
 
  
422 
 
Uqale nini ukuthatha 
amachiza okuthomalisa 
itsholongwane 
kagawulayo?When did you start 
taking ART medicines? 
 
|  |  |  |month 
 
|  |  |  |  year 
 
[If participant unsure, please 
show them calendar and ask 
them to estimate. If they really 
do not know the month, enter 
999] 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
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Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
423 
 
Kw kutheni ukuze uqale 
ukuthatha amachiza 
okuthomalisa 
itsholongwane 
kagawulayo? 
Why did you start taking ART? 
 
(If participant has had 
history of stopping then 
resuming ART, please list 
the most recent reason for 
starting ART) 
 
1...Low CD4 count 
 
0…. Hayi / No 
1…. Ewe /Yes 
 
 
2. .. Pregnancy 
 
0…. Hayi / No 
1…. Ewe /Yes 
 
3. .. Tuberculosis 
 
0…. Hayi / No 
1…. Ewe /Yes 
 
4. .. Other infection due to HIV 
 
0…. Hayi / No 
1…. Ewe /Yes 
 
5. .. Cervical cancer 
 
0…. Hayi / No 
1…. Ewe /Yes 
 
6. .. Other (specify): 
 
0…. Hayi / No 
1…. Ewe /Yes 
 
424 
 
Ingaba ulitshintshile 
uhlobo lwakho 
locwangciso emva 
kokuba uqale amachiza 
okuthomalalisa iHIV 
(ART)? 
Did you change your birth control 
method due to starting ART 
medicines? 
 
0….Hayi / No 
1….Ewe /Yes 
 
0 426 
 
 
425 
 
Ukuba ngu-ewe,ngoba? 
If yes, why? 
 
   
426 
 
Ingaba ukuya kwakho 
exesheni kutshintshile 
uhlobo emva kokuba uqale 
amachiza okuthomalalisa 
iHIV? 
Did your menses change after you 
started ART medicines? 
 
0…. Hayi / No 
1…. Ewe / Yes 
-8. .. akungqamenanga ngenxa 
yokuya exesheni ngohlobo 
locwangciso endilusebenzisayo 
Not applicable due to amenorrhea from 
family planning use 
0 428 
 
 
427 
 
Ukuba ngu-ewe, 
njani? [If yes], how? 
 
1….Ukuya ex sheni kunqabile 
Menses became less regular 
2….Ukuya exesheni kubenje 
ngesiqhelo / Menses became 
more regular 
3….Ukuya exesheni akujiyanga/ 
akuthathanga xesha elide / 
Menses became lighter or didn’t last as 
long 
4….Ukuya exesheni kakhulu / 
kwathatha ixesha elide / 
Menses became heavier/ lasted 
longer 
5…. Okunye(bhala) / Other (write in): 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
428 
 
Ukusebenzisa ikhondom 
nalo naliphi iqabane 
kutshintshile ukusukela oko 
waqala amachiza 
okuthomalalisa iHIV? 
Has using condoms with any sexual 
partner changed since you started 
ART? 
 
0...No
1...Ewe, sisebenzisa ngakumbi 
ngoku Yes, we use them more often 
2...Ewe, sisebenzisa nganeno 
kwesiqhelo Yes, we use them less 
often 3... Ewe, siyekile 
ukusebenzisa ikhondom Yes, we 
stopped using condoms 
  
  
Contraceptive History (500s) 
Ngoku ndizakubuza imibuzo eyongeziweyo malunga namava akho ngocwanciso-ntsapho. 
Now I am going to ask you some additional questions about your experiences with birth control or family planning 
501 
 
Ngaphambi kokungenela 
oluphando, wakhe weva 
nge IUD okanye iloop? 
Prior to joining this study, had you 
ever heard of the IUD or loop? 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
502 
 
Wakhe weva ngolunye 
uhlobo locwangciso-
ntsapho olufakelwayo 
olubizwa ngokuba yi-
implant? 
Have you ever heard of the 
contraceptive method known as the 
implant? 
0…. Hayi / No 
1…. Ewe / Yes 
 
  
503 
 
Wena okanye iqabane lakho nakhe nazisebenzisa na i…./ Have you or your partner ever used….. . 
[funda into nganye] 
A 
 
Ipilisi / eziselwayo 
Pill or Oral Contraceptive 
 
0….Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
B 
 
Net-en / naliti (istofu 
senyanga ezi 2) 
Net-en/2 monthly injectable 
0… Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
C 
 
Idepo naliti (istofu senyanga 
ezi 3) 
DepoProvera/3 monthly Injectable 
0….Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
D 
 
Isivalo-mlomo sesibeleko 
(loop) 
IUD (Loop) 
 
0… Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
E 
 
Ikhondom yamadoda 
Male condom 
 
0… Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
F 
 
Ikhondom yabafazi 
Female condom 
 
0… Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
G 
 
Isivalo nzala samadoda 
Male sterilization 
 
0….Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
H 
 
Ukurhoxisa ubudoda 
phambi kokuchama 
imbewu yobudoda 
Withdrawal (removal of penis 
before ejaculation) 
0….Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
  
I 
 
Okunye (chaza) / other 
method (explain) 
   
 
0….Hayi / No 
1….Ewe / Yes 
99...Adiqinisekanga / Not sure 
 
  
504 
 
Uye watshintsha uhlobo 
locwangciso ntsapho 
kwezi nyanga zi 12 
zidlulileyo? 
Did you change your method of 
contraception in the past 12 
months? 
0…. Hayi / No 
1…. Ewe / Yes 
 
0 506 
 
 
505 
 
Ukuba ewe, kutheni / If Yes, 
why? 
 
[Ungazifundeli ngaphandle 
iiopshini Rhangqa konke 
umthathi nxaxheba 
akuxelela kona] 
[DO NOT READ OPTIONS. CIRCLE ALL 
THAT THE PARTICIPANT IS TELLING 
YOU HERSELF] 
 
1….Ndifuna 
ukukhulelwa 
Wanted to fall pregnant 
  
2….Andabelani ngesondo 
Not sexually active 
  
3….Ndohlukene neqabane 
Broke up with partner 
  
4….Ukopha 
kakhulu/ 
manqaphanqap
ha 
Heavy/irregular bleeding 
  
5….Ndandingayi exesheni 
rhoqo 
Did not have regular menstruation 
  
6….Ukuba nentlungu 
nengqaqambo xa 
ndisexesheni/ Too much 
pain/cramping with periods 
  
7….Luyandityebisa / Gained weight 
 
  
8….Luyandibhityisa / Lost weight 
 
  
9….Iqabane alifuni sisebenzise 
ucwangciso ntsapho 
lwangaphambili / Partner did not 
want us to use the prior method of 
contraception 
  
10...Andazi ukuba uhlobo 
locwangciso ntsapho luza 
kusichaphazela njani isifo 
sam seHIV / Did not know how the 
method will affect my HIV illness 
  
11… Ndixhalabile lulosuleleko / 
Worried abour risk of infections 
  
12….Ezinye, cacisa / Other, specify: 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
506 
 
Ugqibele nini 
ukusebenzisa 
ucwangciso ntsapho 
ngaphambi 
kwanamhlanje? 
When was the last time you 
used a contraceptive method 
before today? 
 
UMYALEZO KUMSEBENZI: ikhondom 
lolunye uhlobo locwangciso ntsapho. 
Ukuba ibisisitofu (DMPA okanye NET-
EN, yongeza inani eliqikelelweyo 
lwenyanga ukususela kwisitofu 
sokugqibela) 
[STAFF NOTE: Condom use is also a 
contraceptive method. If it was an 
injectable (DMPA or Net-En, add 
approximate number of months 
since last injection] 
 
|  |  | iinyanga /months ago 
 
00 = Ukuba ngeneno 
kwenyanga enye ukuza 
kuthi ga namhlanje, xa 
ubuza kubuyela istofu 
esilandelayo 
00 = if less than 1 month ago 
 
Bhala “24” iinyanga ukuba 
kungaphezu kweminyaka 
emi 2 / Enter ‘24” if 2 or more years 
ago 
  
507 
 
Loluphi uhlobo 
l cwangciso- ntsapho 
obulusebenzisa 
ngaphambi 
kwanamhlanje? 
What is the last cont aceptive 
method you used before today? 
 
Khetha ibenye. Ukuba 
usebenzise ikhondom 
nolunye uhlobo 
locwangciso, khetha olunye 
uhlobo] 
 
[STAFF NOTE: Select only one. If they 
used a condom plus another method, 
choose the non-condom method] 
 
1….Ipilisi / eziselwayo / Pill or 
Oral Contraceptive 
2….Net-en inaliti yenyanga 
ezimbini 
Net-en 2 monthly injectable 
3….Idepo inaliti yenyanga 
ezintathu 
DepoProvera 3 monthly Injectable 
4….Isivalo-mlomo sesibeleko (loop) 
IUD (Loop) 
5….Isiciko somlomo wesibeleko 
Diaphragm 
6….Ikhondom yamadoda / Male 
condom 7….Ikhondom yabafazi / 
Female condom 8….Isivalo nzala 
samadoda 
Male sterilization 
9. ... Ukurhoxisa ubudoda phambi 
kokuchama imbewu yobudoda 
Withdrawal (removal of penis 
before ejaculation) 
10..Ukungabelani ngesondo 
Abstinence (not having sexual intercourse) 
11..Okunye (chaza) /other (explain) 
 
  
508 
 
Ngeloxesha, iqabane lakho 
belisazi ukuba usebenzisa 
olu hlobo? At that time, did your 
sexual partner know you were using 
this method? 
0…..Hayi / No 
1…..Ewe / Yes 
99…Andazi / I don’t 
know 
  
509 
 
Ungaluncoma uhlobo 
lwakho lokugqibela 
locwangciso- ntsapho 
kwisihlobo okanye 
kwilungu losapho lwakho? 
Would you recommend your last 
method of birth control to a friend or 
family member? 
 
1….Ewe, ngokuqinisekileyo 
Yes, I would definitely recommend it 
2….Ewe, ndingazama 
Yes, I would probably 
recommend it 
3….Andiqinisekanga / I am 
unsure 4….Hayi, andinako 
No, I would probably not recommend it 
5….Hayi ngokuqinisekiley 
No, I would definitely not recommend it 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
510 
 
Ukuba olu 
phandobelungaqhu beki 
ubuzakuba nomdla 
kangakanani 
wokuqhubekeka 
usebenzisa uhlobo lwakho 
lokugqibela lo wangciso- 
ntsapho? If this study were not 
occurring, how willing are you to 
continue using your last birth control 
method? 
1….Uk ba nomdla kakhulu
kakhulu ndingaqhubeka / 
Extremely willing 
2…Ukubanomdla kakhulu / Very 
willing 3….Ukubanomdla nje / 
Somewhat willing 
4….Ukungabinamdla tu / Not at all 
willing 
 
  
511 
 
Lilonke, ubuwoneliseke 
kangakanani luhlobo 
lwakho lokugqibela 
logcwanciso- ntsapho. ? 
Overall, how satisfied were you with 
your last birth control method? 
 
1….Ndoneliseke ngokugqithileyo/ 
Extremely satisfied 
2. …Ndoneliseke kakhulu 
Very satisfied 
3. …Ndoneliseke nje 
Somewhat satisfied 
4….Ndonelisekile 
andonelisekanga / Neither 
satisfied nor dissatisfied 
5….Andonelisekanga nje / 
Somewhat dissatisfied 
6….Andonelisekanga kakhulu / 
Very dissatisfied 
7….Andonelisekanga 
ngokugqithileyo// Extremely 
dissatisfied 
  
Kolu luhlu lulandelayo lwemibuzo, ndizakubuza izimvo zakho ngokunxulumene noluhlobo lokugqibela 
locwagciso- ntsapho ubulisebenzisa phambi kwanamhl je. For the next series of questions, I will ask about your 
opinions regarding this last method of birth control you used before today 
512 
 
Uthintelo nzala luyalelwe 
ukusetyenziswa ngama-
xesha athile 
acwangcisiweyo. 
Kukulungele kangakanani 
okanye akukulungelanga 
kangakanani ukusebenzisa 
uthintelo nzala ngendlela 
oyalelwe ngayo ngqo (umz: 
yonke imihla, ngeveki, 
ngenyanqa, qho kwinyanga 
ezintathu)?? Birth control is 
prescribed to be used on a specific 
schedule. How convenient or 
inconvenient was it for you to use or 
take your birth control exactly as 
directed (e.g., daily, weekly, monthly, 
every 3 monhts)? 
1….Kuluge ngokugqithileyo 
Extremely convenient 
2….Kulunge kakhulu / Very convenient 
3….Kungandilungela 
/Somewhat convenient 
4….Kulungile kungalunganga / 
Neither convenient or inconvenient 
5….Kungangandilungeli 
Somewhat inconvenient 
6….Kungangandilungeli kakhulu 
Very inconvenient 
7….Kungandandilung
eli 
ngokugqithileyo 
Extremely inconvenient 
-8…. Ayichaphazeli / Not applicable 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
513 
 
Kukangaphi ulibala 
ukuthatha okanye utye 
ucwangcisontsapho 
lwakho ngendlela 
oyalelwe ngayo ngqo? 
How often did you forget to use or take 
your birth control exactly as directed? 
 
1….A dikhe ndiluphose 
(ndilusebenzisa ngendlela 
ngalo lonke xesha) / None of the 
time (use perfectly all the time) 
2….Ixeshana nje /A little of the time 
3. …Ngamanye amaxesha/ Some of 
the time 
4. …Ixesha elininzi / Much of the time 
5. … Ngamaxesha amaninzi/ 
Most of the time 
6….Ngawo onke amaxesha 
All of the time 
-8…Ayichaphazeli / Not applicable 
  
514 
 
Ikuxhalabisa kangakanani 
into yokumitha nangona 
usebenzisa ucwagciso 
ntsapho? How much did you worry 
about getting pregnant even though 
you were using or taking birth control? 
1….Hayi konke konke/ Not at 
all 2….Kancinci/ A little bit 
3….Kancinci nje /Somewhat 
4…Ngaphezulwana nje /Quite 
a bit 5…Kakhulu /A great deal 
  
515 
 
Ubun xhala k ngakanani 
lokuba ungakhulelwa 
kwixesha elizayo emva 
kokuyeka uthintelo nzala 
lwakho? How worried were you 
that you would not be able to get 
pregnant in the future after you 
stopped your birth control? 
1….Hayi konke konke/ Not at all 
worried 
2….Ndixhalabile kancinci 
/Somewhat worried 
3.…Ndixhalabe kakhulu /Very worried 
4….Ndixhalabe ngokugqithileyo 
Extremely worried 
  
Abafazi abaninzi abasebenzisa ucwangciso ntsapho banamava ngeempawu . Kule mibuzo 
ilandelay , nceda usazise ukuba uphawu ngalunye lukukhathaze kangakanani na kwinyanga 
edlulileyo. Ukuba awukhange ufumane mava ngempawu, nceda uthi “kange ndibe nalo” 
Many women who use birth control experience symptoms. For these next questions, please let us know how much each of these symptoms 
have bothered you during the past month. If you did not experience a symptom, please say “did not have”. 
516 
 
Zikhu khathaze njani naziphina kwezimpawu kwinyanga ephelileyo. How bothered were you by 
any of the following symptoms in the last month: [FUNDA NGANYE NGANYE] [READ EACH ONE AND CIRCLE THEIR 
RESPONSE]   
Khangendi
- benayo 
Did not 
have 
 
Khange 
indikhathazeke 
konke konke 
Not at all 
bothered 
Indikhathaze 
kancinci 
A little 
bothered 
Ndikhathazeke 
nje 
Somewhat 
bothered 
Indikhathaze 
kakhulu 
Very bothered 
 
Indikhathaze 
ngokugqithil
e yo 
Extremely 
bothered 
 
Code 
 
A 
 
Ukukrala 
kwamabel
e 
Breast tenderness 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
B 
 
Ukuziva 
ungatyhilekangaF
eeli 
ng moody 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
C 
 
Ukucaphuka 
Feeling irritated 0 1 2 3 4 5 
 
D 
 
Rhashalala / 
amabala / Acne / 
spots 
0 1 2 3 4 5 
 
E 
 
Isiluma/amazan
tsi 
esisu/Cramping/ 
pelvic pain 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 # 
 
Umbuzo / Question 
[Funda ngohlobo 
ebhalwe ngalo /To be read 
verbatim] 
 
Impendulo / Answer Key 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
F 
 
Am chaphaza/ 
ukopha phakathi 
kwamathuba 
okuba sexesheni 
/ Spotting/ bleeding 
between periods 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
G 
 
Intl ko e uhlungu 
H adaches 0 1 2 3 4 5 
 
H 
 
Umoya esuswini 
Bloating 0 1 2 3 4 5 
 
I 
 
Isicaphu-caphu 
Nausea 0 1 2 3 4 5 
 
J 
 
Ukutyeba / 
Weight gain 0 1 2 3 4 5 
 
K 
 
Ukuwelwa 
zinwele/ inwele 
eziyephuyephu 
Hair loss/ thinning 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
L 
 
Ezinye iimpawu 
(cacisa) Other 
symptoms 
(specify):   
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
517 
 
Abanye abafazi baya 
exesheni nyanga zonke, 
ngelixesha abanye bengayi 
roqo ngenxa yocwangciso 
ntsapho abalusebenzisayo. 
Woneliseke kangakanani 
okanye awonelisekanga 
kangakanani 
bubungakanani bokuya 
kwakho exesheni? 
Some women experience a period 
every month, while others experience it 
less frequently due to their method of 
birth control. How pleased or 
displeased are you with the frequency 
with which you have a menstrual 
period? 
1….Ndoneliseke ngokugqitheleyo 
Extremely pleased 
2….Ndoneliseke kakhulu 
Very pleased 
3….Ndingoneliseka / Somewhat pleased 
4….Ndonelisekile ndingoneliseki 
Neither pleased nor displeased 
5….Ndinokungoneliseki nje 
Somewhat displeased 
6….Andonelisekanga kakhulu 
Very displeased 
7….Andonelisekan
ga 
ngokugqhithile
yo 
Extremely displeased 
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Umbuzo /Question 
[To be read verbatim] 
 
Impendulo / Answer 
(Bhala ngaphandle kokuba 
uyalelwe ngolunye uhlobo / 
Write in unless otherwise indicated) 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
 
 
518 
 
Ungawalinganisela kangakanani amandla cwangciso-ntsapho 
lwakho lokugqibela ekwenzeni oku kulandelayo. [FUNDA 
NGANYE NGANYE] 
How would you rate the ability of your last birth control method to do the following: 
[READ EACH ONE] 
  
A 
 
Icutha isiluma 
Reduce menstrual pain 
 
1…Ngokugqithisileyo / 
Excellent 2…Kakuhle kakhulu 
/ Very good 3…Kakuhle / Good 
4…Phakathi / Fair 
5…Kakubi / Poor 
-8…Ayichaphazeli /Not applicable 
  
B 
 
Icwengisa igazi xa 
ndisexesheniLighten the flow of 
your menstrual period 
 
1…Ngokugqithisileyo / 
Excellent 2…Kakuhle kakhulu 
/ Very good 3…Kakuhle / Good 
4…Phakathi / Fair 
5…Kakubi / Poor 
-8…Ayichaphazeli /Not applicable 
  
C 
 
Icutha inani leentsuku 
endiya ngazo exesheni 
Reduce the number of days of your 
period 
 
1…Ngokugqithisileyo / 
Excellent 2…Kakuhle kakhulu 
/ Very good 3…Kakuhle / Good 
4…Phakathi / Fair 
5…Kakubi / Poor 
-8…Ayichaphazeli / Not applicable 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 
 
523 Bonisa izinga lokuvumelana nezintetha 
zilandelayo ngokurhangqa impendulo 
Indicate level of agreement with the following statements by 
circling their response.: 
Ndivuma 
ngamandl
a 
Strongly agree 
 
Ndiyavum
a nje 
Somewhat Agree 
 
Ndivuma 
ndingavu
mi 
Neither agree 
or disagree 
Andivu
mi nje 
Somewha
t 
Disagree 
Andivumi 
ngamandl
a 
Strongly 
Disagre
e 
Ayihapha
z eliNot 
Applicable 
 
Ikhowudi 
Yempendul
o 
Code 
 
A 
 
Ndiziva njengesiqhelo nangona 
ndisebenzisa ucwangciso ntsapho 
I feel like my usual self even though I am using birth control 
1 
 
2 
 
3 
 
4 
 
5 
 
-8 
 
 
B 
 
Akukho miphumela (umz: ukopha 
kancinci, isacaphu-caphu, 
ukungatyhileki,) ezayanyaniswa 
nocwangciso ntsapho 
There are no side effects (for example spotting. 
nausea, moodiness) associated with my birth 
control. 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
C 
 
Imiphumela yocwangciso ntsapho 
iphazamisa ubom bam bemihla ngemihla 
The side effects of my birth control interfere with my 
everyday life 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
D 
 
Imiphumela yocwangciso ntsapho 
iphazamisa ubom bam bokwabelana 
ngesondo. 
The side effects of my birth control interfere with my sex 
life 
1 
 
2 
 
3 
 
4 
 
5 
 
-8 
 
 
E 
 
Ubomi bami bokwabelena ngesondo 
buyazenzekela koluhlobo locwangciso 
ntsapho ndilusebenzisayo / My sex life has 
become more spontaneous with my current birth 
control 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
F 
 
Ucwangciso ntsapho buphazamisa 
imisebenzi yam yemhla ngemihla. 
My birth control interferes with my daily activities 
1 
 
2 
 
3 
 
4 
 
5 
 
-8 
 
 
G Ndonwabile nocwangciso ntsapho lwam. 
I am happy with my birth control 
1 2 3 4 5 -8 
 
H 
 
Inzuzo yocwangciso ntsapho lwam 
zidlula izinto ezingeyiyo inzuzo 
kucwangciso. 
The advantages of my birth control outweigh 
any of its disadvantages 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
I 
 
Kube lula ukufakelela olucwangciso 
ntsapho kubom bam bemihla ngemihla / I 
have easily incorporated my birth control into my usual 
way of life or routine. 
1 
 
2 
 
3 
 
4 
 
5 
 
-8 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 
 
523 Bonisa izinga lokuvumelana nezintetha 
zilandelayo ngokurhangqa impendulo 
Indicate level of agreement with the following statements by 
circling their response.: 
Ndivuma 
ngamandl
a 
Strongly agree 
 
Ndiyavum
a nje 
Somewhat Agree 
 
Ndivuma 
ndingavu
mi 
Neither agree 
or disagree 
Andivu
mi nje 
Somewha
t 
Disagree 
Andivumi 
ngamandl
a 
Strongly 
Disagre
e 
Ayihapha
z eliNot 
Applicable 
 
Ikhowudi 
Yempendul
o 
Code 
 
J 
 
Ucwangciso ntsapho luphazamisa 
amandla endlela endisebenza ngayo 
okanye endizonwabisa ngayo. / My birth 
control interferes with my ability to work or engage in 
recreational activities 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
K 
 
Ucwangciso ntsapho lwam lwaziwa 
kuphela ngabo ndakhetha ukubaxelela 
okanye ukubabonisa (ndiyakwazi 
ukuligcina luyimfihlo ucwangcisontsapho 
lwam) 
My birth control is only known to those I chose to tell or 
show (I am able to keep my birth control private) 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
L 
 
Ndiziva ndizithembile ukuba 
ndisebenzisa ucwangciso ntsapho 
olundilungeleyo. 
I feel confident that I am using birth control that is right for 
me 
1 
 
2 
 
3 
 
4 
 
5 
 
-8 
 
 
M 
 
Ndiyakholwa ukuba ucwangiso-ntsapho 
lwam luhlobo olululungeleyo 
iqabane/amaqabane am kanye nam. / I 
believe that my birth control is the right method for my 
partner(s) and me 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
N 
 
Ndonelisekile kukuba kufuneka 
ndiluthathe roqo kangakanani 
ucwangciso ntsapho lwam. 
I am pleased with how often I need to use or take 
my birth control 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
O 
 
Ndiziva ndikhuselekile kukwazi 
ukuba ucwangciso ntsapho lwam 
luyasebenza. 
I feel secure knowing that my birth control works 
1 
 
2 
 
3 
 
4 
 
5 
 
-8 
 
 
P 
 
Ndiqinisekile uku ucwangciso-ntsapho 
endilustebenzisayo alubeki 
emngciphekweni isifo sam seHIV./ I am 
confident that the method I am using poses no risk 
with my HIV disease 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 
 
523 Bonisa izinga lokuvumelana nezintetha 
zilandelayo ngokurhangqa impendulo 
Indicate level of agreement with the following statements by 
circling their response.: 
Ndivuma 
ngamandl
a 
Strongly agree 
 
Ndiyavum
a nje 
Somewhat Agree 
 
Ndivuma 
ndingavu
mi 
Neither agree 
or disagree 
Andivu
mi nje 
Somewha
t 
Disagree 
Andivumi 
ngamandl
a 
Strongly 
Disagre
e 
Ayihapha
z eliNot 
Applicable 
 
Ikhowudi 
Yempendul
o 
Code 
 
Q 
 
Ndiqinisekile ukuba uhlobo 
endilusebenzisayo aluzuyitshintsha 
ifuthe lamachiza okuthomalalisa iHIV 
I am confident that the method I am using will not 
change the effect of my ART medicines 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
 
 
R 
 
Ndiqinisekile ukuba ifuthe lohlobo 
locwangciso endilusebenzisayo 
ukukhusela ukukhulelwa 
aluzukuncitshiswa ngamachiza 
okuthomalalisa iHIV 
I am confident that the ability of the method I am 
using to prevent pregnancy will not be reduced by my 
ART medicines 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
-8 
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Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 
 
 
ALCOHOL AND CIGARETTE USE (AUDIT SCALE – 600s) 
 
 
Ngoku sizakubuza imibuzo ngokusebenzisa kwakho utywala. Nceda urhangqe impenduloeyiyo ngombuzo ngamnye kule 
ingezantsi: 
We are now going to ask you some questions about your use of alcohol. Please circle the relevant answer for each question bellow: 
 
 
Score 0 1 2 3 4 Code 
 
 
 
601 
 
 
Ubusela kangakanani utywala? 
How often do you have a drink containing alcohol? 
 
 
Zange 
never 
 
Kanye 
ngenyanga 
nangaphantsi 
Once per month 
or less 
Kabini 
ukuya 
kwisine 
enyangeni 
2-4 times a 
month 
Kabini 
ukuya 
kwisithathu 
evekini 
2-3 times per 
week 
Kane 
nangaphezulu 
evekini 
4 times or more 
per week 
 
 
If 0 604 
 
 
602 
 
Zingaphi iglasi zesiselo esinxilisayo 
oziselayo ngemini? 
How many standard drinks containing alcohol do you 
have on a typical day when drinking? 
1 okanye 
2 
1 or 2 
 
3 okanye 4 
3 or 4 
 
5 okanye 6 
5 or 6 
 
 
7 ukuya 9 
7 to 9 
 
10 okanye 
ngaphezulu 
10 or more 
 
 
 
603 
 
 
Kukangaphi usela iglasi ezintandathu 
nangaphezulu ngexesha? 
How many times do you have six standard drinks or more 
at time? 
 
 
Zange 
Never 
 
 
Ngaphantsi 
kwenyanya 
Less than monthly 
 
 
Ngenyanga 
Monthly 
 
 
Ngeveki 
Weekly 
 
Ngosuku 
okanye 
malunga 
nosuku 
Daily or almost 
daily 
 
 Umbuzo /Question 
 
Impendulo / Answer 
 
Gqitha 
Skip 
 
Ikhowudi 
Yempendul
o 
Code 
604 
 
Ukhe watshaya isigareti kwezinyanga zilishumi elinambini zidlulileyo? 
Have you smoked cigarettes in the previous 12 months? 
 
0…. Hayi / No 
1…. Ewe / Yes 
 
0701 
 
 
605 
 
Utshaya izigareti ezingaphi ngosuku okanye ngeveki? 
On average, how many cigarettes do you smoke each day or week? 
 
  cigarettes per 
day or 
  cigarettes per week 
 
 Day:  
Wk:    
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 
 
 MENTAL HEALTH (KESSLER-10, 700s) 
Le mibuzo ilandelayo ikubuza ukuba ubuziva njani kule nyanga idlulileyo. Ngombuzo ngamnye yakha isangqa phants 
kwempendulo echaza ngokupheleleyo ubungakanani bexesha uvakalelwa njalo 
The following questions ask about how you have been feeling in the past 30 days. For each question, circle the option that best describes the amount of time that you feel that way. 
 
  Akukhange 
kubekhi 
xesha 
None of the 
time 
Kubekhona 
ixeshana 
A little of the 
time 
Abekhona 
amanye 
amaxesha 
Some of the 
time 
Kubekho 
amaxesha 
amaninzi 
Most of the 
time 
 
Ibilixesha 
lonke 
All of the time 
 
 
Code 
 
701 
 
Kule nyanga iphelileyo, kukangaphi uziva udiniwe 
ngaphandle kwesizathu? / During the last 30 days, about how often 
did you feel tired out for no good reason? 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
702 
 
Kule nyanga iphelileyo, kukangaphi uziva uphakuphaku? 
During the last 30 days, about how often did you feel nervous? 
0 
 
1 
 
2 
 
3 
 
4 
 
 
703 
 
Uphakuphaku kangangokuba kungekho nto 
inokukuthomalalisa? / During the last 30 days, about how often did 
you feel so nervous that nothing could calm you down? 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
704 
 
Kule nyanga iphelileyo, kukangaphi uziva uphelelwa 
ngamathemba? / During the last 30 days, about how often did you feel 
hopeless? 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
705 
 
Ungazinzanga okanye ugungqa? 
During the last 30 days, about how often did you feel restless or fidgety? 
0 
 
1 
 
2 
 
3 
 
4 
 
 
706 
 
Ungazinzanga de ugugqagungqe xa uhleli? / During the last 30 
days, about how often did you feel so restless you could not sit still? 
0 
 
1 
 
2 
 
3 
 
4 
 
 
707 
 
Kule nyanga iphelileyo, kukangaphi uziva ulusizana 
udakumbile? 
During the last 30 days, about how often did you feel depressed? 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
708 
 
Kule nyanga iphelileyo, kukangaphi uva yonke into 
ibiyimigudu? / During the last 30 days, about how often did you feel that 
everything was an effort? 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
709 
 
Udakumbile kangangokuba kungekho nanye into 
engakonwabisayo? /During the last 30 days, about how often did you 
feel so sad that nothing could cheer you up? 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 
 
 MENTAL HEALTH (KESSLER-10, 700s) 
Le mibuzo ilandelayo ikubuza ukuba ubuziva njani kule nyanga idlulileyo. Ngombuzo ngamnye yakha isangqa phants 
kwempendulo echaza ngokupheleleyo ubungakanani bexesha uvakalelwa njalo 
The following questions ask about how you have been feeling in the past 30 days. For each question, circle the option that best describes the amount of time that you feel that way. 
 
  Akukhange 
kubekhi 
xesha 
None of the 
time 
Kubekhona 
ixeshana 
A little of the 
time 
Abekhona 
amanye 
amaxesha 
Some of the 
time 
Kubekho 
amaxesha 
amaninzi 
Most of the 
time 
 
Ibilixesha 
lonke 
All of the time 
 
 
Code 
 
710 
 
Kule nyanga iphelileyo, kukangaphi uziva ungena 
xabiso? /During the last 30 days, about how often did you feel worthless? 0  
1 
 
2 
 
3 
 
4 
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 Violence Against Women (WHO, 800s) 
Sikwisigaba sokugqibela 
 
Siza kubuza imibizo yokugqibela embalwa ngokunxulumene nobundlobongela 
beqabane. 
We are at the last section of the survey. We are going to ask you a few last questions relating to partner violence. 
Kwinyanga ezi 12 ezidlulileyo ubukhe wehlelwa koku kulandelayo? 
Did you experience any of the following in the last 12 months? 
# 
 
Umbuzo / Question 
[Funda: To be read verbatim] 
Impendulo 
/Answer 
 
Ikhowudi 
Yempendul
o 
Code 
Uhlukumezo lwengqon 
Psychological Violence 801 
 
Iqabane lakho likhe lakuthuka okanye lakwenza awaziva 
kamnandi? 
Has your partner insulted you or made you feel bad about yourself? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
802 
 
Likhe lakwenze wazina umncinci phambi kwabanye 
abantu okanye lakwenza intlekisa phambi kwabanye 
abantu?? 
Has he belittled or humiliated you in front of other people? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
803 
 
Likhe lenza izinto likoyikisa okanye lakungcungcuthekisa 
ngabom? / Has he done things to scare or intimidate you on purpose? 
 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
804 
 
Like lakugrogrisa ngokonzakalisa okanye umntu 
okhathalayo ngaye? 
Has he threatened to hurt you or someone you care about? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
Uhlukumezo lomzimba 
Physical Violence 805 
 
Likhe lakuqhwaba ngempama okanye lakugibisela ngento 
enokukwenzakalisa? 
Has he slapped you or thrown something at you that could hurt you? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
806 
 
Likhe lakutyhala okanye lakunyola? 
Has he pushed or shoved you? 
 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
807 
 
Likhe lakubetha ngenqindi okanye ngento 
enokukonzakalisa? 
Has he hit you with a fist or with something else that could hurt you? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
808 
 
Likhe likukhabe, likurhuqe okanye likubethe? 
Has he kicked you, dragged you or beaten you up? 
 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
809 
 
Likhe likukrwitshe okanye likutshise ngabom? 
Has he choked or burnt you on purpose? 
 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
810 
 
Likhe likugrogrise ngokusebenzisa okanye lisevenzise 
umpu, imesi okanye nasiphina isixhobo kuwe? Has he 
threatened to use or actually used a gun, knife or other weapon against you? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
Sexual Violence 
811 
 
Likhe likunyanzele lise ngokwebalana ngesondo wena 
ungafuni? 
Has he physically forced you to have sexual intercourse when you didn’t want 
to? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
 
812 
 
Wakhe wabelane naye ngesondo ungafuni kuba usoyika 
into anokuyenza? 
Did you ever have sexual intercourse when you didn’t want because you were 
afraid of what he might do? 
0…. H yi / No 
1…. Ewe / Yes 
-8…n/a 
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Enkosi ngexesha lakho ekuphenduleni le mibuzo. Inxaxheba yakho ibalulekile kuthi. 
Thank you for taking the time to answer these questions! Your responses are very important to us. 
To be completed by study nurse or study coordinator: 
Tick all to show completed. 
 ALCOHOL USE: Check questions 602 and 603, if question 602 has been coded 
as 2, 3 or 4, or 603 has been coded as 3 or 4, refer for alcohol counselling. 
 MENTAL HEALTH: Tally the score for 701-710 and record below. Refer for 
counselling if score is greater than or equal to 25 
Mental Health Score:    
 VIOLENCE: Check questions 803-813. If participant answered YES to ANY 
question, provide referral for partner violence services. 
Signature of study nurse or study coordinator:    
Signature date:    
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Date:  /  __/ __    
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 813 
 
Likhe likunyanzelise ngokwabelana ngesondo ngendlela 
oyifumanisa ithoba isidima (eyeanyelisayo) okanye 
ekwenza intlekisa? 
Has he forced you to do something sexual that you found degrading or 
humiliating? 
0…. Hayi / No 
1…. Ewe / Yes 
-8…n/a 
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Date:  /  __/ __    
SCREENING ELIGIBILITY CHECKLIST PRE-ART: 2IUDnCT 
BASIC ELIGIBILITY CRITERIA—to be completed by Counsellor 
2IUDnCT: Screening Eligibility Checklist: Pre-ART, Version 5.0 
FHI 360 Study #10369, IRB Net# 398733 
Last revised on 20-Mar-2015 
Translation verified on 20 Mar 2015 
Page 1 of 6 
    
1. 
 
What is your age? 
|  |  | 
If 18-40, tick “Yes.” 
If under the age of 18 or over the age of 40, tick “No.” 
Yes 
 
No 
 
2. 
 
What is your date of birth? 
|  |  | / |  |  |  | / |  |  |  |  | (dd/mmm/yyyy) 
 
Confirm that DOB matches age. 
 
  
3. 
 
What is your home language? 
1English 2IsiXhosa 4Other 
If English or isiXhosa, tick Yes and skip to question 4. If Other, ask 3b. 
Yes 
 
 
3b. 
 
If Other, are you fluent in English or isiXhosa? 
 
Yes No 
4. 
 
Are you currently pregnant? 
 
Yes No 
5. 
 
Do you plan/wish to become pregnant in the next 2 years? 
 
Yes No 
6. 
 
Are you willing to be randomized to use either a C-IUD or LNG-IUD as a family 
planning method? 
Yes 
 
No 
 
7. 
 
Do you plan to live in the same place or in the Cape Town area for the next 30 
months? 
Yes 
 
No 
 
8. 
 
Have you had a tubal ligation/sterilization or do you have infertility? 
 
Yes No 
9. 
 
Have you been diagnosed with HIV infection? 
 
Yes No 
 a) When were you diagnosed? 
|  |  | / |  |  |  | / |  |  |  |  | (dd/mmm/yyyy) 
  
10. 
 
Have you ever taken antiretroviral medicines (ART)? 
 
 
If no 14. 
 
Yes 
 
No 
 
11. If yes, why did you start?   
Interviewer Instructions: 
 Mark  or a number in the response boxes |  | unless otherwise indicated. 
 Proceed to next study procedure only if the volunteer passes the Screening Eligibility Checklist. 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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Counsellor signature:  Date   
Medical Eligibility Questionnaire—to be completed by study nurse 
2IUDnCT: Screening Eligibility Checklist: Pre-ART, Version 5.0 
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Last revised on 20-Mar-2015 
Translation verified on 20 Mar 2015 
Page 2 of 6 
21. 
 
Have you had PID or an infection in the uterus in the last 3 months? 
If no, skip to question 23. 
Yes 
 
No 
 
22. 
 
If you have had PID or an infection in the uterus in the last 3 months, did you 
 
Yes No 
 
1Pregnancy/breastfeeding 
2 Low CD4 count 
3 Diagnosed with TB or other OI 
4 Other reason : specify :   
 
  
12. 
 
Are you currently taking antiretroviral medicines (ART)? 
 
Yes No 
13. 
 
If no longer taking ART, how long ago did you stop? 
 
 
Date stopped: |  |  | / |  |  |  | / |  |  |  |  | 
(dd/mmm/yyyy) 
 
Number of months since stopped taking ARVs |  |  | 
[Enter ‘24” if 2 or more years ago] 
If number of months is >6, tick Yes. If number of months is <6, tick No. 
Yes 
 
No 
 
14. 
 
Do you agree to follow all procedures for the study? 
 
Yes No 
15. 
 
Do you agree to participate in this research study for up to 24 months? 
 
Yes No 
16. 
 
Do you agree to provide the study staff with an address, phone number, and 
times you can be reached? (Addresses and phone numbers are confidential.) 
Yes 
 
No 
 
17. 
 
Do you agree to allow the study staff to review your clinical records to check 
laboratory information and confirm HIV diagnosis? 
Yes 
 
No 
 
18. 
 
If you enter this trial, do you agree not to participate in any other HIV trial 
requiring medications until this study ends? 
Yes 
 
No 
 
19. 
 
Have you had a termination of pregnancy or miscarriage in the last four weeks? 
 
Yes No 
20. 
 
Based on the responses to question 1-19 is the person eligible to continue? 
If all responses are in shaded boxes tick yes. 
If any of the responses are not shaded tick no, she is not eligible and should be 
asked to complete a Decliner/Ineligible Questionnaire. 
 
Yes 
Continue 
to Q 21. 
 
No 
NOT 
ELIGIBLE- 
End 
interview 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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 complete treatment?    
23. Have you ever had or been diagnosed with any of the following conditions: 
 a) Wilson’s Disease 
 
Yes No 
 b) Hormonally-dependent tumor 
 
Yes No 
 c) Abnormal uterine shape/septum 
 
Yes No 
 d) Liver disease or tumor 
 
Yes No 
 e) Sensitivity to plastic polymer or copper 
 
Yes No 
 f) Tuberculosis (TB) 
If no 23g 
Yes 
 
No 
 
 f1 When were you diagnosed with TB? 
|  |  | / |  |  |  | / |  |  |  |  | (dd/mmm/yyyy) 
 
 
Is this date prior to HIV diagnosis or not concurrent with HIV diagnosis? (#9a) 
Yes 
 
No 
 
 g) Recurrent pneumonia (more than three episodes in the last three 
months) 
Yes 
 
No 
 
 h) Cervical cancer 
 
Yes No 
 i) Ectopic pregnancy 
 
Yes No 
 j) Oesophageal candidiasis 
If no 24 
Yes 
 
No 
 
 j1 When were you diagnosed with oesophageal candidiasis? 
|  |  | / |  |  |  | / |  |  |  |  | (dd/mmm/yyyy) 
Is this date more than three years prior to HIV diagnosis? (#9a) 
 
Yes 
 
No 
 
 
INTERVIEW—to be completed by Study Nurse 
Ask the patient to answer the following. 
 
24. Has the participant had a pap smear within the last three years? 
Yes 
No or don’t know 27. Perform pap smear at this visit. 
 
25.  Date last Pap smear: |  |  | / |  |  |  | / |  |  |  |  | (dd/mmm/yyyy) 
 
26.  Pap Result: 0NEGATIVE 1ASCUS 2LSIL 3HSIL 99 Unknown 
27.  Date Last CD4 Count: |  |  | / |  |  |  | / |  |  |  |  | (dd/mmm/yyyy) 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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Date:  /  __/ __    
CONFIRMATION OF ELIGIBILITY—to be completed by Study Coordinator 
30. Does the volunteer pass the eligibility criteria to be considered for enrolment in this research study 
and agree to continue with screening? 
0 NO 1YES 
If YES: 
 Sign below and proceed with study procedures. 
 If the volunteer is eligible but requires delayed enrolment, reschedule her for re-screening 
If NO: 
 Inform participant they may not enter into the research study at this time or support them in 
their decision to decline enrolment; 
 Complete the SCREENING AND ENROLMENT LOG and ask participant to complete the the 
decliner/ineligible questionnaire. 
Signature of study coordinator verifying eligibility 
Date   
If study coordinator unavailable, one nurse may sign to verify eligibility in her absence. The study 
coordinator must initial this form prior to enrolment. 
Date   
  Study coordinator initials 
CHART REVIEW—TO BE SIGNED OFF BY STUDY COORDINATOR OR STUDY NURSE PRIOR TO ENROLMENT 
2IUDnCT: Screening Eligibility Checklist: Pre-ART, Version 5.0 
FHI 360 Study #10369, IRB Net# 398733 
Last revised on 20-Mar-2015 Translation verified on 20 Mar 2015 Page 4 of 6 
 
OR: 
Participant has never had or doesn’t know if she had a CD4 count test  29 
28. CD4 Count Result:      
 
29. Injectable contraceptive use: 
 Net-en/2 monthly; Date of last injection: |  |   | / |  |   |   | / |  |   |   |   | 
Date next injection due: |  |  | / |  |  |     _| / |  |  |  |  | 
 Depo Provera/3 monthly ; Date of last injection: |  |  | / |  |  |  | / |  |  |  |  | 
Date next injection due: |  |   | / |  |   |     _| / |  |   |   |   | 
 Oral contraceptive pill :Date of last menses|  |  | / |  |  |  | / |  |  |  |  | 
 
 Date of last active pill |  |  | / |  |  |  | / |  |  |  |  | 
 None 
 
Nurse Signature:  Date:    
 
Stop here and review results with study coordinator or second nurse 
for eligibility/potential for delayed enrolment. 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
 
  
   
 
     
     
      
     
     
      
  
     
  
  
 
       
 
Page 166 of 219 
 
 
Date:  /  __/ __    
VERIFICATION OF DOCUMENTED HIV STATUS 
31. Has documented HIV status been filed at the study site? 
0 No, participant is unable to provide documented HIV status and declines rapid HIV testing. If 
participant is present, ask her to complete the Decliner/Ineligible Questionnaire. –> End form 
1 Yes    Date filed:     
32. How was documented HIV status obtained? 
1 Confirmation via NHLS database 
2 Confirmation via GCHC Folder 
3Other, specify:   
33. What is the participant’s documented HIV status? 
1 HIV positive  continue with study procedures 
2 HIV negative ask to complete Decliner/Ineligible questionnaire 
Staff initials  Date    
VERIFICATION OF PAP SMEAR IN THE LAST THREE YEARS 
34. Has documentation of pap smear result in the last three years been filed at the study site? 
0 No  37. Perform pap smear prior to IUD insertion 
1 Yes    Date filed:     
35. How was pap smear result obtained? 
1
2
3
Confirmation via NHLS database 
Confirmation via GCHC Folder 
Other, specify:    
36. What is the pap smear result? 
0NORMAL 
1ASCUS 
2LSIL 
3HSIL  Notify study coordinator immediately 
99Not yet available 
Staff initials  Date    
VERIFICATION OF DATE OF BIRTH 
2IUDnCT: Screening Eligibility Checklist: Pre-ART, Version 5.0 
FHI 360 Study #10369, IRB Net# 398733 
Page 5 of 6 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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Date:  /  __/ __    
37. Has documentation of date of birth has been filed at the study site? 
0No.  Participant is unable to provide documentation of date of birth,  ask participant to complete 
Decliner/Ineligible Questionnaire 
1Yes    Date filed:     
38. How was date of birth verified? 
1 Confirmation via NHLS database 2 
Confirmation via GCHC Folder 3 
Presentation of ID book 
4 Other, specify:    
39. Is the participant 18-40 years old (inclusive) based on her documented date of birth? 
0No  ask participant to complete Decliner/Ineligible Questionnaire 
1Yes  continue with study procedures 
Staff initials  Date    
STUDY COORDINATOR SIGN-OFF 
40. Has chart review been completed and eligibility to proceed with enrolment visit confirmed? 
0  NO 1 YES 
Signature of study coordinator verifying eligibility 
Date   
Page 6 of 6 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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Date:  /  __/ __    
ART USER SCREENING ELIGIBILITY CHECKLIST: 2IUDnCT 
BASIC ELIGIBILITY CRITERIA—to be completed by Counsellor 
2IUDnCT: Screening Eligibility Checklist: ART-User, Version 2.0 
FHI 360 Study #10369, IRB Net# 398733 
Last revised on 20 March 2015 
Translation verified on 20- Mar 2015 
Page 1 of 7 
1. 
 
What is your age? 
|  |  | 
If 18-40, tick “Yes.” 
If under the age of 18 or over the age of 40, tick “No.” 
Yes 
 
No 
 
2. 
 
What is your date of birth? 
|  |  | / |  |  |  | / |  |  |  |  | (dd/mmm/yyyy) 
 
Confirm that DOB matches age. 
 
  
3. 
 
What is your home language? 
1English 2IsiXhosa 4Other 
If English or isiXhosa, tick Yes and skip to question 4. If Other, ask 3b. 
Yes 
 
 
3b. 
 
If Other, are you fluent in English or isiXhosa? 
 
Yes No 
4. 
 
Are you currently pregnant? 
 
Yes No 
5. 
 
Do you plan/wish to become pregnant in the next 30 months? 
 
Yes No 
6. 
 
Are you willing to be randomized to use either a C-IUD or LNG-IUD as a family 
planning method? 
Yes 
 
No 
 
7. 
 
Do you plan to live in the same place or in the Cape Town area for the next 30 
months? 
Yes 
 
No 
 
8. 
 
Have you had a tubal ligation/sterilization or do you have infertility? 
 
Yes No 
9. 
 
Have you been diagnosed with HIV infection? 
 
Yes No 
 a) When were you diagnosed? 
|  |  | / |  |  |  | / |  |  |  |  | (dd/mmm/yyyy) 
 
  
10. 
 
Have you ever taken antiretroviral medicines (ART)? 
 
Yes 
 
No 
 
11. If yes, why did you start?   
Interviewer Instructions: 
 Mark  or a number in the response boxes |  | unless otherwise indicated. 
 Proceed to next study procedure only if the volunteer passes the Screening Eligibility Checklist. 
Place Screening PTID 
label here 
e.g. PTID: 6  -    
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Date:  /  __/ __    
Counsellor signature:  Date   
Medical Eligibility Questionnaire—to be completed by study nurse 
2IUDnCT: Screening Eligibility Checklist: ART-User, Version 2.0 
FHI 360 Study #10369, IRB Net# 398733 
Last revised on 20 March 2015 
Translation verified on 20- Mar 2015 
Page 2 of 7 
21. 
 
Have you had PID or an infection in the uterus in the last 3 months? 
If no, skip to question 23. 
Yes 
 
No 
 
22. 
 
If you have had PID or an infection in the uterus in the last 3 months, did you 
 
Yes No 
 
1Pregnancy/breastfeeding 
2 Low CD4 count 
3 Diagnosed with TB or other OI 
4 Other reason : specify :   
 
  
12. 
 
Are you currently taking antiretroviral medicines (ART)? 
If no Stop. Assess if participant is eligible for screening as pre-ART 
participant (if patient has stopped ART with pregnancy >6 months ago). 
If stopped taking ART by choice, alert study coordinator 
Yes 
 
No 
 
14. 
 
Do you agree to follow all procedures for the study? 
 
Yes No 
15. 
 
Do you agree to participate in this research study for up to 24 months? 
 
Yes No 
16. 
 
Do you agree to provide the study staff with an address, phone number, and 
times you can be reached? (Addresses and phone numbers are confidential.) 
Yes 
 
No 
 
17. 
 
Do you agree to allow the study staff to review your clinical records to check 
laboratory information and confirm HIV diagnosis, possibly including a blood 
test for HIV? 
Yes 
 
No 
 
18. 
 
If you enter this trial, do you agree not to participate in any other HIV trial of 
medications or other biomedical interventions until this study ends? 
 
Yes 
 
No 
 
19. 
 
Have you had a termination of pregnancy or miscarriage in the last four weeks? 
 
Yes 
 
No 
 
20. 
 
Based on the responses to question 1-19 is the person eligible to continue? 
If all responses are in shaded boxes tick yes. 
If any of the responses are not shaded tick no, she is not eligible and should be 
asked to complete a Decliner/Ineligible Questionnaire. 
 
Yes 
Continue 
to Q 21. 
 
No 
NOT 
ELIGIBLE- 
End 
interview 
Place Screening PTID 
label here 
e.g. PTID: 6  -    
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Date:  /  __/ __    
2IUDnCT: Screening Eligibility Checklist: ART-User, Version 2.0 
FHI 360 Study #10369, IRB Net# 398733 
Last revised on 20 March 2015 
Translation verified on 20- Mar 2015 
Page 3 of 7 
 complete treatment?   
23. Have you ever had or been diagnosed with any of the following conditions: 
 a) Wilson’s Disease 
 
Yes No 
 b) Hormonally-dependent tumor 
 
Yes No 
 c) Abnormal uterine shape/septum 
 
Yes No 
 d) Liver disease or tumor 
 
Yes No 
 e) Sensitivity to plastic polymer or copper 
 
Yes No 
 f) Tuberculosis (TB) 
If no 23g 
Yes 
 
No 
 
 f1 When were you diagnosed with TB? 
|  |  | / |  |  |  | / |  |  |  |  | (dd/mmm/yyyy) 
 
  
 g) Recurrent pneumonia (more than three episodes in the last three 
months) 
Yes 
 
No 
 
 h) Cervical cancer 
 
Yes No 
 i) Ectopic pregnancy 
 
Yes No 
 j) Oesophageal candidiasis 
If no 24 
Yes 
 
No 
 
 j1 When were you diagnosed with oesophageal candidiasis? 
|  |  | / |  |  |  | / |  |  |  |  | (dd/mmm/yyyy) 
Is this date prior to HIV diagnosis? (#9a) 
 
Yes 
 
No 
 
 
INTERVIEW—to be completed by Study Nurse 
Ask the patient to answer the following: 
 
24. Has the participant had a pap smear within the last three years? 
Yes 
No or don’t know 27. Perform pap smear at this visit. 
 
25.  Date last Pap smear: |  |  | / |  |  |  | / |  |  |  |  | (dd/mmm/yyyy) 
 
26.  Pap Result: 0NEGATIVE 1ASCUS 2LSIL3HSIL 99 Unknown 
27a.  Date Last Plasma Viral load count: |  |  | / |  |  |  | / |  |  |  |  | 
 
Place Screening PTID 
label here 
e.g. PTID: 6  -    
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Date:  /  __/ __    
CONFIRMATION OF ELIGIBILITY—to be completed by Study Coordinator 
30. Does the volunteer pass the eligibility criteria to be considered for enrolment in this research study 
and agree to continue with screening? 
0 NO If 
YES: 
1YES 
 Sign below and proceed with study procedures. 
 If the volunteer is eligible but requires delayed enrolment, reschedule her for re-screening 
If NO: 
 Inform participant they may not enter into the research study at this time or support them in 
their decision to decline enrolment; 
 Complete the SCREENING AND ENROLMENT LOG and ask participant to complete the the 
decliner/ineligible questionnaire. 
Signature of study coordinator verifying eligibility 
Date   
If study coordinator unavailable, one nurse may sign to verify eligibility in her absence. The study 
coordinator must initial this form prior to enrolment. 
2IUDnCT: Screening Eligibility Checklist: ART-User, Version 2.0 
FHI 360 Study #10369, IRB Net# 398733 
Last revised on 20 March 2015 
Translation verified on 20- Mar 2015 Page 4 of 7 
(If no documented plasma viral load, please inform the study coordinator; eligibility cannot be 
determined at this time) 
28a. Plasma viral Load 0>1000 copies/mL 
1 <1000 copies/mL or undetectable 
(If >1000 copies/mL , please inform study coordinator) 
2 Do not know 
29. Injectable contraceptive use: 
 Net-en/2 monthly; Date of last injection: |  |   | / |  |   |   | / |  |   |   |   | 
Date next injection due: |  |  | / |  |  |     _| / |  |  |  |  | 
 Depo Provera/3 monthly ; Date of last injection: |  |  | / |  |  |  | /|  |  |  |_ | 
 
Date next injection due: |  |  | / |  |  |     _| / |  |  |  |  | 
 
 Oral contraceptive pill :Date of last menses|  |  | / |  |  |  | / |  |  |  |  | 
 
 Date of last active pill |  |  | / |  |  |  | / |  |  |  |  | 
 None 
 
Nurse Signature:  Date:    
 
Stop here and review results with study coordinator or second nurse 
for eligibility/potential for delayed enrolment. 
Place Screening PTID 
label here 
e.g. PTID: 6  -    
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Date:  /  __/ __    
Date   
  Study coordinator initials 
CHART REVIEW—TO BE SIGNED OFF BY STUDY COORDINATOR OR STUDY NURSE PRIOR TO ENROLMENT 
VERIFICATION OF DOCUMENTED HIV STATUS 
31. Has documented HIV status been filed at the study site? 
0 No, participant is unable to provide documented HIV status and declines rapid HIV testing. If 
participant is present, ask her to complete the Decliner/Ineligible Questionnaire. –> End form 
1 Yes    Date filed:     
32. How was documented HIV status obtained? 
1 Confirmation via NHLS database 
2 Confirmation via GCHC Folder 
3Other, specify:   
33. What is the participant’s documented HIV status? 
1 HIV positive  continue with study procedures 
2 HIV negative ask to complete Decliner/Ineligible questionnaire 
Staff initials  Date    
VERIFICATION OF ART USE AND NON-DETECTABLE PLASMA VIRAL LOAD 
34. Has documentation of plasma viral load in the last 6 months been filed at the study site? 
0No.  Participant is unable to provide documentation of most recent plasma viral load. Ask 
participant to either obtain documentation from her home clinic or get an updated plasma VL test if 
she desires enrolment. Patient is ineligible at this point. 
1Yes    Date filed:     
35. How was documentation of most recent plasma viral load verified? 
1 Confirmation via NHLS database 
2 Confirmation via GCHC Folder 
3 Other, specify:    
36. Was the participant’s most recent viral load suppressed (<1000 copies/mL)? 
2IUDnCT: Screening Eligibility Checklist: ART-User, Version 2.0 
FHI 360 Study #10369, IRB Net# 398733 
Last revised on 20 March 2015 
Translation verified on 20- Mar 2015 
Page 5 of 7 
Place Screening PTID 
label here 
e.g. PTID: 6  -    
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Date:  /  __/ __    
1 No, participant is on ART but viral load not suppressed   ask to complete Decliner/Ineligible 
questionnaire and advise return to clinic for provider consultation. 
2 Yes, participant is on ART and the most recent viral load is <1000 copies/mL.   continue with 
study procedures. 
Staff initials  Date    
VERIFICATION OF PAP SMEAR IN THE LAST THREE YEARS 
37. Has documentation of pap smear result in the last three years been filed at the study site? 
0 No  37. Perform pap smear prior to IUD insertion 
1 Yes    Date filed:     
38. How was pap smear result obtained? 
1
2
3
Confirmation via NHLS database 
Confirmation via GCHC Folder 
Other, specify:    
39. What is the pap smear result? 
0NORMAL 
1ASCUS 
2LSIL 
3HSIL  Notify study coordinator immediately 
99Not yet available 
Staff initials  Date    
VERIFICATION OF DATE OF BIRTH 
2IUDnCT: Screening Eligibility Checklist: ART-User, Version 2.0 
FHI 360 Study #10369, IRB Net# 398733 
Last revised on 20 March 2015 
Translation verified on 20- Mar 2015 
Page 6 of 7 
Place Screening PTID 
label here 
e.g. PTID: 6  -    
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Date:  /  __/ __    
40. Has documentation of date of birth been filed at the study site? 
0No.  Participant is unable to provide documentation of date of birth, ask participant to complete 
Decliner/Ineligible Questionnaire 
1Yes    Date filed:     
41. How was date of birth verified? 
1 Confirmation via NHLS database 2 
Confirmation via GCHC Folder 3 
Presentation of ID book 
4 Other, specify:    
42. Is the participant 18-40 years old (inclusive) based on her documented date of birth? 
0No  ask participant to complete Decliner/Ineligible Questionnaire 
1Yes  continue with study procedures 
Staff initials  Date    
STUDY COORDINATOR SIGN-OFF 
43. Has chart review been completed and eligibility to proceed with enrolment visit confirmed? 
0  NO 1 YES 
Signature of study coordinator verifying eligibility 
Date   
2IUDnCT: Screening Eligibility Checklist: ART-User, Version 2.0 
FHI 360 Study #10369, IRB Net# 398733 
Last revised on 20 March 2015 
Translation verified on 20- Mar 2015 
Page 7 of 7 
Place Screening PTID 
label here 
e.g. PTID: 6  -    
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Date:  /  __/ __    
Clinical CRF for Screening Pre-ART : 2IUDnCT 
Pregnancy and Medical History 
0. U- alegic kwi latex / Are you allergic to 
latex? 
1 Yes  Use nitrile gloves 
0 No 
Height: |  | | cm 
1. 
Weight: |  | | kg2. 
3. hCG Pregnancy Test: 
1 Positive  Stop form and inform study coordinator 
0 Negative 
Wakhe wakhulelwa embhabheni/ etyhubhini / Have you ever had an ectopic pregnancy? 
1 Yes  Stop form and inform study coordinator 
0 No 
Wakhe wenziwa utyando lomlomo sibeleko / Have you had previous cervical surgery? 
4. 
5. 
1  YesDescribe and confirm with PI before scheduling enrolment:    
0 No 
Wakhe Wawathatha amachiza okuthomalalisa intsholongwane kagawulayo? 
Have you taken any medication(s)/treatment(s) for your HIV infection? 
1 Yes 
0 No  7 
a. Yayingamachiza okuthomalalisa intsholongwane na? 
Were these medications antiretrovirals (e.g. odimune, tenofovir/tdf, efavirenz, lamivudine/3tc, 
combivir, viramune, AZT/zidovudine)? 
6. 
1 Yes 
0 No 7 
2IUDnCT Clinical CRF—Screening: Per-ART, Version 3.0 
FHI Study #10369 
Last revised on 08-May-2014 
Translation verified on 20 Mar 2015 
Page 1 of 8 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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Date:  /  __/ __    
b. Ukuba ewe, uyawathatha ngoku lamayeza okanye ubuwathatha kwinyanga ezintandathu 
ezidlulileyo? 
If yes, are you currently taking these medications or have you taken them in the last 6 months? 
1 Yes  Stop form and inform study coordinator 
0 No 
7. Ungaba uyopha kangangokuba usebenzisa ipad/ liner namhlanje? 
Do you have vaginal bleeding such that you need to use a liner/pad today? 
1 Yes  Stop form and reschedule participant 
0 No 
8. Ubunini umhla wakho oqale ngawo ukuya exesheni kweli lixa lokugqibela 
lokuhlamba? When was the first day of your last menstrual period? 
Date: |  | | / |  | | | / |  | | |
 | 
OR 
 Not menstruating on current contraceptive method 6_1 
(dd/mmm/yyyy) 
a. 
Kuthatha iintsuku ezingaphi oko kuya exesheni / 
How many days did that period last? 
|  | | number of days 
2IUDnCT Clinical CRF—Screening: Per-ART, Version 3.0 
FHI Study #10369 
Last revised on 08-May-2014 
Translation verified on 20 Mar 2015 
Page 2 of 8 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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Date:  /  __/ __    
9. Ingaba oku kulandelayo kuyezeka na kuwe ? Are you currently experiencing any of the 
following symptoms: Read list. 
2IUDnCT Clinical CRF—Screening: Per-ART, Version 3.0 
FHI Study #10369 
Last revised on 08-May-2014 
Translation verified on 20 Mar 2015 
Page 3 of 8 
Symptom Yes/No If yes, duration 
a. Izilonda okanye inyebethu 
kwilungu langasese 
Genital sores or ulcers 
 
1 Yes 0 No 
 
 
  days 
 
b. Ukurhawuzelela kwilungu 
langasese 
Genital itching 
1 Yes 0 No 
 
  days 
 
c. Ukutshisa kwilungu langasese 
Genital burning 
1 Yes 0 No   days 
d. Ezinye iintlungu kwilungu 
langasese 
Other genital pain 
1 Yes 0 No 
 
  days 
 
e. Iintlungu xa uchama 
Pain when urinating 
1 Yes 0 No   days 
f. Ukuchama okongezelelekileyo 
rhoqo 
Increased urinary frequency 
1 Yes 0 No 
 
  days 
 
g. Ukopha okungaqhelekanga 
ebufazini(ingekuko ukuya 
exesheni) 
Abnormal vaginal bleeding 
(non-menstrual) 
1 Yes 0 No 
 
 
 
  days 
 
h. Ukoma okung qhelekanga 
ebufazini(ungasebenzisi zomiso 
Abnormal vaginal dryness (without 
using any drying agents) 
1 Yes 0 No 
 
 
  days 
 
i. Iintlungu xa usabelana ngesondo 
Pain during sex 
1 Yes 0 No -8 No sex   days 
j. Iintlungu emazantsi esisu 
Lower abdominal pain 
1 Yes 0 No   days 
k. Iintlungu emazantsi omqolo 
Lower back pain 
1 Yes 0 No   days 
l. Ubumanzi apha ebufazini 
obungaqhelekanga 
Abnormal vaginal discharge 
1 Yes 0 No 
 
  days 
 
m. Ukujikelezelwa yintloko 
Dizziness 
1 Yes 0 No   days 
n. Isicafu cafu 
Nausea 
1 Yes 0 No   days 
o. Ukugabha 
Vomiting 
1 Yes 0 No   days 
p. Ukudinwa 
Fatigue 
1 Yes 0 No   days 
q. Umkhuhlane ongachazekiyo 
Unexplained fever 
1 Yes 0 No   days 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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Date:  /  __/ __    
*If any “Yes” answers provided, follow up on pelvic exam for genital complaints or refer for evaluation of other 
symptoms. 
Pelvic Exam 
10. Were there any palpable inguinal lymph 
nodes? 
0 None 1 Unilateral left 2 Unilateral right 3 Bilateral 
11. Were any abnormalities detected on the external genitalia by naked eye 
exam? 
0
1
No 
Yes  If yes, record below: 
1
2
3
4
5
6
7
8
Warts 
Painful ulcer 
Non-painful 
ulcer 
Vesicle(s) 
Tearing/ bruising at vaginal 
introitus 
Cyst 
Enlarged Bartholin’s gland 
Other (specify):    
2IUDnCT Clinical CRF—Screening: Per-ART, Version 3.0 
FHI Study #10369 
Last revised on 08-May-2014 
Translation verified on 20 Mar 2015 
Page 4 of 8 
Symptom Yes/No If yes, duration 
r. Ukubila ebusuku 
Night sweats 
1 Yes 0 No   days 
s. Ukungabinamdla wokutya 
nokuya kuncipha 
Loss of appetite and/or weight 
1 Yes 0 No 
 
  days 
 
t. Ukumimitheka 
Weight gain 
1 Yes 0 No   days 
u. Ukuhambisa okumandla 
(>kwentsuku ezi7) 
Chronic diarrhea (> 7 days) 
1 Yes 0 No 
 
  days 
 
v. Ulosuleleko emlonyeni 
Yeast infection in mouth 
1 Yes 0 No   days 
w. Ukudumba kwamadlala la 
asemqaleni ngasezindlebeni 
Swollen lymph nodes (glands) 
1 Yes 0 No 
 
  days 
 
x. Intloko ebuhlungu 
ngokugqithisileyo 
Severe headaches 
1 Yes 0 No 
 
  days 
 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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Date:  /  __/ __    
12. On speculum examination, was vaginal discharge present? 
1 
0 
-8
Yes 
No  13 
Not assessed/evident bleeding. IF BLEEDINGStop form and inform study coordinator 
a. If yes, record colour of discharge: c. If yes, consistency of discharge: 
1 Clear 
2White 
3 Yellow/green 
4 Bloody/brown 
6 Cream-colored/gray 
5 Mixed (specify):    
1 Non-homogenous, normal 
2 Non-homogenous, curd-like 
3 Homogenous, smooth 
4 Homogenous, frothy 
b. Is an abnormal odour present? 1 Yes 0 No 
13. What was the quantity of cervical mucus? 
1
2
3
No mucus visible at os  15. 
Mild-moderate mucus visible at 
os 
Abundant mucus flowing from 
os 
14. Colour of cervical mucus: 
1
2
3
4
6
5
Clear 
Whit
e 
Yellow/gree
n 
Bloody/brow
n 
Cream-
colored/gray 
Mixed. Specify:   
15. Was there any contact bleeding when swabs were taken for STI testing? 
1 Yes 0 No 
15a. Was there any visible abnormality/lesion suspicious for neoplasia on the 
cervix? 
2IUDnCT Clinical CRF—Screening: Per-ART, Version 3.0 
FHI Study #10369 
Last revised on 08-May-2014 
Translation verified on 20 Mar 2015 
Page 5 of 8 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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Date:  /  __/ __    
1 Yes 0 No 
16. Was there any pain on bimanual examination? 
1 Yes 0 No  17 
a. If YES, how would you rate this pain? 
1
2
3
Mild (reported by woman, no change in facial expression or muscle 
tone) 
Moderate (change in facial expression/muscle tone, but woman tolerates 
exam) 
Severe (woman cannot tolerate exam without body 
movement) 
17. Was there any cervical motion tenderness? 
1 Yes 0 No  18 
a. If YES, how would you rate this tenderness? 
1
2
3
Mild (reported by woman, no change in facial expression or muscle 
tone) 
Moderate (change in facial expression/muscle tone, but woman tolerates 
exam) 
Severe (woman cannot tolerate exam without body 
movement) 
18. Were there any adnexal mass(es)? 
1  Yes (Specify location(s):  Left  Right ) 
0  No 
-8 Could not palpate adnexae 
19. Was the uterus enlarged? 
1 Yes, describe:   
0 No 
2IUDnCT Clinical CRF—Screening: Per-ART, Version 3.0 
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Date:  /  __/ __    
20. Perform rapid tests now and record results and lot numbers on Screening Lab CRF 
Clinical Summary 
23. Were any diagnoses made at today’s visit? 
1 Yes  Specify:    
0 No 
24. Were any referrals made at today’s visit? 
1 Yes  Specify:    
0 No 
25. Were any medications prescribed at today’s 
visit? 
1
0
Yes  specify:   
Check for allergies; record on Concomitant Medications Log. 
No  Comments 
2IUDnCT Clinical CRF—Screening: Per-ART, Version 3.0 
FHI Study #10369 
Last revised on 08-May-2014 
Translation verified on 20 Mar 2015 
Page 7 of 8 
Remember: Record all medications on the Concomitant Medications Log, including anything she is 
currently taking or was prescribed at this visit. 
 Rapid Test 
 
Test done and results 
recorded 
Kit info 
 
 
a 
 
 
Pregnancy 
 
1 Yes 0 No 
 
kit # :                                               
Expiry date: |__|__| /|__|__| | / |__|__|__|__| 
 
b 
 
 
OSOM Trich 
 
1 Yes 0 No 
 
kit # :                                               
Expiry date: |__|__| /|__|__| | / |__|__|__|__| 
 
c 
 
 
OSOM BV 
 
1 Yes 0 No 
 
kit # :                                               
Expiry date: |__|__| /|__|__| | / |__|__|__|__| 
 
d 
 
 
Syphilis 
 
1 Yes 0 No 
 
kit # :                                               
Expiry date: |__|__| /|__|__| | / |__|__|__|__| 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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Date:  /  __/ __    
Nurse signature:  Date:    
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Stamp for Data Entry:  Stamp for Quality Control:    
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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Date:  /  __/ __    
Clinical CRF for Screening ART-User: 2IUDnCT 
Pregnancy and Medical History 
0. U- alegic kwi latex /Are you allergic to 
latex? 
1 Yes  Use nitrile gloves 
0 No 
Height: |  | | cm 
1. 
Weight: |  | | kg 2. 
3. hCG Pregnancy Test: 
1 Positive  Stop form and inform study coordinator 
0 Negative 
Wakhe wakhulelwa embhabheni/ etyhubhini / Have you ever had an ectopic pregnancy? 
1 Yes  Stop form and inform study coordinator 
0 No 
Wakhe wenziwa utyando lomlomo sibeleko /Have you had previous cervical surgery? 
1  YesDescribe and confirm with PI before scheduling enrolment:    
4. 
5. 
0 No 
Wakhe Wawathatha amachiza okuthomalalisa intsholongwane kagawulayo? 
Have you taken any medication(s)/treatment(s) for your HIV infection? 
1 Yes 
0 No   Stop form and inform study coordinator 
a. Yayingamachiza okuthomalalisa intsholongwane na? 
Were these medications antiretrovirals (e.g. odimune, tenofovir/tdf, efavirenz, lamivudine/3tc, 
combivir, viramune, AZT/zidovudine)? 
1 Yes 
0 No    Stop form and inform study coordinator 
6. 
b. Ukuba ewe, uyawathatha ngoku lamayeza? If yes, are you currently taking these medications 
months? 
1 Yes 
0 No  Stop form and inform study coordinator 
2IUDnCT: Clinical CRF Screening ART-User (Combined), Version 3.0 
FHI Study #10369 IRB Net# 398733 
Last revised on 03 Aug 2015 
Translation verified 14 Aug 2015 Page 1 of 8 
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Date:  /  __/ __    
. 
c. iAR uzithatha kangaphi ngemini/ How many times a day do you take your ART pills? 
|  | | 
Zingaphi ipilisi ozityayo ngexesha /How many pills do you take each time you take your ART 
medicines? 
d. 
Morning (am) |  |
 | 
Afternoon (pm)  |  |
 | 
e. Ingama layeza e ART ozityayo ngokui /What 
are taking right now? 
is/are the names of the ART medicine(s) you 
1 
2 
3 
4 
9  Atroiza 10 
 3TC 
11  Nevirapine 
12  Aluvia 
13  Zidovudine 
Tribus 
Odimune 
Combivir 
Tenofovir/t
df 
5 Lamivudime 
6  Efavirenz 
7  Viramune 
8  Other, specify:    
[Note: please use picture chart to assist participant in identifying the correct pill.] 
f. Igama leklinic lofuma khona kunanakelwa kwentsholongwane ngawulayo kanye nama chiza akho 
ART? What is the name of the clinic where you receive your ART medicines and HIV care? 
1 
2 
3 
4 
5 
6 
7 
8 
Hannan Crusade Old Crossroad Clinic 
Nyanga clinic NY1 clinic 
New Crossroad Clinic Mzamonhl
e 
Vuyani other; specify:    
7. Ungaba uyopha kangangokuba usebenzisa ipad/ liner namhlanje? Do you have vaginal 
bleeding such that you need to use a liner/pad today? 
1 Yes  Stop form and reschedule the participant 
0 No 
2IUDnCT: Clinical CRF Screening ART-User (Combined), Version 3.0 
FHI Study #10369 IRB Net# 398733 
Last revised on 03 Aug 2015 
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Date:  /  __/ __    
8. Ubunini umhla wakho oqale ngawo ukuya exesheni kweli lixa lokugqibela lokuhlamba 
When was the first day of your last menstrual period? 
Date: |  | | / |  | | | / |  | | | | (dd/mmm/yyyy) 
OR 
 Not menstruating on current contraceptive method 9_a 
a. Inani leentsuku  How many days did that period last? |  | | number of days 
9. Ingaba oku kulandelayo kuyezeka na kuwe ? Are you currently experiencing any of the 
following symptoms: Read list. 
2IUDnCT: Clinical CRF Screening ART-User (Combined), Version 3.0 
FHI Study #10369 IRB Net# 398733 
Last revised on 03 Aug 2015 
Translation verified 14 Aug 2015 
Page 3 of 8 
Symptom Yes/No If yes, duration 
a. Izilonda okanye inyebethu 
kwilungu langasese 
Genital sores or ulcers 
 
1 Yes 0 No 
 
 
  days 
 
b. Ukurhawuzelela kwilungu 
langasese 
Genital itching 
1 Yes 0 No 
 
  days 
 
c. Ukutshisa kwilungu langasese 
Genital burning 
1 Yes 0 No   days 
d. Ezinye iintlungu kwilungu 
langasese 
Other genital pain 
1 Yes 0 No 
 
  days 
 
e. Iintlungu xa uchama 
Pain when urinating 
1 Yes 0 No   days 
f. Ukuchama okongezelelekileyo 
rhoqo 
Increased urinary frequency 
1 Yes 0 No 
 
  days 
 
g. Ukopha okungaqhelekanga 
ebufazini(ingekuko ukuya 
exesheni) 
Abnormal vaginal bleeding 
(non-menstrual) 
1 Yes 0 No 
 
 
 
  days 
 
h. Ukoma okung qhelekanga 
ebufazini(ungasebenzisi zomiso 
Abnormal vaginal dryness (without 
using any drying agents) 
1 Yes 0 No 
 
 
  days 
 
i. Iintlungu xa usabelana ngesondo 
Pain during sex 
1 Yes 0 No -8 No sex   days 
j. Iintlungu emazantsi esisu 
Lower abdominal pain 
1 Yes 0 No   days 
k. Iintlungu emazantsi omqolo 
Lower back pain 
1 Yes 0 No   days 
Place Screening PTID 
label here 
e.g. PTID: 6  -    
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Date:  /  __/ __    
*If any “Yes” answers provided, follow up on pelvic exam for genital complaints or refer for evaluation of other 
symptoms. 
2IUDnCT: Clinical CRF Screening ART-User (Combined), Version 3.0 
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Symptom Yes/No If yes, duration 
l. Ubumanzi apha ebufazini 
obungaqhelekanga 
Abnormal vaginal discharge 
1 Yes 0 No 
 
  days 
 
m. Ukujikelezelwa yintloko 
Dizziness 
1 Yes 0 No   days 
n. Isicafu cafu 
Nausea 
1 Yes 0 No   days 
o. Ukugabha 
Vomiting 
1 Yes 0 No   days 
p. Ukudinwa 
Fatigue 
1 Yes 0 No   days 
q. Umkhuhlane ongachazekiyo 
Unexplained fever 
1 Yes 0 No   days 
r. Ukubila ebusuku 
Night sweats 
1 Yes 0 No   days 
s. Ukungabinamdla wokutya 
nokuya kuncipha 
Loss of appetite and/or weight 
1 Yes 0 No 
 
  days 
 
t. Ukumimitheka 
Weight gain 
1 Yes 0 No   days 
u. Ukuhambisa okumandla 
(>kwentsuku ezi7) 
Chronic diarrhea (> 7 days) 
1 Yes 0 No 
 
  days 
 
v. Ulosuleleko emlonyeni 
Yeast infection in mouth 
1 Yes 0 No   days 
w. Ukudumba kwamadlala la 
asemqaleni ngasezindlebeni 
Swollen lymph nodes (glands) 
1 Yes 0 No 
 
  days 
 
x. Intloko ebuhlungu 
ngokugqithisileyo 
Severe headaches 
1 Yes 0 No 
 
  days 
 
Place Screening PTID 
label here 
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Date:  /  __/ __    
Pelvic Exam 
10. Were there any palpable inguinal lymph 
nodes? 
0 None 1 Unilateral left 2 Unilateral right 3 Bilateral 
11. Were any abnormalities detected on the external genitalia by naked eye 
exam? 
0
1
No 
Yes  If yes, record below: 
1
2
3
4
5
6
7
8
Warts 
Painful ulcer 
Non-painful 
ulcer 
Vesicle(s) 
Tearing/ bruising at vaginal 
introitus 
Cyst 
Enlarged Bartholin’s gland 
Other (specify):    
12. On speculum examination, was vaginal discharge present? 
1 
0 
-8
Yes 
No  13 
Not assessed/evident bleeding. IF BLEEDINGStop form and inform study coordinator 
a. If yes, record colour of discharge: c. If yes, consistency of discharge: 
1 Clear 
2White 
3 Yellow/green 
4 Bloody/brown 
6 Cream-colored/gray 
5 Mixed (specify):    
1 Non-homogenous, normal 
2 Non-homogenous, curd-like 
3 Homogenous, smooth 
4 Homogenous, frothy 
b. Is an abnormal odour present? 1 Yes 0 No 
2IUDnCT: Clinical CRF Screening ART-User (Combined), Version 3.0 
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Date:  /  __/ __    
13. What was the quantity of cervical 
mucus? 
1
2
3
No mucus visible at os  15. 
Mild-moderate mucus visible at 
os 
Abundant mucus flowing from 
os 
14. Colour of cervical mucus: 
1
2
3
4
6
5
Clear 
Whit
e 
Yellow/gree
n 
Bloody/brow
n 
Cream-
colored/gray 
Mixed. Specify:   
15. Was there any contact bleeding when swabs were taken for STI testing? 
1 Yes 0 No 
15a. Was there any visible abnormality/lesion suspicious for neoplasia on the 
cervix? 
1 Yes 0 No 
16. Was there any pain on bimanual examination? 
1 Yes 0 No  17 
a. If YES, how would you rate this pain? 
1
2
3
Mild (reported by woman, no change in facial expression or muscle 
tone) 
Moderate (change in facial expression/muscle tone, but woman tolerates 
exam) 
Severe (woman cannot tolerate exam without body 
movement) 
17. Was there any cervical motion tenderness? 
1 Yes 0 No  18 
a. If YES, how would you rate this tenderness? 
1
2
3
Mild (reported by woman, no change in facial expression or muscle 
tone) 
Moderate (change in facial expression/muscle tone, but woman tolerates 
exam) 
Severe (woman cannot tolerate exam without body 
movement) 
2IUDnCT: Clinical CRF Screening ART-User (Combined), Version 3.0 
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Date:  /  __/ __    
18. Were there any adnexal mass(es)? 
1  Yes (Specify location(s):  Left  Right ) 
0  No 
-8 Could not palpate adnexae 
19. Was the uterus enlarged? 
1 Yes, describe:_   
0 No 
20. Perform rapid tests now and record results on Screening Lab CRF 
Clinical Summary 
23. Were any diagnoses made at today’s visit? 
1 Yes  Specify:    
0 No 
24. Were any referrals made at today’s visit? 
1 Yes  Specify:    
0 No 
2IUDnCT: Clinical CRF Screening ART-User (Combined), Version 3.0 
FHI Study #10369 IRB Net# 398733 
Last revised on 03 Aug 2015 
Translation verified 14 Aug 2015 
Page 7 of 8 
 Rapid Test 
 
Test done and results 
recorded 
Kit info 
 
 
a 
 
 
Pregnancy 
 
1 Yes 0 No 
 
kit # :                                               
Expiry date: |__|__| /|__|__| | / |__|__|__|__| 
 
b 
 
 
OSOM Trich 
 
1 Yes 0 No 
 
kit # :                                               
Expiry date: |__|__| /|__|__| | / |__|__|__|__| 
 
c 
 
 
OSOM BV 
 
1 Yes 0 No 
 
kit # :                                               
Expiry date: |__|__| /|__|__| | / |__|__|__|__| 
 
d 
 
 
Syphilis 
 
1 Yes 0 No 
 
kit # :                                               
Expiry date: |__|__| /|__|__| | / |__|__|__|__| 
Place Screening PTID 
label here 
e.g. PTID: 6  -    
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Date:  /  __/ __    
25. Were any medications prescribed at today’s 
visit? 
1
0
Yes  specify:   
Check for allergies; record on Concomitant Medications Log. 
No  Comments 
Nurse signature:  Date:    
2IUDnCT: Clinical CRF Screening ART-User (Combined), Version 3.0 
FHI Study #10369 IRB Net# 398733 
Last revised on 03 Aug 2015 
Translation verified 14 Aug 2015 
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Stamp for Data Entry:  Stamp for Quality Control:    
Remember: Record all medications on the Concomitant Medications Log, including anything she is 
currently taking or was prescribed at this visit. 
Place Screening PTID 
label here 
e.g. PTID: 6  -    
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Date:  /  __/ __    
Clinical CRF for Enrolment Pre-ART: 2IUDnCT 
Pregnancy and Medical History 
Are you allergic to latex? 
1 Yes  Use nitrile gloves 
0 No 
Weight: |  | | kg 
0. 
1. 
2. hCG Pregnancy Test: 
1 Positive  Stop form and inform study coordinator 
0 Negative 
Wakhe Wawathatha amachiza okuthomalalisa intsholongwane kagawulayo /Have you taken any 
medication(s)/treatment(s) for your HIV infection? 
1 Yes 
0 No   4 
a. Yayingamachiza okuthomalalisa intsholongwane na ? Were these antiretroviral medications (e.g. 
odimune, tenofovir/tdf, efavirenz, lamivudine/3tc, combivir, viramune, AZT/zidovudine)? 
1 Yes  Stop form and inform study coordinator 
0 No 
b. Ukuba ewe, uyawathatha ngoku lamayeza? If yes, are you currently taking these medications ? 
1 Yes 
0 No  update con med log 
a. Ungaba uyopha kangangokuba usebenzisa ipad/ liner namhlanje? Do you have vaginal 
bleeding such that you need to use a liner/pad today? 
1 Yes   Stop form and ask participant to return 3 days after bleeding has stopped 
0 No 
3. 
4. 
b. Ukhe wazityura okanye wahlambisisa imiphakatho yakho izolo, namhlanje okanye izolo 
elinye? Did you douche or wash inside your vagina yesterday, today, or the day before? 
1 Yes  Stop form and re-schedule pt.  Remind participant to not insert anything in the vagina 
for 3 days prior to a scheduled study visit 
0 No 
c. Ukhe wabelana ngesondo kwintsuku ezintathu ezidlulileyo? Did you have sexual intercourse in the 
last 3 days? 
1 Yes  Stop form and re-schedule pt.  Remind participant to not insert anything in the vagina 
for 3 days prior to a scheduled study visit 
0 No 
2IUDnCT Clinical CRF Enrolment Pre-ART (Combined), Version 4.0 
FHI Study #10369. IRB Net# 398733 
Translation verified 20 Mar 2015 Page 1 of 9 
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Date:  /  __/ __    
5. Ubunini umhla wakho oqale ngawo ukuya exesheni kweli lixa lokugqibela lokuhlamba 
When was the first day of your last menstrual period? 
Date: |  | | / |  | | | / |  | | | | (dd/mmm/yyyy) 
OR 
 Not menstruating on current contraceptive method 6_1 
a. Inani leentsuku   How many days did that period last? |  | | number of days 
6_1. Ngaphambi kokuba ungenele oluphando, ukhe waxelelwa ngugqirha okanye unesi 
ngokukulandelayo / Prior to joining this study, have you ever been told you have one of the 
following by a doctor or nurse? 
6_2. Ukhe waxelelwa ngu nesi okanye ugqirha ukuba unezinye zezizifo zilandelayo? 
Have you ever been told by a doctor or nurse that you have one of the following conditions? 
If they reported having had syphilis in question 6_1 or any of the conditions in question 6_2, note these 
conditions on the Pre-existing conditions CRF 
2IUDnCT Clinical CRF Enrolment Pre-ART (Combined), Version 4.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
Translation verified 20 Mar 2015 
Page 2 of 9 
Condition Yes/No/Don’t know 
a. isifo sesibindi 
Hepatitis 
1 Yes   0 No 99 Don’t know 
b. Isifo sentliziyo 
Heart disease 
1 Yes   0 No 99 Don’t know 
c. Iswekile 
Diabetes 
1 Yes   0 No 99 Don’t know 
d. Isifuba esiminxanayo 
Asthma/Breathing Problems 
1 Yes   0 No 99 Don’t know 
e. Ukuba ngqindilili kwegazi 
Problems with your blood clotting 
1 Yes   0 No 99 Don’t know 
f. Isifo senzintso 
Kidney disease 
1 Yes   0 No 99 Don’t know 
g. Igazi elincinci emzimbeni 
Anemia 
1 Yes   0 No 99 Don’t know 
Condition Yes/No/Don’t know 
If YES, in the past 
year? 
a. Idischarge engaqhelekanga ephuma 
ebufazini /Abnormal vaginal discharge 1 Yes   0 No 99 Don’t know 1 Yes   0 No 
b. Amazantsi esisu adumbileyo 
Pelvic Inflammatory Disease 
1 Yes   0 No 99 Don’t know 1 Yes   0 No 
c. Inyebethu yangaphantsi (Izilonda) 
Genital ulcers or herpes 
1 Yes   0 No 99 Don’t know 1 Yes   0 No 
d. Intsumpa zangaphantsi 
Genital warts 
1 Yes   0 No 99 Don’t know 1 Yes   0 No 
e. Igcushuwa 
Syphilis 
1 Yes   0 No 99 Don’t know 1 Yes   0 No 
Place Enrolment PTID 
label here 
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Date:  /  __/ __    
6. Ingaba oku kulandelayo kuyezeka na kuwe sukela kutyelelo lwakho lokugqibela? Have you 
experienced any of the following symptoms since your last study visit? Read list. 
2IUDnCT Clinical CRF Enrolment Pre-ART (Combined), Version 4.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
Translation verified 20 Mar 2015 
Page 3 of 9 
Symptom Yes/No If yes, duration 
a. Izilonda okanye inyebethu 
kwilungu langasese 
Genital sores or ulcers 
1 Yes 0 No 
 
  days 
 
b. Ukurhawuzelela kwilungu 
langasese 
Genital itching 
1 Yes 0 No 
 
  days 
 
c. Ukutshisa kwilungu langasese 
Genital burning 
1 Yes 0 No   days 
d. Ezinye iintlungu kwilungu 
langasese 
Other genital pain 
1 Yes 0 No 
 
  days 
 
e. Iintlungu xa uchama 
Pain when urinating 
1 Yes 0 No   days 
f. Ukuchama okongezelelekileyo 
rhoqo 
Increased urinary frequency 
1 Yes 0 No 
 
  days 
 
g. Ukopha okungaqhelekanga 
ebufazini(ingekuko ukuya 
exesheni) 
Abnormal vaginal bleeding 
(non-menstrual) 
1 Yes 0 No 
 
 
 
  days 
 
h. Ukoma okung qhelekanga 
ebufazini(ungasebenzisi zomiso 
Abnormal vaginal dryness (without 
using any drying agents) 
1 Yes 0 No 
 
 
  days 
 
i. Iintlungu xa usabelana ngesondo 
Pain during sex 
1 Yes 0 No -8 No sex   days 
j. Iintlungu emazantsi esisu 
Lower abdominal pain 
1 Yes 0 No   days 
k. Iintlungu emazantsi omqolo 
Lower back pain 
1 Yes 0 No   days 
l. Ubumanzi apha ebufazini 
obungaqhelekanga 
Abnormal vaginal discharge 
1 Yes 0 No 
 
  days 
 
m. Ukujikelezelwa yintloko 
Dizziness 
1 Yes 0 No   days 
n. Isicafu cafu 
Nausea 
1 Yes 0 No   days 
o. Ukugabha 
Vomiting 
1 Yes 0 No   days 
p. Ukudinwa 
Fatigue 
1 Yes 0 No   days 
q. Umkhuhlane ongachazekiyo 
Unexplained fever 
1 Yes 0 No   days 
r. Ukubila ebusuku 
Night sweats 
1 Yes 0 No   days 
Place Enrolment PTID 
label here 
e.g. PTID: 7  -    
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Date:  /  __/ __    
*If any “Yes” answers provided, follow up on pelvic exam for genital complaints or refer for evaluation of other 
symptoms. 
7. Ubukhe walala esibhedlela sukela kutyelelo lwakho lokugqibela? Have you been hospitalized since your last 
visit? 
1 Yes  AE log and SAE form (following exam) and inform study coordinator. 
0 No 
2IUDnCT Clinical CRF Enrolment Pre-ART (Combined), Version 4.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
Translation verified 20 Mar 2015 
Page 4 of 9 
Symptom Yes/No If yes, duration 
s. Ukungabinamdla wokutya 
nokuya kuncipha 
Loss of appetite and/or weight 
1 Yes 0 No 
 
  days 
 
t. Ukumimitheka 
Weight gain 
1 Yes 0 No   days 
u. Ukuhambisa okumandla 
(>kwentsuku ezi7) 
Chronic diarrhea (> 7 days) 
1 Yes 0 No 
 
  days 
 
v. Ulosuleleko emlonyeni 
Yeast infection in mouth 
1 Yes 0 No   days 
w. Ukudumba kwamadlala la 
asemqaleni ngasezindlebeni 
Swollen lymph nodes (glands) 
1 Yes 0 No 
 
  days 
 
x. Intloko ebuhlungu 
ngokugqithisileyo 
Severe headaches 
1 Yes 0 No 
 
  days 
 
Place Enrolment PTID 
label here 
e.g. PTID: 7  -    
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Date:  /  __/ __    
Pelvic exam 
Note: The pelvic exam should be performed following collection of genital tract specimens. 
8. Were there any palpable inguinal lymph 
nodes? 
1 None 2 Unilateral left 3 Unilateral right 4 Bilateral 
9. Were any abnormalities detected on the external genitalia by naked eye 
exam? 
0 No 
1 Yes  If yes, record below: 
1Warts 
2 Painful ulcer 
3 Non-painful ulcer 
4 Vesicle(s) 
5 Tearing/ bruising at vaginal introitus 
6 Cyst 
7 Enlarged Bartholin’s gland 
8 Other (specify):    
10. On speculum examination, was vaginal discharge present? 
1 Yes 
0 No  11 
-8 Not assessed/evident bleeding. IF BLEEDINGStop form and inform study coordinator a. If yes, record colour of discharge: 
1 Clear 
2White 
3 Yellow/green 
4 Bloody/brown 
6 Cream-colored/gray 
5 Mixed (specify):    
b. Is an abnormal odour present? 1
c. If yes, consistency of discharge: 
1 Non-homogenous, normal 
2 Non-homogenous, curd-like 
3 Homogenous, smooth 
4 Homogenous, frothy 
Yes 0 No 
2IUDnCT Clinical CRF Enrolment Pre-ART (Combined), Version 4.0 
FHI Study #10369. IRB Net# 398733 
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Date:  /  __/ __    
11. What was the quantity of cervical mucus? 
1 No mucus visible at os  13 
2 Mild-moderate mucus visible at os 
3 Abundant mucus flowing from os 
12. Colour of cervical mucus: 
1 Clear 
2White 
3 Yellow/green 
4 Bloody/brown 
6 Cream-colored/gray 
5 Mixed (specify):    
13. Was there any contact bleeding when swabs were taken for genital tract specimens? 1 Yes 0 No 
14. Was there any pain on bimanual examination? 
1 Yes 0 No  15 
a. If YES, how would you rate this pain? 
1
2
3
Mild (reported by woman, no change in facial expression or muscle 
tone) 
Moderate (change in facial expression/muscle tone, but woman tolerates 
exam) 
Severe (woman cannot tolerate exam without body 
movement) 
15. Was there any cervical motion tenderness? 
1 Yes 0 No  16 
a. If YES, how would you rate this tenderness? 
1
2
3
Mild (reported by woman, no change in facial expression or muscle 
tone) 
Moderate (change in facial expression/muscle tone, but woman tolerates 
exam) 
Severe (woman cannot tolerate exam without body 
movement) 
2IUDnCT Clinical CRF Enrolment Pre-ART (Combined), Version 4.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
Translation verified 20 Mar 2015 
Page 6 of 9 
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Date:  /  __/ __    
16. Were there any adnexal mass(es)? 
1  Yes (Specify location(s):  Left  Right ) 
0  No 
-8 Could not palpate adnexae 
17. Was the uterus enlarged? 
1 Yes, describe:   
0 No 
Clinical Summary 
18. Were any diagnoses made at today’s visit? 
1 Yes  Specify:    
0 No  Comments. 
19. Were any referrals made at today’s visit? (Please be sure to check questionnaire for alcohol, mental 
health and violence responses for additional need for referrals) 
1 Yes  Specify:    
0 No 
If evidence of infection or pregnant, notify study coordinator immediately and DO NOT proceed 
with randomisation and IUD insertion. 
2IUDnCT Clinical CRF Enrolment Pre-ART (Combined), Version 4.0 
FHI Study #10369. IRB Net# 398733 
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Date:  /  __/ __    
Randomisation 
20. Injectable status: 
Date of last injection: |  | | / |  | | | / |  | | | | (dd/mmm/yyyy) 
1 Yes, she has had recent (in the last 120 days) exposure to injectable contraceptive 
0 No exposure to injectable contraceptives in the last 120 days 
Age group: 
118-23 years 
224-31 years 
332-40 years 
Group assignment: 
21. 
22. 
1
2
3
4
5
Group 1 = No recent exposure to injectable, 18-23 years 
old 
Group 2 = No recent exposure to injectable, 24-31 years 
old 
Group 3 = No recent exposure to injectable, 32-40 years 
old 
Group 4 = Recent exposure to injectable, 18-23 years old 
Group 5 = Recent exposure to injectable, 24-31 years old 
6Group 6 = Recent exposure to injectable, 32-40 years old 
Randomisation number: -
Arm assignment: 
1 Arm A 
2 Arm B 
23. 
24. 
2IUDnCT Clinical CRF Enrolment Pre-ART (Combined), Version 4.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
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Date:  /  __/ __    
IUD Insertion 
25. 
27. Was the IUD inserted? 
1 Yes 
0 No  explain:   __   
Was there anything difficult about the IUD insertion? 
1 Yes  describe:    
0 No 
Was the participant stable following the procedure? 
1 Yes 
0 No  describe:    
Were any medications prescribed at today’s visit, including pain medication to take home? 
1
0No 
Nurse signature:  Date:    
Page 9 of 9 
 
 
 
Stamp for Data Entry:  Stamp for Quality Control:    
 
Remember: Record all medications on the Concomitant Medications Log, including ibuprofen given during 
this visit, anything she is currently taking or was prescribed at this visit. Record all pre-existing conditions on 
the Pre-existing Conditions CRF 
Place Enrolment PTID 
label here 
e.g. PTID: 7  -    
 
  
   
 
 
 
  
 
 
 
  
  
Was ibuprofen provided at least 40 minutes prior to insertion? 
1 Yes 
0 No  explain:    
What was the uterine depth during sounding?  cm 26. 
28. 
29. 
30. Yes  specify:    
Check for allergies; record on Concomitant Medications Log. 
2IUDnCT Clinical CRF Enrolment Pre-ART (Combined), Version 4.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
Translation verified 20 Mar 2015 
Clinical CRF for Enrolment ART User: 2IUDnCT 
Pregnancy and Medical History 
Are you allergic to latex? 
1 Yes  Use nitrile gloves 
0 No 
Weight: |  | | kg 
0. 
1. 
2. hCG Pregnancy Test: 
1 Positive  Stop form and inform study coordinator 
0 Negative 
Wakhe Wawathatha amachiza okuthomalalisa intsholongwane kagawulayo /Have you taken any 
medication(s)/treatment(s) for your HIV infection? 
1 Yes 
0 No  Stop form and inform study coordinator 
a. Yayingamachiza okuthomalalisa intsholongwane na ? Were these antiretroviral medications (e.g. 
odimune, tenofovir/tdf, efavirenz, lamivudine/3tc, combivir, viramune, AZT/zidovudine)? 
1  Yes 
0 No  Stop form and inform study coordinator 
b. Ukuba ewe, uyawathatha ngoku lamayeza? If yes, are you currently taking these medications ? 
1 Yes 
0 No  Stop form and inform study coordinator 
a. Ungaba uyopha kangangokuba usebenzisa ipad/ liner namhlanje? Do you have vaginal 
bleeding such that you need to use a liner/pad today? 
1 Yes  Stop form and ask participant to return 3 days af er bleeding has stopped 
0 No 
b. Ukhe wazityura okanye wahlambisisa imiphakatho yakho izolo, namhlanje okanye izolo elinye? 
3. 
4. 
Did you douche or wash inside your vagina yesterday, today, or the day before? 
1 Yes  Stop form and re-schedule pt.  Remind participant to not insert anything in the vagina 
for 3 days prior to a scheduled study visit 
0 No 
2IUDnCT Clinical CRF Enrolment ART-User (Combined), Version 3.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
Translation verified 28 Sept 2015 
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Date:  /  __/ __    
c. Ukhe wabelana ngesondo kwintsuku ezintathu ezidlulileyo? Did you have sexual intercourse in 
the last 3 days? 
1 Yes  Stop form and re-schedule pt.  Remind participant to not insert anything in the vagina 
for 3 days prior to a scheduled study visit 
0 No 
5. Ubunini umhla wakho oqale ngawo ukuya exesheni kweli lixa lokugqibela lokuhlamba 
When was the first day of your last menstrual period? Dat : |  | | / | | | | / |  | | | | (dd/mmm/yyyy) 
OR 
 Not menstruating on current contraceptive method 6_1 
a. Inani leentsuku   How many days did that period last? |  | | number of days 
b. iAR uzithatha kangaphi ngemini How many times a day do you take your ART pills? 
|  | | 
c. Zingaphi ipilisi ozityayo ngexesha How many pills do you take each time you take your ART 
medicines? 
Morning (am) |  | | 
Afternoon (pm)  |  | | 
d. Ingama layeza e ART ozityayo ngoku ? What is/are the names of the ART medicine(s) you are 
taking right now? 
1 
2 
3 
4 
5 
9  Atroiza 
10  3TC 
11  Nevirapine 
12  Aluvia 
13  Zidovudine 
Tribus 
Odimune 
Combivir 
Tenofovir/t
df 
Lamivudime 
6  Efavirenz 
7  Viramune 
8  Other, specify:    
[Note: please use picture chart to assist participant in identifying the correct pill.] 
2IUDnCT Clinical CRF Enrolment ART-User (Combined), Version 3.0 
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Date:  /  __/ __    
e. Igama leklinic lofuma khona kunanakelwa kwentsholongwane ngawulayo kanye nama chiza akho 
ART? What is the name of the clinic where you receive your ART medicines and HIV care? 
1 
2 
3 
4 
5 
6 
7 
8 
Hannan Crusade Old Crossroad Clinic 
Nyanga clinic NY1 clinic 
New Crossroad Clinic Mzamonhl
e 
Vuyani other; specify:    
f) Kwintsuku ezi-30 ezidlulileyo, zimini ezinfaphi okhe walibala ukutya amchiza akho entsholongwana Kanye 
nje? 
In the last 30 days, on how many days did you miss at least one dose of your HIV medication? 
|  | | # days 
g) Kwezi ntsuku zi-30 zidlulileyo, uwatye kakuhle kanjani amachiza akho entsolongwane njengohlobo 
omele ukuwatya ngalo? 
In the last 30 days, how good a job did you do at taking your HIV medicines in the way that you were 
supposed to? 
1 
2 
3 
4 
5 
6 
kabi kakhulu / Very poor 
Kakubi /Poor 
Ndiphakathi /Fair 
kakuhle /Good 
Kakuhle kakhulu / Very good 
kakhuhle okugqithisileyo /Excellent 
h) Kwezi ntsuku zi-30 zidlulileyo, kukangaphi usitya amachiza akho entsholongwane ngendlela omele 
kuwatay ngayo? In the last 30 days, how often did you take your HIV medicines in the way that you were 
supposed to? 
1 
2 
3 
4 
5 
6 
Zange / Never 
Nqqbile/Rarely 
Ngamanye amaxesha /Sometimes 
Ngesiqhelo /Usually 
Malunga lonke ixesha /Almost always 
Lonke ixesha/ Always 
2IUDnCT Clinical CRF Enrolment ART-User (Combined), Version 3.0 
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Translation verified 28 Sept 2015 
Page 3 of 11 
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 
  
   
 
 
 
Page 202 of 219 
 
 
Date:  /  __/ __    
6_1. Ngaphambi kokuba ungenele oluphando, ukhe waxelelwa ngugqirha okanye unesi 
ngokukulandelayo / Prior to joining this study, have you ever been told you have one of the 
following by a doctor or nurse? 
6_2. Ukhe waxelelwa ngu nesi okanye ugqirha ukuba unezinye zezizifo zilandelayo? 
Have you ever been told by a doctor or nurse that you have one of the following conditions? 
If they reported having had syphilis in question 6_1 or any of the conditions in question 6_2, note these 
conditions on the Pre-existing conditions CRF 
2IUDnCT Clinical CRF Enrolment ART-User (Combined), Version 3.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
Translation verified 28 Sept 2015 
Page 4 of 11 
Condition Yes/No/Don’t know 
a. isifo sesibindi 
Hepatitis 
1 Yes   0 No 99 Don’t know 
b. Isifo sentliziyo 
Heart disease 
1 Yes   0 No 99 Don’t know 
c. Iswekile 
Diabetes 
1 Yes   0 No 99 Don’t know 
d. Isifuba esiminxanayo 
Asthma/Breathing Problems 
1 Yes   0 No 99 Don’t know 
e. Ukuba ngqindilili kwegazi 
Problems with your blood clotting 
1 Yes   0 No 99 Don’t know 
f. Isifo senzintso 
Kidney disease 
1 Yes   0 No 99 Don’t know 
g. Igazi elincinci emzimbeni 
Anemia 
1 Yes   0 No 99 Don’t know 
Condition Yes/No/Don’t know 
If YES, in the past 
year? 
a. Idischarge engaqhelekanga ephuma 
ebufazini /Abnormal vaginal discharge 1 Yes   0 No 99 Don’t know 1 Yes   0 No 
b. Amazantsi esisu adumbileyo 
Pelvic Inflammatory Disease 
1 Yes   0 No 99 Don’t know 1 Yes   0 No 
c. Inyebethu yangaphantsi (Izilonda) 
Genital ulcers or herpes 
1 Yes   0 No 99 Don’t know 1 Yes   0 No 
d. Intsumpa zangaphantsi 
Genital warts 
1 Yes   0 No 99 Don’t know 1 Yes   0 No 
e. Igcushuwa 
Syphilis 
1 Yes   0 No 99 Don’t know 1 Yes   0 No 
Place Enrolment PTID 
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Date:  /  __/ __    
6. Ingaba oku kulandelayo kuyezeka na kuwe sukela kutyelelo lwakho lokugqibela? Have you 
experienced any of the following symptoms since your last study visit? Read list. 
2IUDnCT Clinical CRF Enrolment ART-User (Combined), Version 3.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
Translation verified 28 Sept 2015 
Page 5 of 11 
Symptom Yes/No If yes, duration 
a. Izilonda okanye inyebethu 
kwilungu langasese 
Genital sores or ulcers 
1 Yes 0 No 
 
  days 
 
b. Ukurhawuzelela kwilungu 
langasese 
Genital itching 
1 Yes 0 No 
 
  days 
 
c. Ukutshisa kwilungu langasese 
Genital burning 
1 Yes 0 No   days 
d. Ezinye iintlungu kwilungu 
langasese 
Other genital pain 
1 Yes 0 No 
 
  days 
 
e. Iintlungu xa uchama 
Pain when urinating 
1 Yes 0 No   days 
f. Ukuchama okongezelelekileyo 
rhoqo 
Increased urinary frequency 
1 Yes 0 No 
 
  days 
 
g. Ukopha okungaqhelekanga 
ebufazini(ingekuko ukuya 
exesheni) 
Abnormal vaginal bleeding 
(non-menstrual) 
1 Yes 0 No 
 
 
 
  days 
 
h. Ukoma okung qhelekanga 
ebufazini(ungasebenzisi zomiso 
Abnormal vaginal dryness (without 
using any drying agents) 
1 Yes 0 No 
 
 
  days 
 
i. Iintlungu xa usabelana ngesondo 
Pain during sex 
1 Yes 0 No -8 No sex   days 
j. Iintlungu emazantsi esisu 
Lower abdominal pain 
1 Yes 0 No   days 
k. Iintlungu emazantsi omqolo 
Lower back pain 
1 Yes 0 No   days 
l. Ubumanzi apha ebufazini 
obungaqhelekanga 
Abnormal vaginal discharge 
1 Yes 0 No 
 
  days 
 
m. Ukujikelezelwa yintloko 
Dizziness 
1 Yes 0 No   days 
n. Isicafu cafu 
Nausea 
1 Yes 0 No   days 
o. Ukugabha 
Vomiting 
1 Yes 0 No   days 
p. Ukudinwa 
Fatigue 
1 Yes 0 No   days 
q. Umkhuhlane ongachazekiyo 
Unexplained fever 
1 Yes 0 No   days 
r. Ukubila ebusuku 
Night sweats 
1 Yes 0 No   days 
Place Enrolment PTID 
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Date:  /  __/ __    
*If any “Yes” answers provided, follow up on pelvic exam for genital complaints or refer for evaluation of other 
symptoms. 
7. Ubukhe walala esibhedlela sukela kutyelelo lwakho lokugqibela? Have you been hospitalized since your last 
visit? 
1 Yes  AE log and SAE form (following exam) and inform study coordinator. 
0 No 
2IUDnCT Clinical CRF Enrolment ART-User (Combined), Version 3.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
Translation verified 28 Sept 2015 
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Symptom Yes/No If yes, duration 
s. Ukungabinamdla wokutya 
nokuya kuncipha 
Loss of appetite and/or weight 
1 Yes 0 No 
 
  days 
 
t. Ukumimitheka 
Weight gain 
1 Yes 0 No   days 
u. Ukuhambisa okumandla 
(>kwentsuku ezi7) 
Chronic diarrhea (> 7 days) 
1 Yes 0 No 
 
  days 
 
v. Ulosuleleko emlonyeni 
Yeast infection in mouth 
1 Yes 0 No   days 
w. Ukudumba kwamadlala la 
asemqaleni ngasezindlebeni 
Swollen lymph nodes (glands) 
1 Yes 0 No 
 
  days 
 
x. Intloko ebuhlungu 
ngokugqithisileyo 
Severe headaches 
1 Yes 0 No 
 
  days 
 
Place Enrolment PTID 
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Date:  /  __/ __    
Pelvic exam 
Note: The pelvic exam should be performed following collection of genital tract specimens. 
8. Were there any palpable inguinal lymph 
nodes? 
1 None 2 Unilateral left 3 Unilateral right 4 Bilateral 
9. Were any abnormalities detected on the external genitalia by naked eye 
exam? 
0 No 
1 Yes  If yes, record below: 
1Warts 
2 Painful ulcer 
3 Non-painful ulcer 
4 Vesicle(s) 
5 Tearing/ bruising at vaginal introitus 
6 Cyst 
7 Enlarged Bartholin’s gland 
8 Other (specify):    
10. On speculum examination, was vaginal discharge present? 
1 Yes 
0 No  11 
-8 Not assessed/evident bleeding. IF BLEEDINGStop form and inform study coordinator a. If yes, record colour of discharge: 
1 Clear 
2White 
3 Yellow/green 
4 Bloody/brown 
6 Cream-colored/gray 
5 Mixed (specify):    
c. If yes, consistency of discharge: 
1 Non-homogenous, normal 
2 Non-homogenous, curd-like 
3 Homogenous, smooth 
4 Homogenous, frothy 
b. Is an abnormal odour present? 1 Yes 0 No 
2IUDnCT Clinical CRF Enrolment ART-User (Combined), Version 3.0 
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Date:  /  __/ __    
11. What was the quantity of cervical mucus? 
1 No mucus visible at os  13 
2 Mild-moderate mucus visible at os 
3 Abundant mucus flowing from os 
12. Colour of cervical mucus: 
1 Clear 
2White 
3 Yellow/green 
4 Bloody/brown 
6 Cream-colored/gray 5  Mixed (specify):    
13. Was there any contact bleeding when swabs were taken for genital tract 
specimens? 
1 Yes 0 No 
14. Was there any pain on bimanual examination? 
1 Yes 0 No  15 
a. If YES, how would you rate this pain? 
1
2
3
Mild (reported by woman, no change in facial expression or muscle 
tone) 
Moderate (change in facial expression/muscle tone, but woman tolerates 
exam) 
Severe (woman cannot tolerate exam without body 
movement) 
15. Was there any cervical motion tenderness? 
1 Yes 0 No  16 
a. If YES, how would you rate this tenderness? 
1
2
3
Mild (reported by woman, no change in facial expression or muscle 
tone) 
Moderate (change in facial expression/muscle tone, but woman tolerates 
exam) 
Severe (woman cannot tolerate exam without body 
movement) 
16. Were there any adnexal mass(es)? 
1  Yes (Specify location(s):  Left  Right ) 
0  No 
-8 Could not palpate adnexae 
2IUDnCT Clinical CRF Enrolment ART-User (Combined), Version 3.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
Translation verified 28 Sept 2015 
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Place Enrolment PTID 
label here 
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Date:  /  __/ __    
17. Was the uterus enlarged? 
1 Yes, describe:   
0 No 
Clinical Summary 
18. Were any diagnoses made at today’s visit? 
1 Yes  Specify:    
0 No  Comments. 
19. Were any referrals made at today’s visit? (Please be sure to check questionnaire for alcohol, mental 
health and violence responses for additional need for referrals) 
1 Yes  Specify:    
0 No 
If evidence of infection or pregnant, notify study coordinator immediately and DO NOT proceed 
with randomisation and IUD insertion. 
2IUDnCT Clinical CRF Enrolment ART-User (Combined), Version 3.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
Translation verified 28 Sept 2015 
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Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
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Date:  /  __/ __    
Randomisation 
20. Injectable status: 
Date  of last injection: |  | | / |  | | | / |  | | |
 | (dd/mmm/yyyy) 
1 Yes, she has had recent (in the last 120 days) exposure to injectable contraceptive 
0 No exposure to injectable contraceptives in the last 120 days 
21. Age group: 
118-23 years 
224-31 years 
332-40 years 
Group assignment: 22. 
1
2
3
4
5
6
Group 1 = No recent exposure to injectable, 18-23 years 
old 
Group 2 = No recent exposure to injectable, 24-31 years 
old 
Group 3 = No recent exposure to injectable, 32-40 years 
old 
Group 4 = Recent exposure to injectable, 18-23 years old 
Group 5 = Recent exposure to injectable, 24-31 years old 
Group 6 = Recent exposure to injectable, 32-40 years old 
Randomisation number: -23. 
(ART will be given randomization envelopes sequentially from the last envelope (100th) 
moving backward numerically) 
24.  Arm assignment: 
1 Arm A 
2 Arm B 
2IUDnCT Clinical CRF Enrolment ART-User (Combined), Version 3.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
Translation verified 28 Sept 2015 
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Date:  /  __/ __    
IUD Insertion 
25. Was ibuprofen provided at least 40 minutes prior to insertion? 
1 Yes 
0 No  explain:    
What was the uterine depth during sounding?  cm 
26. 
27. Was the IUD inserted? 
1 Yes 
0 No  explain:   __   
Was there anything difficult about the IUD insertion? 
1 Yes  describe:    
0 No 
Was the participant stable following the procedure? 
1 Yes 
0 No  describe:    
Were any medications prescribed at today’s visit, including pain medication to take home? 
28. 
29. 
30. 
1
0
Yes  specify:    
Check for allergies; record on Concomitant Medications Log. 
No 
Notes: 
Nurse signature: 
  Date:    
2IUDnCT Clinical CRF Enrolment ART-User (Combined), Version 3.0 
FHI Study #10369. IRB Net# 398733 
Last revised on 25 Sept 2015 
Translation verified 28 Sept 2015 
Page 11 of 11 
 
 
 
Stamp for Data Entry:  Stamp for Quality Control:    
 
Remember: Record all medications on the Concomitant Medications Log, including ibuprofen given during 
this visit, anything she is currently taking or was prescribed at this visit. Record all pre-existing conditions on 
the Pre-existing Conditions CRF 
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
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Screening Laboratory Results CRF Pre-ART: 2IUDnCT 
Instructions: Staff should initial on the day results are available/received. 
2IUDnCT Lab Results CRF—Screening Pre-ART, Version 5.0 
FHI Study #10369 
Last revised on 01-Apr-2015 
Page 1 of 2 
Screening Lab Results 
 
Date of 
collection 
(dd/mmm/yyyy) 
Test result 
 
Date received 
results 
(dd/mmm/yyyy) 
Staff Initials 
 
1. 
 
Pregnancy test 
 
 
  /  /    0 Negative 1 Positive -8 Not done 
  
2. 
 
OSOM Trich rapid test 
 
 
  /  /    0 Negative 1 Positive -8 Not done 
 
3. 
 
OSOM BV blue rapid 
test 
 
  /  /    0 Negative 1 Positive -8 Not done 
 
 
4. 
 
Determine Syphilis 
rapid test 
 
 
  /  /    
 
0 Negative 1 Positive -8 Not done 
Determine test negative 6 
If rpr done at previous visit and within 3months 6 
 
5. 
 
(If POSITIVE rapid 
syphilis test): 
RPR titre 
 
 
  /  /    
 
0 non-reactive 
21:2 161:16 
41:4 321:32 
81:8 641:64 or higher 
-8Not done, but rapid test positive  If repeating 
specimen, please complete a separate CRF 
 
  /  /    
 
1:4 or higher  notify 
coordinator 
 
 
6. 
 
Chlamydia 
 
 
  /  /    
 
0 Negativ  1 Positive 
-8 Invalid or not done  If repeating specimen, 
please complete a separate CRF 
  /  /    
Positive notify 
coordinator 
 
 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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Screening Laboratory Results CRF Pre-ART: 2IUDnCT 
Notes:    
2IUDnCT Lab Results CRF—Screening Pre-ART, Version 5.0 
FHI Study #10369 
Last revised on 01-Apr-2015 
Page 2 of 2 
 
 
Stamp for Data Entry:  Stamp for Quality Control:    
 
Screening Lab Results 
 
Date of 
collection 
(dd/mmm/yyyy) 
Test result 
 
Date received 
results 
(dd/mmm/yyyy) 
Staff Initials 
 
7. 
 
Gonorrhoea 
 
 
  /  /    
 
0 Negative 1 Positive 
-8 Invalid or not done  If repeating specimen, 
please complete a separate CRF 
  /  /    
Positive notify 
coordinator 
 
 
8. 
 
Screening CD4 count 
 
 
  /  /    
 
 
  cells/mm3 
If indeterminate or not done, enter -8  If 
repeating specimen, please complete a separate 
CRF 
 
  /  /    
 
 
9. 
 
Pap result 
 
  /  /    
 
0 Normal 
1 ASCUS 
2 LSIL 
3 HSIL  notify PI 
4 Other, specify: 
-8  Indeterminate or not done  If 
repeating specimen, please complete a 
separate CRF 
 
  /  /  
( If pap smear results were 
obtained from DISA, record 
day results were retrieved) 
 
 
Place Screening PTID 
label here 
e.g. PTID: 5  -    
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Screening Laboratory Results CRF ART-User: 2IUDnCT 
Instructions: Staff should initial on the day results are available/received. 
2IUDnCT Lab Results CRF Screening- ART-User , Version 2.0 
FHI Study #10369 
Last revised on 12 Apr 2015 
Page 1 of 2 
Screening Lab Results 
 
Date of 
collection 
(dd/mmm/yyyy) 
Test result 
 
Date received 
results 
(dd/mmm/yyyy) 
Staff Initials 
 
1. 
 
Pregnancy test 
 
 
  /  /    0 Negative 1 Positive -8Not done 
  
2. 
 
OSOM Trich rapid test 
 
 
  /  /    0 Negative 1 Positive -8Not done 
 
3. 
 
OSOM BV blue rapid 
test 
 
  /  /    0 Negative 1 Positive -8Not done 
 
 
4. 
 
Determine 
Syphilis rapid test 
 
 
  /  /    
 
0 Negative 1 Positive   -8Not done 
Determine test negative 6 
If rpr done at previous visit and within 3 months 6 
 
5. 
 
(If POSITIVE rapid 
syphilis test): 
RPR titre 
 
 
  /  /    
 
0 non-reactive 
21:2 161:16 
41:4 321:32 
81:8 641:64 or higher 
-8Not done, but rapid test positive  If repeating 
specimen, please complete a separate CRF 
 
  /  /    
 
1:4 or higher  notify 
coordinator 
 
 
6. 
 
Chlamydia 
 
 
  /  /    
 
0 Negativ  1 Positive 
-8 Invalid or not done  If repeating specimen, 
please complete a separate CRF 
  /  /    
Positive notify 
coordinator 
 
 
Place Screening PTID 
label here 
e.g. PTID: 6  -    
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Screening Laboratory Results CRF ART-User: 2IUDnCT 
2IUDnCT Lab Results CRF Screening- ART-User , Version 2.0 
FHI Study #10369 
Last revised on 12 Apr 2015 
Page 2 of 2 
 
Stamp for Data Entry:    Stamp for Quality Control:    
 
Screening Lab Results 
 
Date of 
collection 
(dd/mmm/yyyy) 
Test result 
 
Date received 
results 
(dd/mmm/yyyy) 
Staff Initials 
 
7. 
 
Gonorrhoea 
 
 
  /  /    
 
0 Negative 1 Positive 
-8 Invalid or not done  If repeating specimen, 
please complete a separate CRF 
  /  /    
Positive notify 
coordinator 
 
 
9 
 
Pap result 
 
 
  /  /    
 
0 Normal 
1 ASCUS 
2 LSIL 
3 HSIL  notify PI 
4 Other, specify: 
-8  Indeterminate or not done  If 
repeating specimen, please complete a 
separate CRF 
  /  /  
( If pap smear results were 
obtained from DISA, record 
day results were retrieved) 
 
 
10 
 
Plasma Viral load 
 
 
  /  /  
Source of information: 
1 DISA 
2 Printed records from 
outside clinic/lab. 
a. Detectable? 
0No 1Yes 2NQ (<40 copies/ml) 
b. If detectable, 
  copies/ mL 
-8Could not find documentation of plasma VL 
 
  /  /    
 
 
Place Screening PTID 
label here 
e.g. PTID: 6  -    
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Enrolment Laboratory Results CRF Pre-ART: 2IUDnCT 
Instructions: Staff should initial on the day results are 
available/received. 
2IUDnCT Lab Results CRF—Enrolment Pre-ART, Version 6.0 
FHI Study #10369 
Last revised on 30 Dec 2015 
Page 1 of 2 
Enrolment Lab R sults 
 
Date of 
collection 
(dd/mmm/yyyy) 
Test result 
 
Date received 
results 
(dd/mmm/yyyy) 
Staff Initials 
 
1. 
 
Plasma viral load 
(“blood” result 
from NHLS) 
 
 
  /  /    
 
a. Detectable? 
0 No 1 Yes 2 NQ (<20 
copies/ml) 
b. If detectable, 
  copies/ mL 
-8 Invalid or not done  If repeating 
specimen, please complete a separate CRF 
 
  /  /    
 
 
2. 
 
Full blood count 
 
 
  /  /    
 
 
a. HGB :  g/dl 
 
b. HCT  :  l/l 
 
c. MCV   :  fl 
-8 Invalid or not done  If repeating 
specimen, please complete a separate CRF 
 
  /  /    
 
IF Hgb<10.0, 
prescribe FeSO4 
If less than 8.0 prescribe 
FeSO4 and inform 
study coordinator 
 
 
3. 
 
Pregnancy test 
 
 
  /  /    0 Negative   1 Positive -8 Not done 
  
Place Enrolment PTID 
label here 
e.g. PTID: 7  -    
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Notes: 
2IUDnCT Lab Results CRF—Enrolment Pre-ART, Version 6.0 
FHI Study #10369 
Last revised on 30 Dec 2015 
Page 2 of 2 
 
 
Stamp for Data Entry:   Stamp for Quality Control:    
 
Enrolment Laboratory Results CRF Pre-ART: 2IUDnCT 
 
Place Enrolment PTID 
label here 
e.g. PTID: 7  -    
 
 
Enrolment Lab Results 
 
Date of 
collection 
(dd/mmm/yyyy) 
Test result 
 
Date received 
results 
(dd/mmm/yyyy) 
Staff Initials 
 
4. 
 
Genital tract viral 
load (MC specimen) 
 
 
  /  /    
 
a. Detectable? 
0 No 1 Yes  2 NQ (<20 copies/ml) 
b. If detectable, 
  copies/ mL 
-8 Invalid or not done  If repeating 
specimen, please complete a separate CRF 
 
  /  /    
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Enrolment Laboratory Results CRF ART-User: 2IUDnCT 
Instructions: Staff should initial on the day results are 
available/received. 
2IUDnCT Lab Results CRF—Enrolment ART-User, Version 2.0 
FHI Study #10369 
Last revised on 30 Dec -2015 
Page 1 of 2 
Enrolment Lab R sults 
 
Date of 
collection 
(dd/mmm/yyyy) 
Test result 
 
Date received 
results 
(dd/mmm/yyyy) 
Staff Initials 
 
1. 
 
Plasma viral load 
(“blood” result 
from NHLS) 
 
 
_ 
_  /  /    
 
a. Detectable? 
0 No 1 Yes 2 NQ (<20 
copies/ml) 
b. If detectable, 
  copies/ mL 
-8 Invalid or not done  If repeating 
specimen, please complete a separate CRF 
 
  /  /    
 
 
2. 
 
Full blood count 
 
 
  /  /    
 
 
a. HGB :  g/dl 
 
b. HCT  :  l/l 
 
c. MCV   :  fl 
-8 Invalid or not done  If repeating 
specimen, please complete a separate CRF 
 
  /  /    
 
IF Hgb<10.0, 
prescribe FeSO4 
 
If less than 8.0 prescribe 
FeSO4 and inform 
study coordinator. 
 
3. 
 
Pregnancy test 
 
 
  /  /    0 Negative   1 Positive -8 Not done 
  
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
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Notes: 
2IUDnCT Lab Results CRF—Enrolment ART-User, Version 2.0 
FHI Study #10369 
Last revised on 30 Dec -2015 
Page 2 of 2 
 
 
Stamp for Data Entry:   Stamp for Quality Control:    
 
Enrolment Laboratory Results CRF ART-User: 2IUDnCT 
 
Place Enrolment PTID 
label here 
e.g. PTID: 8  -    
 
 
Enrolment Lab Results 
 
Date of 
collection 
(dd/mmm/yyyy) 
Test result 
 
Date received 
results 
(dd/mmm/yyyy) 
Staff Initials 
 
4. 
 
Genital tract viral 
load (MC specimen) 
 
 
  /  /    
 
a. Detectable? 
0 No 1 Yes  2 NQ (<20 copies/ml) 
b. If detectable, 
  copies/ mL 
-8 Invalid or not done  If repeating 
specimen, please complete a separate CRF 
 
  /  /    
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Appendix IV –  
Supplementary Table 
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Supplementary Table 1 
 
Table 1a Association of ART status and plasma HIV-1 viral load at baseline 
 ART- Naïve ART- Using 
Plasma HIV VL (0-49 copies / ml) 2 (4.2%) 45 (80.4%) 
Plasma HIV VL (50-999 copies / ml) 6 (12.5%) 6 (10.7%) 
Plasma HIV VL (1000-9999 copies / ml) 22 (45.8%) 3 (5.4%) 
Plasma HIV VL ((≥10000  copies / ml) 18 (37.5%) 2 (3.6%) 
Total 48 (100%) 56 
 
Table 1b Association of ART status and plasma HIV-1 viral load at 3 Months followed up visit 
 ART- Naïve ART- Using 
Plasma HIV VL (0-49 copies / ml) 2 (4.4%) 39 (78.0%) 
Plasma HIV VL (50-999 copies / ml) 10 (22.2%) 6 (12.0%) 
Plasma HIV VL (1000-9999 copies / ml) 14 (31.1%) 2 (4.0%) 
Plasma HIV VL ((≥10000  copies / ml) 19 (42.2%) 3 (6.0%) 
Total 45 (100%) 50 (100%) 
 
Table 1c Association of ART status and plasma HIV-1 viral load at 6 Months followed up visit 
 ART- Naïve ART- Using 
Plasma HIV VL (0-49 copies / ml) 1 (2%) 37 (75.5%) 
Plasma HIV VL (50-999 copies / ml) 6 (12.8%) 6 (12.2%) 
Plasma HIV VL (1000-9999 copies / ml) 27 (57.5%) 1 (2.0%) 
Plasma HIV VL ((≥10000  copies / ml) 13 (27.7%) 5 (1.2%) 
Total 47 (100%) 49 (100%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
